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Substances and Disease Registry, the Public Health Service, or the U.S. Department of Health and Human 
Services. 
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applicable information quality guidelines.  It has not been formally disseminated by the Agency for Toxic 
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iii 1,2,3-TRICHLOROPROPANE
FOREWORD 
This toxicological profile is prepared in accordance with guidelines developed by the Agency for Toxic 
Substances and Disease Registry (ATSDR) and the Environmental Protection Agency (EPA).  The 
original guidelines were published in the Federal Register on April 17, 1987. Each profile will be revised 
and republished as necessary. 
The ATSDR toxicological profile succinctly characterizes the toxicologic and adverse health effects 
information for these toxic substances described therein.  Each peer-reviewed profile identifies and 
reviews the key literature that describes a substance's toxicologic properties.  Other pertinent literature is 
also presented, but is described in less detail than the key studies.  The profile is not intended to be an 
exhaustive document; however, more comprehensive sources of specialty information are referenced.
The focus of the profiles is on health and toxicologic information; therefore, each toxicological profile 
begins with a relevance to public health discussion which would allow a public health professional to 
make a real-time determination of whether the presence of a particular substance in the environment 
poses a potential threat to human health.  The adequacy of information to determine a substance's health 
effects is described in a health effects summary.  Data needs that are of significance to the protection of 
public health are identified by ATSDR and EPA. 
Each profile includes the following:
(A) The examination, summary, and interpretation of available toxicologic information and 
epidemiologic evaluations on a toxic substance to ascertain the levels of significant human 
exposure for the substance and the associated acute, intermediate, and chronic health effects;
(B) A determination of whether adequate information on the health effects of each substance is 
available or in the process of development to determine the levels of exposure that present a 
significant risk to human health due to acute, intermediate, and chronic duration exposures; 
and 
(C) Where appropriate, identification of toxicologic testing needed to identify the types or levels 
of exposure that may present significant risk of adverse health effects in humans.
The principal audiences for the toxicological profiles are health professionals at the Federal, State, and 
local levels; interested private sector organizations and groups; and members of the public.  ATSDR plans 
to revise these documents in response to public comments and as additional data become available.  
Therefore, we encourage comments that will make the toxicological profile series of the greatest use.
Electronic comments may be submitted via: www.regulations.gov.  Follow the on-line instructions for 
submitting comments. 
Written comments may also be sent to:  Agency for Toxic Substances and Disease Registry 
     Division  of  Toxicology  and  Human  Health  Sciences
     Environmental  Toxicology  Branch  
1600 Clifton Road, N.E. 
Mail Stop S102-1
Atlanta, Georgia 30329-4027
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The toxicological profiles are developed under the Comprehensive Environmental Response, 
Compensation, and Liability Act of 1980, as amended (CERCLA or Superfund).  CERCLA section 
104(i)(1) directs the Administrator of ATSDR to “…effectuate and implement the health related 
authorities” of the statute.  This includes the preparation of toxicological profiles for hazardous 
substances most commonly found at facilities on the CERCLA National Priorities List (NPL) and that 
pose the most significant potential threat to human health, as determined by ATSDR and the EPA.  
Section 104(i)(3) of CERCLA, as amended, directs the Administrator of ATSDR to prepare a 
toxicological profile for each substance on the list.  In addition, ATSDR has the authority to prepare 
toxicological profiles for substances not found at sites on the NPL, in an effort to “…establish and 
maintain inventory of literature, research, and studies on the health effects of toxic substances” under 
CERCLA Section 104(i)(1)(B), to respond to requests for consultation under section 104(i)(4), and as 
otherwise necessary to support the site-specific response actions conducted by ATSDR.  
This profile reflects ATSDR’s assessment of all relevant toxicologic testing and information that has been 
peer-reviewed.  Staffs of the Centers for Disease Control and Prevention and other Federal scientists have 
also reviewed the profile.  In addition, this profile has been peer-reviewed by a nongovernmental panel 
and is being made available for public review.  Final responsibility for the contents and views expressed 
in this toxicological profile resides with ATSDR. 
Patrick N. Breysse, Ph.D., CIH 
Director, National Center for Environmental Health and 
Agency for Toxic Substances and Disease Registry 
Centers for Disease Control and Prevention 
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CHAPTER 1.  RELEVANCE TO PUBLIC HEALTH 
 
1.1   OVERVIEW AND U.S. EXPOSURES 
 
ATSDR’s Toxicological Profile for 1,2,3-Trichloropropane was released in 1992.  In order to update the 
literature in this profile, ATSDR conducted a literature search focused on health effects information as 
described in Appendix B.  Chapters 2, 3, and 7 were revised to reflect the most current health effects and 
regulations/guidelines data.  In some cases, other sections of the profile were updated as needed or for 
consistency or with the updated health effects data.  However, the focus of the update to this profile is on 
health effects information. 
 
1,2,3-Trichloropropane (C3H5Cl3; CAS number 96-18-4) is a man-made chemical that is present in the 
environment as a result of anthropogenic activity.  It is primarily used in the production of other 
chemicals.  In the past, it was used as a solvent and extractive agent.  Exposure can occur through 
ingestion of contaminated food and water, inhalation, and dermal contact.  Data regarding the 
concentrations of 1,2,3-trichloropropane in the environment are limited; low levels have been found in a 
few rivers and bays, drinking water, groundwater, and hazardous waste sites in the United States.  
 
1.2   SUMMARY OF HEALTH EFFECTS  
 
Information on the toxicity of 1,2,3-trichloropropane primarily comes from studies conducted in 
experimental animals.  Three studies have evaluated the toxicity of 1,2,3-trichloropropane in humans.  
Approximately 30 experiments have been conducted in experimental animals, although there are less than 
15 publication or unpublished studies.  Approximately 50% of the studies are by the oral route, 30% by 
inhalation, and the remainder are dermal/ocular studies.  As illustrated in Figures 1-1 and 1-2, the most 
sensitive effects appear to be liver damage, kidney damage, respiratory tract damage, hematological 
effects, heart damage, and cancer.   
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Figure 1-1.  Health Effects Found in Animals Following Inhalation Exposure to 
1,2,3-Trichloropropane 
 
 
  
   
 
 
 
 
 
 
 
 
 
 
       
      
    
        
      
    
  
     
 
 
      
       
 
    
   
  
    
Figure 1-2.  Health Effects Found in Animals Following Oral Exposure to 
1,2,3-Trichloropropane 
Dose (mg/kg/day) 
171-180 
111-120 
81-90 
51-60 
41-50 
1-10 
11-20 
21-30 
0.06 mg/kg/day 
0.005 mg/kg/day 
Effects in Animals 
Acute: Necrosis in liver and kidney 
Acute: Heart inflammation, degeneration, and necrosis 
Intermediate: Impaired reproduction in offspring 
Intermediate: Necrosis in nasal turbinates; hepatocellular necrosis and 
hemorrhage 
Intermediate: Heart inflammation, degeneration, necrosis 
Intermediate: Regeneration of bronchiolar epithelium; regenerative
hyperplasia in kidneys; impaired reproduction 
Chronic: Bronchiole hyperplasia; hepatocellular necrosis 
Acute: Increased liver weight 
Intermediate: increased kidneyweight 
Chronic: Bile duct hyperplasia 
Intermediate: Increased liver weight, decreased erythrocyte parameters 
Chronic: Increased liver and kidney weight, increased severityof
nephropathy, neoplastic lesions in oral mucosa and forestomach 
Provisional Intermediate MRL 
Provisional Chronic MRL 
31,2,3-TRICHLOROPROPANE
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Respiratory Effects.  Throat irritation was observed in humans exposed to 1,2,3-trichloropropane for 
15 minutes (Silverman et al. 1946).  The respiratory tract, specifically the nasal olfactory epithelium, is 
the most sensitive target of toxicity in experimental animals following inhalation exposure to 1,2,3-tri-
chloropropane.  The earliest sign of toxicity in the olfactory epithelium is a decrease in epithelial 
thickness; at higher concentrations, degeneration, inflammation, and fibrosis occur (Miller et al. 1986a, 
1986b).  Peribronchial hyperplasia has also been observed in rats following inhalation exposure 
(Johannsen et al. 1988).  Oral exposure to relatively high doses of 1,2,3-trichloropropane also resulted in 
inflammation and necrotic lesions in the nasal cavity of rats and mice following acute- or intermediate-
duration exposure (NTP 1993) and regenerative hyperplasia of bronchiolar epithelium in mice following 
chronic exposure (NTP 1993).  Additionally, lung hemorrhages have resulted in rabbits administered a 
lethal dermal dose of 1,2,3-trichloropropane (Alpert 1982; Union Carbide 1958). 
 
Cardiovascular Effects.  Heart inflammation, degeneration, and necrosis have been observed in rats 
administered 1,2,3-trichloropropane for an acute- or intermediate-duration exposure (Merrick et al. 1991).  
However, other oral studies and inhalation studies have not found histological alterations in the heart 
(Johannsen et al. 1988; Miller et al. 1986a; NTP 1993; Villeneuve et al. 1985). 
 
Hematological Effects.  Decreases in hematocrit, hemoglobin, and erythrocyte levels have been observed 
in rats following intermediate-duration oral exposure (NTP 1993); the resulting anemia appeared to be 
due to depressed erythropoiesis.  Similar decreases in hematological parameters were also observed in 
rats and mice following chronic oral exposure, but this may have been due to blood loss associated with 
tumors (NTP 1993).  In addition to the alterations in hematological parameters, splenic extramedullary 
hematopoiesis has been observed following inhalation (Johannsen et al. 1988) and oral (NTP 1993) 
exposures. 
 
Liver Effects.  Human data on the hepatotoxicity of 1,2,3-trichloropropane is limited to a case report of an 
individual with rapid progressive degeneration of liver function after ingesting 1,2,3-trichloropropane 
(Han 2010).  Evidence of liver damage has been observed in rats and mice following inhalation or oral 
exposure.  Observed effects include increases in liver weight, often observed at lower doses than those 
associated with histological damage; clinical chemistry alterations including alterations in serum 
enzymes, increases in serum bilirubin, and decreases in pseudocholinesterase levels; hepatocellular 
vacuolization; hepatocellular necrosis; and bile duct hyperplasia (Johannsen et al. 1988; Merrick et al. 
1991; NTP 1993; Villeneuve et al. 1985).  Following oral exposure, liver damage is one of the most 
sensitive effects. 
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Kidney Effects.  The kidney is one of the most sensitive targets of toxicity following oral exposure.  
Increases in kidney weight were observed at lower doses; at higher doses, regenerative hyperplasia, 
tubular necrosis, and increases in the severity of chronic nephropathy have been observed (NTP 1993; 
Villeneuve et al. 1985).  In contrast, renal effects have not been observed following inhalation exposure 
(Johannsen et al. 1988; Miller et al. 1986a). 
Cancer Effects.  The carcinogenicity of 1,2,3-trichloropropane was evaluated in rats and mice in a 
chronic gavage study (NTP 1993).  In both species, forestomach squamous cell papillomas or carcinomas 
were observed at the lowest doses tested.  Other sites with neoplastic lesions included the oral mucosa, 
liver, renal tubules, clitoral gland, mammary gland, preputial gland, harderian gland, and Zymbal’s gland. 
The U.S. Department of Health and Human Services categorized 1,2,3-trichloropropane as reasonably 
anticipated to be a human carcinogen (NTP 2016), the U.S. Environmental Protection Agency (EPA) 
categorized it as likely to be carcinogenic to humans (EPA 2009b), and the International Agency for 
Research on Cancer (IARC) categorized it as a suspected human carcinogen (IARC 2017). 
1.3   MINIMAL RISK LEVELS (MRLs) 
The inhalation database was considered adequate for derivation of a provisional acute-duration inhalation 
MRL for 1,2,3-trichloropropane.  The data were not considered adequate for derivation of an 
intermediate-duration inhalation MRL and no chronic inhalation studies were identified.  As presented in 
Figure 1-3, the available inhalation data for 1,2,3-trichloropropane suggest that the respiratory tract, 
hematological erythrocyte, liver, and eyes are sensitive targets of toxicity.   
The oral database was considered adequate for derivation of a provisional intermediate-duration oral 
MRL and a provisional chronic-duration oral MRL for 1,2,3-trichloropropane.  The liver, kidney, 
erythrocytes, and cancer are sensitive targets following oral exposure to 1,2,3-trichloropropane.  
Reproductive and cardiovascular endpoints also have relatively low lowest-observed-adverse-effect level 
(LOAEL) values, as illustrated in Figure 1-4.  The MRL values are summarized in Table 1-1 and 
discussed in greater detail in Appendix A. 
***DRAFT FOR PUBLIC COMMENT*** 
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Figure 1-3.  Summary of Sensitive Targets of 1,2,3-Trichloropropane – Inhalation 
  
The respiratory tract, liver, erythrocyte, and eye are the most sensitive targets of 
1,2,3-trichloropropane.   
Numbers in triangles and circles are the lowest LOAELs among health effects 
in humans and animals, respectively.  
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Figure 1-4.  Summary of Sensitive Targets of 1,2,3-Trichloropropane – Oral 
  
The heart, liver, erythrocyte, and kidney are the most sensitive targets of 1,2,3-trichloropropane.   
Numbers in circles are the lowest LOAELs for all health effects in animals; no reliable dose-response data 
were available for humans. 
 
 
 
   
 
 
 
 
 
 
 
 
 
 
   
 
 
 
 
 
  
   
  
 
 
    
 
 
  
 
  
 
 
 
 
 
Table 1-1.  Minimal Risk Levels (MRLs) for 1,2,3-Trichloropropane
81,2,3-TRICHLOROPROPANE
1.  RELEVANCE TO PUBLIC HEALTH
a 
Exposure 
duration MRL Critical effect 
Point of 
departure 
Uncertainty 
factor Reference 
Inhalation exposure (ppm)
 Acute  0.001 Decreased thickness of NOAELHEC of 30 Miller et al. 
(provisional) nasal olfactory 
epithelium
0.03 ppm 1986b
Intermediate Insufficient data for MRL derivation
Chronic Insufficient data for MRL derivation
Oral exposure (mg/kg/day)
Acute Insufficient data for MRL derivation 
Intermediate 0.06 Increased absolute NOAEL of 100 NTP 1993
(provisional) liver weight and 5.7 mg/kg/day 
decreased hemoglobin 
and erythrocyte levels 
Chronic 0.005 Bile duct hyperplasia BMDL10 of 100 NTP 1993
(provisional) 0.47 mg/kg/day
aSee Appendix A for additional information.
BMDL = benchmark dose, 95% lower confidence limit; HEC = human equivalent concentration; NOAEL = no-
observed-adverse-effect level;
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CHAPTER 2.  HEALTH EFFECTS 
 
2.1   INTRODUCTION  
 
The primary purpose of this chapter is to provide public health officials, physicians, toxicologists, and 
other interested individuals and groups with an overall perspective on the toxicology of 1,2,3-trichloro-
propane.  It contains descriptions and evaluations of toxicological studies and epidemiological 
investigations and provides conclusions, where possible, on the relevance of toxicity and toxicokinetic 
data to public health.  When available, mechanisms of action are discussed along with the health effects 
data; toxicokinetic mechanistic data are discussed in Section 3.1.   
 
A glossary and list of acronyms, abbreviations, and symbols can be found at the end of this profile. 
 
To help public health professionals and others address the needs of persons living or working near hazardous 
waste sites, the information in this section is organized by health effect.  These data are discussed in terms of 
route of exposure (inhalation, oral, and dermal) and three exposure periods:  acute (≤14 days), intermediate 
(15–364 days), and chronic (≥365 days). 
 
As discussed in Appendix B, a literature search was conducted to identify relevant studies examining health 
effect endpoints.  Figure 2-1 provides an overview of the database of studies in humans or experimental 
animals included in this chapter of the profile.  These studies evaluate the potential health effects associated 
with inhalation, oral, or dermal exposure to 1,2,3-trichloropropane, but may not be inclusive of the entire 
body of literature.   
 
Human and animal inhalation studies are presented in Table 2-1 and Figure 2-2, animal oral studies are 
presented in Table 2-2 and Figure 2-3, and animal dermal/ocular studies are presented in Table 2-3. 
 
Levels of significant exposure (LSEs) for each route and duration are presented in tables and illustrated in 
figures.  The points in the figures showing no-observed-adverse-effect levels (NOAELs) or lowest-
observed-adverse-effect levels (LOAELs) reflect the actual doses (levels of exposure) used in the studies.  
LOAELs have been classified into "less serious" or "serious" effects.  "Serious" effects are those that 
evoke failure in a biological system and can lead to morbidity or mortality (e.g., acute respiratory distress 
or death).  "Less serious" effects are those that are not expected to cause significant dysfunction or death, 
or those whose significance to the organism is not entirely clear.  ATSDR acknowledges that a 
considerable amount of judgment may be required in establishing whether an endpoint should be 
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classified as a NOAEL, "less serious" LOAEL, or "serious" LOAEL, and that in some cases, there will be 
insufficient data to decide whether the effect is indicative of significant dysfunction.  However, the 
Agency has established guidelines and policies that are used to classify these endpoints.  ATSDR believes 
that there is sufficient merit in this approach to warrant an attempt at distinguishing between "less 
serious" and "serious" effects.  The distinction between "less serious" effects and "serious" effects is 
considered to be important because it helps the users of the profiles to identify levels of exposure at which 
major health effects start to appear.  LOAELs or NOAELs should also help in determining whether the 
effects vary with dose and/or duration, and place into perspective the possible significance of these effects 
to human health.  Levels of exposure associated with cancer (Cancer Effect Levels, CELs) of 1,2,3-tri-
chloropropane are indicated in Table 2-2 and Figure 2-3.   
 
A User's Guide has been provided at the end of this profile (see Appendix C).  This guide should aid in 
the interpretation of the tables and figures for LSEs and MRLs. 
 
The health effects of 1,2,3-trichloropropane have been primarily evaluated in experimental animal 
studies.  As illustrated in Figure 2-1, approximately half of the health effects data come from oral 
exposure studies in animals.  Animal data are available for each health effect category and exposure 
duration category.  The most examined endpoints in inhalation and oral studies were hepatic, body 
weight, respiratory, and renal; approximately 40% of the studies examine each of these endpoints.  
Dermal/ocular exposure studies primarily focused on portal-of-entry effects.  Human data are limited to 
three studies examining portal-of-entry effects following exposure to airborne 1,2,3-trichloropropane, 
developmental toxicity in the general population, and a case report of liver effects following ingestion.  
Based on these data, the following targets of toxicity have been identified: 
 
• Respiratory Endpoints:  Damage to the nasal olfactory epithelium have been observed in rats 
and mice following acute and intermediate inhalation exposure.  Necrosis has also been observed 
in the nasal cavity following oral exposure.  Throat irritation was reported in humans following a 
short exposure to a relatively high concentration of 1,2,3-trichloropropane.  Peribronchial 
hyperplasia, bronchiolar epithelial regenerative hyperplasia, and lung hemorrhages have been 
observed in experimental animals following inhalation, oral, and dermal exposure, respectively. 
 
• Hepatic Endpoints:  Hepatic effects have been observed in a case study of an individual 
ingesting 1,2,3-trichloropropane and in experimental animal studies following acute and 
intermediate inhalation exposure and acute, intermediate, or chronic oral studies.  Increases in 
liver weight, hepatocellular vacuolization, and bile duct hyperplasia were observed in these 
studies.   
 
• Renal Endpoints:  Renal effects have been observed in experimental animals following acute, 
intermediate, and chronic oral exposure.  Effects included increases in kidney weight, 
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regenerative tubular hyperplasia, tubular necrosis, and increases in the severity of chronic 
nephropathy.   
 
• Hematological Endpoints:  Anemia, as evidenced by decreases in hematocrit, hemoglobin, and 
erythrocyte levels, and/or splenic extramedullary hematopoiesis have been observed in 
experimental animals following inhalation and oral exposure. 
 
• Cancer Endpoints.  Chronic oral exposure resulted in increases in neoplastic lesions in multiple 
sites in rats and mice.  The most sensitive target tissue appears to be the forestomach; squamous 
cell papillomas and carcinomas in the forestomach were observed at the lowest doses tested.  
Other targets included the oral mucosa, liver, and kidneys.   
 
• Other Endpoints.  Alterations in body weight, lacrimation, impaired reproduction, and 
developmental toxicity have also been observed in inhalation and/or oral exposure studies in 
experimental animals; however, these do not appear to be sensitive targets of 1,2,3-trichloro-
propane toxicity. 
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Figure 2-1.  Overview of the Number of Studies Examining 1,2,3-Trichloropropane Health Effects 
  
Most studies examined the potential hepatic, respiratory, body weight, and renal effects of 1,2,3-trichloropropane. 
Fewer studies evaluated health effects in humans than animals (counts represent studies examining endpoint) 
 
 
*Includes studies discussed in Chapter 2.  A total of 32 studies (including those finding no effect) have examined toxicity; most studies examined multiple 
endpoints. 
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Table 2-1.  Levels of Significant Exposure to 1,2,3-Trichloropropane – Inhalation 
 
Figure 
keya 
Species 
(strain) 
No./group 
Exposure 
parameters 
Doses 
(ppm) 
Parameters 
monitored Endpoint 
NOAEL 
(ppm) 
Less 
serious 
LOAEL 
(ppm) 
Serious 
LOAEL 
(ppm) Effect 
ACUTE EXPOSURE 
1 Human 
12 
1 days 
15 minutes/day 
50, 100 CS Resp  100  Throat irritation 
   Ocular  100  Eye irritation 
Silverman et al. 1946 
2 Rat 
(F344) 
6 M 
1 day 
4 hours/day 
0, 126, 
343, 697, 
2,160 
CS, GN Death   697 100% death at 697 and 2,160 ppm  
   Ocular  126  Eye irritation 
Gushow and Quast 1984 
3 Rat 
(CD) 
5 M, 5 F 
1 day 
6 hours/day 
0, 888 CS Death   888 9/10 died 
Johannsen et al. 1988 
4 Rat 
(F344) 
5 M, 5 F 
11 days 
9 exposures 
6 hours/day 
0, 13, 40, 
132 
HP, BC, BI, 
OW, BW 
Death    No deaths observed 
   Bd wt 40 132  10–15% decrease in body weight 
gain 
   Resp  13  Degeneration and inflammation of 
nasal olfactory epithelium at 
≥13 ppm; multifocal fibrosis in nasal 
submucosa at 132 ppm 
   Cardio 132    
   Gastro 132    
   Hemato 132    
   Musc/skel 132    
   Hepatic 40 132  Very slight hepatocellular necrosis 
   Renal 132    
   Endocr 132    
   Immuno 132   No histological alterations in 
thymus or lymphoid tissue 
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Table 2-1.  Levels of Significant Exposure to 1,2,3-Trichloropropane – Inhalation 
 
Figure 
keya 
Species 
(strain) 
No./group 
Exposure 
parameters 
Doses 
(ppm) 
Parameters 
monitored Endpoint 
NOAEL 
(ppm) 
Less 
serious 
LOAEL 
(ppm) 
Serious 
LOAEL 
(ppm) Effect 
     Neuro 132   No histological alterations in brain, 
spinal cord, or peripheral nerves 
     Repro 132   No histological alterations in 
reproductive tissues 
Miller et al. 1986a 
5 Rat 
(F344) 
5 M, 5 F 
11 days 
9 exposures 
6 hours/day 
0, 1, 3, 10 HP, OW, GN, 
BW 
Resp 1b 3  Decreased thickness of olfactory 
epithelium 
Miller et al. 1986b 
6 Rat 
(Carworth-
Wistar) 
6 NS 
1 day 
4 hours/day 
1,000 CS Death   1,000 5/6 died within 14-day observation 
period 
        
Smyth et al. 1962 
7 Rat 
(NS) 
6 F 
1 day 
1–4 hours/day 
500, 
1,000, 
2,000, 
5,650 
CS Death   500 4/6 died 
Union Carbide 1958 
8 Mouse 
(B6C3F1) 
6 M 
1 day 
4 hours/day 
0, 126, 
343, 697, 
2,160 
CS, GN Death   343 100% death at 697 and 2,160 ppm 
Gushow and Quast 1984 
9 Mouse 
(B6C3F1) 
6 M 
11 days 
9 exposures 
6 hours/day 
0, 13, 40, 
132 
CS, GN Death    No deaths observed 
  Bd wt 132    
  Resp  13  Decreased thickness of olfactory 
epithelium at 13 ppm and subacute 
inflammation of olfactory epithelium 
at ≥40 ppm 
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Table 2-1.  Levels of Significant Exposure to 1,2,3-Trichloropropane – Inhalation 
Figure 
keya 
Species 
(strain) 
No./group 
Exposure 
parameters 
Doses 
(ppm) 
Parameters 
monitored Endpoint 
NOAEL 
(ppm) 
Less 
serious 
LOAEL 
(ppm) 
Serious 
LOAEL 
(ppm) Effect 
Cardio 132 
Gastro 132 
Hemato 132 
Musc/skel 132 
Hepatic 40 132 Hepatocellular vacuolization 
Renal 132 
Miller et al. 1986a 
10 Mouse 
(B6C3F1) 
5 M, 5 F 
11 days 
9 exposures 
6 hours/day 
0, 1, 3, 10 HP, OW, GN, 
BW 
Resp 3 10 Nasal olfactory inflammation 
Miller et al. 1986b 
INTERMEDIATE EXPOSURE 
11 Rat 
(CD) 
5 M, 5 F 
4 weeks 
5 days/week 
6 hours/day 
0, 95, 
297, 
579 
BW, OW, 
GN, CS 
Death 579 3/10 rats died 
Bd wt 297 Decreased weight gain 
Resp 597 
Hepatic 95 Increased liver weight 
Renal 579 
Immuno 579 Decreased spleen weight 
Neuro 579 No histological alterations 
Repro 579 No histological alterations 
Johannsen et al. 1988 
12 Rat 
(CD) 
15 M, 15 F 
13 weeks 
5 days/week 
6 hours/day 
0, 0.5, 
1.54, 4.5, 
15, 49 
OW, GN, HP, 
BC, UR, CS 
Resp 1.54 4.5 Peribronchial hyperplasia 
Cardio 49 
Gastro 49 
Hemato 4.5F Extramedullary hematopoiesis in 
spleen 
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Table 2-1.  Levels of Significant Exposure to 1,2,3-Trichloropropane – Inhalation 
 
Figure 
keya 
Species 
(strain) 
No./group 
Exposure 
parameters 
Doses 
(ppm) 
Parameters 
monitored Endpoint 
NOAEL 
(ppm) 
Less 
serious 
LOAEL 
(ppm) 
Serious 
LOAEL 
(ppm) Effect 
 Musc/skel 49    
 Hepatic 1.54M 4.5M  Midzonal hepatocellular 
hypertrophy 
 Renal 49    
     Ocular 4.5 15  Excessive lacrimation 
Johannsen et al. 1988 
13 Rat 
(CD) 
10 M, 20 F 
10 weeks 
premating 
period, 30–
40 day mating 
period, and 
GDs 0–14 
5 days/week 
6 hours/day 
0, 0.49, 
1.47, 4.5, 
15 
OW, CS, OF, 
GN, HP, DX 
Repro 15    
Johannsen et al. 1988 
 
aThe number corresponds to entries in Figure 2-2. 
bUsed to derive an acute inhalation Minimal Risk Level (MRL) of 0.001 ppm; NOAEL dose adjusted for intermittent exposure, converted to an equivalent 
concentration in humans, and divided by an uncertainty factor of 30 (3 for extrapolation from animals to humans with dosimetric adjustments, and 10 for human 
variability). 
 
BC = blood chemistry; Bd Wt or BW = body weight; BI = biochemical changes; Cardio = cardiovascular; CS = clinical signs; DX = developmental toxicity; 
Endocr = endocrine; F = female(s); Gastro = gastrointestinal; GD = gestation day; GN = gross necropsy; Hemato = hematological; HP = histopathology; 
Immuno = immunological; LOAEL = lowest-observed-adverse-effect level; M = male(s); Musc/skel = musculoskeletal; Neuro = neurological; NOAEL = no-
observed-adverse-effect level; NS = not specified; OF = organ function; OW = organ weight; Resp = respiratory; UR = urinalysis 
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Figure 2-2.  Levels of Significant Exposure to 1,2,3-Trichloropropane – Inhalation 
Acute (≤14 days) 
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Figure 2-2.  Levels of Significant Exposure to 1,2,3-Trichloropropane – Inhalation 
Acute (≤14 days) 
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Figure 2-2.  Levels of Significant Exposure to 1,2,3-Trichloropropane – Inhalation 
Intermediate (15-364 days) 
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Figure 2-2.  Levels of Significant Exposure to 1,2,3-Trichloropropane – Inhalation 
Intermediate (15-364 days) 
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Table 2-2.  Levels of Significant Exposure to 1,2,3-Trichloropropane – Oral 
 
Figure 
keya 
Species 
(strain) 
No./group 
Exposure 
parameters 
Doses 
(mg/kg/day) 
Parameters 
monitored Endpoint 
NOAEL 
(mg/kg/day) 
Less 
serious 
LOAEL 
(mg/kg/day) 
Serious 
LOAEL 
(mg/kg/day) Effect 
ACUTE EXPOSURE 
1 Rat 
(Sprague-
Dawley) 
5 M, 5 F 
1 time  
(G) 
78, 139, 250, 
445, 778, 
1,390, 2,500 
GN, CS Death   150 LD50 
Alpert 1982 
2 Rat 
(Wistar) 
10 M 
14 days 
1 time/day 
(GO) 
0, 15, 60 HP Bd Wt 60    
   Renal 60    
   Repro 60   No histological alterations 
in male reproductive 
tissues 
Dix 1979 
3 Rat 
(Sprague-
Dawley) 
10 M, 10 F 
10 days 
(GO) 
0, 1.5, 7.4, 
29.5, 118 
BW, OW, HP Bd wt 29.5 118  22–25% decrease body 
weight gain 
Cardio  29.5 118  Heart inflammation, 
degeneration, and necrosis 
Hepatic 7.4 29.5  Increased relative liver 
weight 
Immuno 29.5 118  Diffuse thymic atrophy 
Merrick et al. 1991 
4 Rat 
(F344) 
20 M, 20 F 
2 weeks 
5 days/week 
(GO) 
0, 8, 16, 32, 
63, 125, 250 
GN, CS, HP Death   250 100% mortality 
   Resp  250  Nasal necrosis 
   Hepatic   250 Necrosis 
   Renal   250 Necrosis 
NTP 1993 
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Table 2-2.  Levels of Significant Exposure to 1,2,3-Trichloropropane – Oral 
 
Figure 
keya 
Species 
(strain) 
No./group 
Exposure 
parameters 
Doses 
(mg/kg/day) 
Parameters 
monitored Endpoint 
NOAEL 
(mg/kg/day) 
Less 
serious 
LOAEL 
(mg/kg/day) 
Serious 
LOAEL 
(mg/kg/day) Effect 
5 Rat 
(NS) 
15 M 
5 days 
1 time/day 
(GO) 
0, 80 HP, OF, FX Repro 80   No evidence of dominant 
lethality or histological 
alterations in testes 
Saito-Suzuki et al. 1982 
6 Rat 
(Carworth-
Wistar) 
5 M 
1 time  
(G) 
 CS Death   444 LD50 
Smyth et al. 1962 
7 Mice 
(Swiss)  
8 M, 8 F 
14 days 
(GO) 
0, 12,5, 25,0, 
50.0, 100.0, 
200.0 
CS, BW Bd wt 200    
NTP 1990 
INTERMEDIATE EXPOSURE 
8 Rat 
(Sprague-
Dawley) 
10 M, 10 F 
90 days 
(GO) 
0, 1.5, 7.4, 
14.7, 58.9 
BW, OW, HP Bd wt 14.7 58.9  14–20% decrease in body 
weight gain 
Cardio 14.7 58.9  Heart inflammation, 
degeneration, and necrosis 
Hepatic 7.4 14.7  Increased relative liver 
weight at ≥14.7 mg/kg/day; 
bile duct hyperplasia at 
58.9 mg/kg/day 
 Immuno 14.7 58.9  Plasma cell hyperplasia in 
mandibular lymph nodes 
Merrick et al. 1991 
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Table 2-2.  Levels of Significant Exposure to 1,2,3-Trichloropropane – Oral 
 
Figure 
keya 
Species 
(strain) 
No./group 
Exposure 
parameters 
Doses 
(mg/kg/day) 
Parameters 
monitored Endpoint 
NOAEL 
(mg/kg/day) 
Less 
serious 
LOAEL 
(mg/kg/day) 
Serious 
LOAEL 
(mg/kg/day) Effect 
9 Rat 
(F344) 
20 M, 20 F 
17 weeks 
5 days/week 
(GO) 
0, 8, 16, 32, 
63, 125, 250 
OW, GN, HP, 
BC, FI 
Death   125 One male and five females 
died  
 Bd Wt 32 M 63 M  11 and 21% decreases in 
body weight gain in males 
at 63 and 125 mg/kg; 24% 
decrease in females at 
125 mg/kg 
 Resp 63 125  Necrosis in nasal turbinates 
 Cardio 125    
 Gastro 125    
 Hemato 8b 16  Decreases in hematocrit, 
hemoglobin, and 
erythrocyte levels after 
8 and 17 weeks 
  Musc/skel 125    
    Hepatic 8 Fb 16 F  Increases in liver weight in 
females at ≥16 mg/kg; 
hepatocellular necrosis and 
hemorrhage and bile duct 
hyperplasia in females at 
≥125 mg/kg 
    Renal 16 M 32 M  Increases in absolute and 
relative kidney weights in 
males at ≥32 mg/kg; 
Regenerative hyperplasia 
after 8 weeks of exposure 
at ≥63 mg/kg 
     Endocr 125    
NTP 1993 
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Table 2-2.  Levels of Significant Exposure to 1,2,3-Trichloropropane – Oral 
 
Figure 
keya 
Species 
(strain) 
No./group 
Exposure 
parameters 
Doses 
(mg/kg/day) 
Parameters 
monitored Endpoint 
NOAEL 
(mg/kg/day) 
Less 
serious 
LOAEL 
(mg/kg/day) 
Serious 
LOAEL 
(mg/kg/day) Effect 
10 Rat  
(Sprague-
Dawley) 
10 M,10 F 
13 weeks 
7 days/week 
(W) 
M:  0, 0.17, 
1.7, 17, 113; 
F:  0, 0.26, 
2.6, 17.6, 
149 
OW, BC, GN, 
HP, BI, WI 
Death    No deaths were observed 
 Bd Wt 17 113  Reduced body weight gain 
 Cardio 149    
 Hemato 149    
 Hepatic 17 M 113 M  Anisokaryosis, accentuated 
zonation and fatty 
vacuolation 
 Hepatic 17.6 F 149 F  Biliary hyperplasia in 
females only 
 Renal 17 113  Eosinophilic inclusions, 
pyknosis, nuclear 
displacement, fine 
glomerular adhesions, 
interstitial reactions, and 
histologic proteinuria 
 Endocr 17 113  Angular collapse of some 
follicles, reduced colloid 
density, increased epithelial 
height in thyroid 
Villeneuve et al. 1985 
11 Mouse 
(B6C3F1) 
20 M, 20 F 
17 weeks 
5 days/week 
(GO) 
0, 8, 16, 32, 
63, 125, 250 
HP, OW, BC, 
BI, GN, OF, 
FI 
Death   250 Majority of deaths occurred 
by week 2 in females and 
week 4 in males 
   Bd Wt 250    
   Resp 32 F 63 F  Regeneration of 
bronchiolar epithelium in 
the lungs of males at 
≥125 mg/kg and females at 
≥63 mg/kg 
   Cardio 250    
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Table 2-2.  Levels of Significant Exposure to 1,2,3-Trichloropropane – Oral 
 
Figure 
keya 
Species 
(strain) 
No./group 
Exposure 
parameters 
Doses 
(mg/kg/day) 
Parameters 
monitored Endpoint 
NOAEL 
(mg/kg/day) 
Less 
serious 
LOAEL 
(mg/kg/day) 
Serious 
LOAEL 
(mg/kg/day) Effect 
   Gastro 32 F 63 F  Hyperkeratosis and 
acanthosis of forestomach 
   Hemato 250    
   Musc/skel 250    
   Hepatic 63 125  Increased liver weights at 
≥125 mg/kg; focal 
hepatocellular necrosis at 
250 mg/kg  
   Renal 125  250 Multifocal tubular necrosis 
in animals dying early 
     Endocr 125    
NTP 1993 
12 Mice 
(Swiss) 
20 M, 20 F 
 
98 days 
(GO) 
0, 30.0, 60.0, 
120.0 
CS, BW, FX Repro 30 60  Decreased number of live 
pups in 5th litter and 
decreased fertility; at 
120 mg/kg/day: decreased 
number of litters starting at 
the 3rd breeding, increased 
days to litter in the 4th and 
5th litters, and decreased 
number of live pups per 
litter in 2–5 litters 
   Repro 120 M   No alterations in epididymal 
sperm motility, count, or 
morphology  
   Repro  120 F  Ovarian amyloidosis; no 
alterations in average 
estrous cycle length 
NTP 1990 
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Table 2-2.  Levels of Significant Exposure to 1,2,3-Trichloropropane – Oral 
 
Figure 
keya 
Species 
(strain) 
No./group 
Exposure 
parameters 
Doses 
(mg/kg/day) 
Parameters 
monitored Endpoint 
NOAEL 
(mg/kg/day) 
Less 
serious 
LOAEL 
(mg/kg/day) 
Serious 
LOAEL 
(mg/kg/day) Effect 
13 Mice 
(Swiss) 
20 M, 20 F 
Prenatal 
exposure, 
post 
weaning, 
mating, and 
gestation 
exposure 
0, 30.0, 60.0, 
120.0 
CS, BW, FX Develop 60 120  Decreases in mating, 
fertility, and pregnancy 
indices. 
NTP 1990 
CHRONIC EXPOSURE 
14 Rat 
(F344/N) 
60 M, 60 F 
 
2 years 
5 days/week 
(GO) 
0, 3, 10, 
30 mg/kg 
CS, BW, HE, 
BC, OW, HP 
Death   10 Decreased survival 
 Bd wt 10 F 30 F  15% decrease in body 
weight gain in females 
 Resp 30    
 Cardio 30    
 Gastro 3 10  Hyperkeratosis of 
esophagus and acute 
inflammation of tongue in 
females at ≥10 mg/kg and 
males at 30 mg/kg 
 Hemato 3 10  Hematopoietic cell 
proliferation in spleen at 
≥10 mg/kg; decreased 
hemoglobin, increased 
leukocytes, increased 
segmented neutrophils 
(measured after 
15 months) at 30 mg/kg 
 Musc/skel 30    
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Table 2-2.  Levels of Significant Exposure to 1,2,3-Trichloropropane – Oral 
 
Figure 
keya 
Species 
(strain) 
No./group 
Exposure 
parameters 
Doses 
(mg/kg/day) 
Parameters 
monitored Endpoint 
NOAEL 
(mg/kg/day) 
Less 
serious 
LOAEL 
(mg/kg/day) 
Serious 
LOAEL 
(mg/kg/day) Effect 
   Hepatic  3 Mc 10 M  Bile duct hyperplasia in 
males at 10 mg/kg at 
15 months (at 30 mg/kg 
after 2 years); increased 
liver weight at ≥10 mg/kg 
   Renal  3 M  Increased absolute kidney 
weight at ≥3 mg/kg; renal 
tubular hyperplasia at 
≥10 mg/kg (males only) 
and increased severity of 
nephropathy (males only); 
renal tubular hyperplasia in 
females at 30 mg/kg 
   Endocr  3  Focal hyperplasia of 
pancreatic acini 
   Repro 10 30  Interstitial cell hyperplasia 
in testes 
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Table 2-2.  Levels of Significant Exposure to 1,2,3-Trichloropropane – Oral 
 
Figure 
keya 
Species 
(strain) 
No./group 
Exposure 
parameters 
Doses 
(mg/kg/day) 
Parameters 
monitored Endpoint 
NOAEL 
(mg/kg/day) 
Less 
serious 
LOAEL 
(mg/kg/day) 
Serious 
LOAEL 
(mg/kg/day) Effect 
   Cancer   3  CEL: squamous cell 
papillomas or carcinomas 
in forestomach and 
adenomas of the pancreas; 
at ≥10 mg/kg: squamous 
cell papillomas or 
carcinomas in oral mucosa, 
adenoma in renal tubules, 
adenoma or carcinoma of 
the clitoral gland, and 
adenocarcinoma of the 
mammary gland (females 
only); at 30 mg/kg: 
adenoma or carcinoma in 
preputial gland, carcinoma 
in Zymbal gland (females 
only) 
NTP 1993 
15 Mouse 
(B6C3F1) 
60 M, 60 F 
 
2 years 
5 days/week 
(GO) 
 
0, 6, 20, 
60 mg/kg 
CS, BW, HE, 
SC, OW, HP 
Death    6 Decreased survival 
 Bd wt 20 60  12–18% decrease in body 
weight gain 
 Resp 20 60  Bronchiole hyperplasia 
 Cardio 60    
 Gastro  6  Squamous hyperplasia in 
forestomach in females  
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Table 2-2.  Levels of Significant Exposure to 1,2,3-Trichloropropane – Oral 
 
Figure 
keya 
Species 
(strain) 
No./group 
Exposure 
parameters 
Doses 
(mg/kg/day) 
Parameters 
monitored Endpoint 
NOAEL 
(mg/kg/day) 
Less 
serious 
LOAEL 
(mg/kg/day) 
Serious 
LOAEL 
(mg/kg/day) Effect 
 Hemato  6  Hematopoietic cell 
proliferation in spleen at 
≥6 mg/kg; decreased 
erythrocyte, hematocrit and 
hemoglobin and increased 
leukocyte and segmented 
neutrophil counts at 
60 mg/kg 
   Musc/skel 60    
   Hepatic 20 60  Hepatocellular necrosis 
and increases in relative 
liver weight 
   Renal 60    
   Ocular 60   No histological alterations 
were observed in the eye 
   Endocr 60    
   Repro 60   No histological alterations 
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Table 2-2.  Levels of Significant Exposure to 1,2,3-Trichloropropane – Oral 
 
Figure 
keya 
Species 
(strain) 
No./group 
Exposure 
parameters 
Doses 
(mg/kg/day) 
Parameters 
monitored Endpoint 
NOAEL 
(mg/kg/day) 
Less 
serious 
LOAEL 
(mg/kg/day) 
Serious 
LOAEL 
(mg/kg/day) Effect 
   Cancer   6 CEL 6 mg/kg: squamous 
cell papilloma or carcinoma 
in forestomach, 
hepatocellular adenoma or 
carcinoma in males; 
20 mg/kg:  harderian gland 
adenoma in males; 
60 mg/kg:  squamous cell 
papilloma or carcinoma in 
oral mucosa in females, 
harderian gland adenoma 
in females; uterine stromal 
polyps and endometrial 
adenoma or 
adenocarcinoma 
NTP 1993 
 
aThe number corresponds to entries in Figure 2-3; differences in levels of health effects and cancer effects between male and females are not indicated in 
Figure 2-3.  Where such differences exist, only the levels of effect for the most sensitive gender are presented. 
bUsed to derive an intermediate oral Minimal Risk Level (MRL) of 0.06 mg/kg/day based on duration-adjusted NOAEL of 5.7 mg/kg/day divided by an uncertainty 
factor of 100 (10 for extrapolation from animals to humans and 10 for human variability). 
cUsed to derive a chronic oral MRL of 0.005 mg/kg/day based on a duration adjusted BMDLRD10 of 0.47 mg/kg/day and divided by an uncertainty factor of 
100 (10 for extrapolation from animals to humans and 10 for human variability). 
 
Bd Wt = body weight; BI = biochemical changes; Cardio = cardiovascular; CEL = cancer effect level; CS = clinical signs; Endocr = endocrine; F = female(s); 
FI = food intake; FX = fetal toxicity; (G) = gavage, not specified; GN = gross necropsy; (GO) = gavage in oil vehicle; Gastro = gastrointestinal; HE = hematology; 
Hemato = hematological; HP = histopathology; Immuno = immunological; LD50 = lethal dose; 50% kill; LOAEL = lowest-observed-adverse-effect level; 
M = male(s); Musc/skel = musculoskeletal; No = number; NOAEL = no-observed-adverse-effect level; NS = not specified; OF = organ function; OW= organ 
weight; Repro = reproductive; Resp = respiratory; (W) = drinking water; WI = water intake 
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Figure 2-3.  Levels of Significant Exposure to 1,2,3-Trichloropropane – Oral  
Acute (≤14 days) 
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Figure 2-3.  Levels of Significant Exposure to 1,2,3-Trichloropropane – Oral 
Intermediate (15-364 days) 
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Figure 2-3.  Levels of Significant Exposure to 1,2,3-Trichloropropane – Oral 
Intermediate (15-364 days) 
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Figure 2-3.  Levels of Significant Exposure to 1,2,3-Trichloropropane – Oral 
Chronic (≥365 days) 
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Figure 2-3.  Levels of Significant Exposure to 1,2,3-Trichloropropane – Oral 
Chronic (≥365 days) 
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Table 2-3.  Levels of Significant Exposure to 1,2,3-Trichloropropane – Dermal 
 
Species (strain) 
No./group 
Exposure 
parameters Doses 
Parameters 
monitored Endpoint NOAEL  
Less 
serious 
LOAEL  
Serious 
LOAEL  Effect 
ACUTE EXPOSURE 
Rat  
4 M, 4 F 
24 hours 278, 556, 
695, 1,112, 
1,390 mg/kg 
CS Death   836 mg/kg LD50 
Clark 1977 
Rabbit 
(New Zealand 
white) 
6 M,6 F 
24 hours 250, 445, 
723, 1,084, 
1,390, 
2,500, 
4,450 mg/kg 
CS Death   250 mg/kg 2/6 males died 
 Resp   250 mg/kg Lung discoloration 
 Gastro   250 mg/kg Stomach ulceration 
 Hepatic   250 mg/kg Liver discoloration 
 Renal   250 mg/kg Discoloration of kidneys and 
bladder contents 
Alpert 1982 
Rabbit 
(New Zealand 
white) 
6 M,6 F 
24 hours 278 mg/kg CS Dermal  278 mg/kg  Skin irritation 
Alpert 1982 
Rabbit 
(New Zealand 
white) 
6 M,3 F 
1 time 0.1 mL CS Ocular  0.1 mL  Eye irritation 
Alpert 1982 
Rabbit 
(NS) 
4M,4F 
24 hours 0, 
174 mg/cm2 
GN, CS Dermal  174 mg/cm2  Severe skin irritation 
Clark 1977 
Rabbit (NS) 
4 NS 
1 time NS CS Ocular  0.1 mL  Eye irritation 
Clark 1977 
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Table 2-3.  Levels of Significant Exposure to 1,2,3-Trichloropropane – Dermal 
 
Species (strain) 
No./group 
Exposure 
parameters Doses 
Parameters 
monitored Endpoint NOAEL  
Less 
serious 
LOAEL  
Serious 
LOAEL  Effect 
 Rabbit 
(NS) 
7 NS 
10 times in 
15 minutes 
2 mL GN, CS Dermal  2 mL  Intense skin irritation, subdermal 
bleeding 
McOmie and Barnes 1949 
 Rabbit 
(NS) 
4 M 
1 day  
24 hours/day 
Log series CS Death   2,458 mg/kg LD50 
Smyth et al. 1962 
INTERMEDIATE EXPOSURE 
 Guinea 
pig 
(Duncan-
Hartley) 
5 M, 5 F 
3 weeks 
1 days/week 
6 hours/day 
0, 1.83 CS Dermal 0.51 mLa    
Alpert 1982 
 
aChallenge dose applied to sensitized and virgin skin for 6 hours 14 days after the last sensitizing dose.  Both sensitizing and challenge doses were covered. 
 
CS = clinical signs; F = female(s); GN = gross necropsy; LOAEL = lowest-observed-adverse-effect level; LD50 = lethal dose, 50% kill; M = male(s); NOAEL = no-
observed-adverse-effect level; NS = not specified 
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2.2   DEATH 
 
No studies were located regarding death in humans after exposure to 1,2,3-trichloropropane.  
 
Inhalation exposure to 1,2,3-trichloropropane for 4–6 hours caused death in mice at concentrations as low 
as 343 ppm (Gushow and Quast 1984) and rats at concentrations as low as 500 ppm (Gushow and Quast 
1984; Johannsen et al. 1988; Smyth et al. 1962; Union Carbide 1958).  In a repeated-exposure studies, no 
deaths were observed in rats or mice exposed to concentrations as high as 132 ppm (Miller et al. 1986a) 
for 11 days or in rats exposed to 49 ppm for 13 weeks (Johannsen et al. 1988).  The cause of death in the 
acute studies is unclear, but signs suggestive of central nervous system (CNS) impairment (e.g., 
incoordination and convulsions) have been observed prior to death in both species.  
 
Oral LD50 values of 150 mg/kg (Alpert 1982) and 444 mg/kg (Smyth et al. 1962) have been determined 
for rats.  Variations in LD50 values are apparent, which could be due to differences in animal strain, sex, 
fed/fasted state or compound purity.  The cause of death is unclear, but signs suggestive of CNS 
impairment (e.g., piloerection, salivation, ataxia, coma) prior to death and hemorrhagic damage in 
visceral tissues (e.g., liver, kidney) were observed.  Repeated gavage administration (5 days/week) of 
1,2,3-trichloropropane caused death due to liver and kidney toxicity in 15% of female rats by the 
13th week at a dose of 125 mg/kg, in 100% of female rats by week 2 at 250 mg/kg, and in 80% of female 
mice by week 4 at 250 mg/kg (NTP 1993).  Doses as high as 149 mg/kg/day were not lethal in rats, 
however, when administered in the drinking water for the 13 weeks (Villeneuve et al. 1985).  Although 
absorption of 1,2,3-trichloropropane from drinking water could have been decreased due to use of a 
solubilizer, this suggests that 1,2,3-trichloropropane may be less toxic when ingested gradually 
throughout the day than when administered as a bolus.  In chronic studies, decreases in survival were 
observed in rats and mice administered via gavage 10 or 6 mg/kg 5 days/week for 2 years (NTP 1993); 
the early deaths were likely secondary to neoplastic lesions.   
 
Single dermal doses as low as 250 mg/kg caused death in rabbits (Alpert 1982).  Dermal LD50 values of 
836 mg/kg in rats (Clark 1977) and 2,458 mg/kg in rabbits (Smyth et al. 1962) have been identified.  The 
treated skin of the animals in these studies was covered with an impervious barrier for 24 hours to prevent 
evaporation of the volatile compound.  The cause of death is unclear, but symptoms suggestive of CNS 
impairment (e.g., ataxia, tremors, coma) and internal hemorrhage have been observed.  
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2.3   BODY WEIGHT 
 
Intermittent exposure to 1,2,3-trichloropropane concentrations as high as 132 ppm for 11 days did not 
adversely affect body weight gain in rats or mice (Miller et al. 1986a).  Body weight gain was decreased 
in rats that were intermittently exposed to lethal concentrations (≥297 ppm) of 1,2,3-trichloropropane for 
4 weeks and concentrations as low as 15 ppm 1,2,3-trichloropropane for 13 weeks (Johannsen et al. 
1988).  The decreased weight gain was more severe at higher concentrations and there was initial weight 
loss at 600 ppm in the 4-week study. 
 
Reduced body weight gain occurred in rats treated with 1,2,3-trichloropropane by gavage at doses 
≥58.9 mg/kg for acute- (Kimura et al. 2016) or intermediate-durations (Kimura et al. 2016; Merrick et al. 
1991; NTP 1993; Villeneuve et al. 1985).  No effect on body weight gain was observed in mice 
administered 250 mg/kg (5 days/week) for 17 weeks (NTP 1993).  Less than 20% decreases in body 
weight gain were observed in rats and mice administered 30 or 60 mg/kg, respectively, 5 days/week for 
2 years (NTP 1993). 
 
2.4   RESPIRATORY 
 
Limited information indicates that brief exposure (15 minutes) to 100 ppm 1,2,3-trichloropropane (purity 
unknown) can cause throat irritation in humans (Silverman et al. 1946).  Repeated exposure of animals to 
1,2,3-trichloropropane concentrations much lower than 100 ppm causes respiratory system effects that are 
indicative of irritant action.  Intermittent 6-hour exposures for 11 days produced alterations in nasal 
tissues, particularly of the olfactory epithelium, of rats and mice (Miller et al. 1986a, 1986b).  These 
changes included decreased thickness of the olfactory epithelium in rats and mice at 3 ppm, degeneration 
of the olfactory epithelium in rats at ≥10 ppm concentrations, and inflammation and decreased thickness 
of the olfactory epithelium in mice at 3–13 ppm with degeneration at higher concentrations.  At 132 ppm, 
nasal submucosal fibrosis was observed in rats (Miller et al. 1986a).  Intermittent exposure to ≥4.5 ppm 
for 13 weeks caused focal peribronchial hyperplasia in rats (Johannsen et al. 1988).  
 
Nasal effects have also been observed in rats and mice orally administered 1,2,3-trichloropropane.  These 
changes were produced by daily doses of 250 mg/kg (rats and mice) for 2 weeks and 125 mg/kg (rats) or 
250 mg/kg (mice) for up to 17 weeks.  Effects were similar in both species; these typically included 
inflammation, attenuation of the epithelial lining, and necrotic alterations, and principally occurred in the 
dorsal posterior areas of the nasal passages.  The oral doses that produced the nasal alterations were in the 
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near lethal range.  Repeated daily exposure of mice to lower doses of 1,2,3-trichloropropane (as low as 
63 mg/kg) by oral intubation over a period of 17 weeks or 60 mg/kg for 2 years caused regenerative 
changes (e.g., hyperplasia) in the bronchiolar epithelium (NTP 1993).   
 
Lung hemorrhage and apparently related effects (e.g., discoloration of the lungs and liquid in the thoracic 
cavity) have been observed in rabbits exposed to lethal dermal doses of 1,2,3-trichloropropane (Alpert 
1982; Union Carbide 1958). 
 
2.5   CARDIOVASCULAR 
 
No studies were located regarding cardiovascular effects in humans after exposure to 1,2,3-trichloro-
propane.  There were no histopathological changes in the hearts of rats and mice that were intermittently 
exposed to concentrations as high as 132 ppm 1,2,3-trichloropropane for 11 days (Miller et al. 1986a) or 
rats that were similarly exposed to up to 49 ppm 1,2,3-trichloropropane for 13 weeks (Johannsen et al. 
1988). 
 
Animal studies found that administration by gavage of 1,2,3-trichloropropane resulted in heart 
inflammation, degeneration, and necrosis in rats administered 118 mg/kg/day for 10 days (Merrick et al. 
1991) or 58.9 mg/kg/day for 90 days (Merrick et al. 1991).  In contrast, other studies have not found 
histological alterations in the heart of rats administered 125 mg/kg by gavage 5 days/week for 17 weeks 
(NTP 1993), 149 mg/kg/day by drinking water for 13 weeks (Villeneuve et al. 1985), or 30 mg/kg 
administered by gavage 5 days/week for 2 years (NTP 1993), or in mice administered 250 mg/kg 
5 days/week for 17 weeks (NTP 1993) or 60 mg/kg 5 days/week for 2 years (NTP 1993).  
 
2.6   GASTROINTESTINAL 
 
No studies were located regarding gastrointestinal effects in humans after exposure to 1,2,3-trichloro-
propane.  
 
There were no histopathological changes in the stomach and intestines of rats and mice that were 
intermittently exposed to airborne concentrations as high as 132 ppm 1,2,3-trichloropropane for 11 days 
(Miller et al. 1986a) or rats that were similarly exposed to up to 49 ppm 1,2,3-trichloropropane for 
13 weeks (Johannsen et al. 1988). 
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In mice administered 63 mg/kg 1,2,3-trichloropropane for 17 weeks (5 days/week), hyperkeratosis and 
acanthosis of the forestomach were observed (NTP 1993).  Chronic exposure also resulted in 
gastrointestinal lesions.  Hyperkeratosis of the esophagus and acute inflammation of the tongue were 
observed in female rats administered via gavage (5 days/week) 10 mg/kg and in male rats administered 
30 mg/kg (NTP 1993).  In female mice, squamous hyperplasia was observed in the forestomach following 
5 days/week administration of 6 mg/kg (NTP 1993).  Ulceration of the stomach wall was observed in 
rabbits dermally exposed to lethal dermal doses of 1,2,3-trichloropropane (Alpert 1982).  
 
2.7   HEMATOLOGICAL 
 
No studies were located regarding hematological effects in humans after exposure to 1,2,3-trichloro-
propane.  Hematological evaluations were normal in rats and mice that were intermittently exposed to 
inhalation concentrations as high as 132 ppm 1,2,3-trichloropropane for 11 days (Miller et al. 1986a).  
Hematological evaluations of rats that were similarly exposed to up to 49 ppm 1,2,3-trichloropropane for 
13 weeks also were normal, but splenic extramedullary hematopoiesis was increased at ≥4.5 ppm 
(Johannsen et al. 1988).  Although increased splenic hematopoiesis was observed, other hematology 
parameters were unremarkable.  Spleen weights were decreased in rats that were intermittently exposed to 
579 ppm 1,2,3-trichloropropane for 4 weeks, but the hematological significance of this effect cannot be 
determined because evaluation of hematology and histology was not performed (Johannsen et al. 1988). 
 
An oral study found evidence of anemia, indicated by decreased hematocrit, hemoglobin, and erythrocyte 
counts, in rats that were administered 1,2,3-trichloropropane by gavage (5 days/week) at doses as low as 
16 mg/kg over a period of 17 weeks (NTP 1993).  The anemia was mild at the lower doses and appears to 
be nonregenerative and associated with depressed erythropoiesis.  1,2,3-Trichloropropane did not produce 
significant hematological alterations in rats when administered in the drinking water at doses as high as 
149 mg/kg/day for 13 weeks (Villeneuve et al. 1985) or in mice administered up to 250 mg/kg via gavage 
(5 days/week) for 17 weeks (NTP 1993).  Chronic administration of 10 mg/kg in rats and 6 mg/kg in mice 
resulted in hematopoietic cell proliferation in the spleen (NTP 1993); higher doses (30 and 60 mg/kg in 
rats and mice, respectively) resulted in decreased erythrocyte, hematocrit, and hemoglobin concentrations.  
The investigators noted that the hematological effects were likely due to depressed erythropoiesis or from 
blood loss associated with forestomach and/or oral mucosal neoplasms (NTP 1993).  The NTP study also 
reported that increases in leukocyte levels, particularly segmented neutrophils, in the rats and mice were 
likely due to neoplasm-induced inflammation. 
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2.8   MUSCULOSKELETAL 
 
No studies were located regarding musculoskeletal effects in humans after exposure to 1,2,3-trichloro-
propane.  There were no histopathological changes in the skeletal muscle or bone of rats and mice 
intermittently exposed via inhalation to concentrations as high as 132 ppm 1,2,3-trichloropropane for 
11 days (Miller et al. 1986a) or rats that were similarly exposed to up to 49 ppm 1,2,3-trichloropropane 
for 13 weeks (Johannsen et al. 1988).  Similarly, no pathological effects in bone or skeletal muscle of rats 
and mice that were administered via gavage 1,2,3-trichloropropane at doses as high as 125 and 
250 mg/kg, respectively, over a period of 17 weeks (NTP 1993) or 30 or 60 mg/kg, respectively, for 
2 years (NTP 1993). 
 
2.9   HEPATIC 
 
Data on the hepatic toxicity of 1,2,3-trichloropropane are limited to a case report of a man consuming 10–
15 mL of an unknown liquid; 1,2,3-trichloropropane exposure was suspected based on elevated levels of 
1,2,3-trichloropropane in the blood (Han 2010).  Rapid progressive deterioration of liver function was 
noted 2 days post-exposure. 
 
Acute- and intermediate-duration inhalation exposure to 1,2,3-trichloropropane resulted in histological 
alterations in the livers of rats and mice.  Exposure to 132 ppm for 2 weeks resulted in very slight 
hepatocellular necrosis in rats and hepatocellular vacuolization in mice (Miller et al. 1986a).  Following 
intermediate-duration inhalation exposure, mild hepatocellular hypertrophy was observed in rats exposed 
to ≥4.5 ppm in a 13-week study (Johannsen et al. 1988).  
 
Oral studies clearly support the identification of the liver as a target of 1,2,3-trichloropropane toxicity.  
The most sensitive effect appears to be decreases in liver weight which have been observed in acute 
studies at ≥29.5 mg/kg/day (Merrick et al. 1991), intermediate-duration studies at ≥14.7 mg/kg/day 
(Merrick et al. 1991; NTP 1993), and chronic studies at ≥10 mg/kg (NTP 1993).  The NTP (1993) 
17-week study also found decreases in pseudocholinesterase at low doses (≥8 mg/kg) in rats; the 
investigators noted that the decrease in pseudocholinesterase may be due to a hepatocellular damage-
induced decrease in synthesis (NTP 1993).  Increases in serum total bilirubin and alanine 
aminotransferase (ALT) have also been observed in rats exposed to ≥63 mg/kg (5 days/week) for 
17 weeks (NTP 1993).  Histological alterations have been observed following acute, intermediate, and 
chronic oral exposure.  Gavage administration of 250 mg/kg (5 days/week) produced hepatocellular 
necrosis in rats and mice within 2 weeks; the liver effects were considered a contributing factor to the 
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early mortality (NTP 1993).  Necrotic changes also occurred in the livers of rats and mice treated with 
daily gavage doses as low as 125 mg/kg over a period of 17 weeks (NTP 1993).  Exposure to 113 or 
149 mg/kg/day 1,2,3-trichloropropane administered in drinking water for 13 weeks produced mild hepatic 
changes (e.g., occasional fatty vacuolization and biliary hyperplasia) in rats (Villeneuve et al. 1985), 
suggesting that 1,2,3-trichloropropane may be less toxic when ingested gradually throughout the day than 
when administered as a bolus.  Hepatocellular necrosis has also been observed in mice chronically 
administered 60 mg/kg 5 days/week for 2 years (NTP 1993).  In addition to the reported hepatocellular 
effects, several oral studies have found bile duct hyperplasia in rats administered 58.9 mg/kg/day 
1,2,3-trichloropropane for 90 days (Merrick et al. 1991), 113 mg/kg/day for 13 weeks (Villeneuve et al. 
1985), or 30 mg/kg 5 days/week for 2 years (NTP 1993).  Turgid and discolored livers were observed in 
rabbits exposed to lethal dermal doses of 1,2,3-trichloropropane (Alpert 1982; Union Carbide 1958).  
These macroscopic alterations are consistent with oral and inhalation evidence of hepatotoxicity.  
 
2.10   RENAL 
 
No studies were located regarding renal effects in humans after exposure to 1,2,3-trichloropropane.  
Based on available data, the kidney does not appear to be a sensitive target following inhalation exposure 
to 1,2,3-trichloropropane.  No histological alterations were observed in rats and mice exposed to 132 ppm 
for 2 weeks (Miller et al. 1986a) or 49 ppm for 13 weeks (Johannsen et al. 1988); increases in kidney 
weights were observed in the 13-week study, but this was not considered adverse in the absence of other 
indicators of renal toxicity. 
 
In contrast to the inhalation studies, oral exposure studies have reported kidney toxicity.  Daily gavage 
doses of 250 mg/kg produced serious renal toxicity (e.g., tubular nephropathy, necrosis) in rats and mice 
within 2 weeks (NTP 1993).  The kidney damage in rats was severe enough to contribute to death.  At a 
lower dose, regenerative hyperplasia in the outer medulla and proximal tubule karyomegaly were 
observed after 3 or 7 days of administration of 125 mg/kg/day 1,2,3-trichloropropane (Kimura et al. 
2016).  Increases in relative and absolute kidney weights have been observed at ≥32 and ≥64 mg/kg, 
respectively, following intermediate-duration exposure (Kimura et al. 2016; NTP 1993).  Regenerative 
hyperplasia was observed in rats after 28 day of administration of 125 mg/kg/day (Kimura et al. 2016), 
8 weeks of administration of 63 mg/kg 5 days/week (NTP 1993) and at 125 mg/kg after 17 weeks of 
exposure (NTP 1993).  Similar doses of 1,2,3-trichloropropane (113 or 149 mg/kg) administered in 
drinking water for 13 weeks produced mild renal changes (e.g., pyknosis, fine glomerular adhesions, and 
occasional histologic proteinuria) in rats (Villeneuve et al. 1985).  The mild renal changes suggest that 
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1,2,3-trichloropropane may be less toxic when ingested gradually throughout the day than when 
administered as a bolus.  Necrotic changes occurred in the kidneys of mice treated with daily gavage 
doses of 250 mg/kg over a period of 17 weeks (NTP 1993).  Chronic administration (5 days/week) 
resulted in several renal effects (NTP 1993):  increases in absolute kidney weights in males at ≥3 mg/kg, 
increases in absolute kidney weight in females and relative kidney weights in males and females at 
≥10 mg/kg, renal hyperplasia in rats at ≥10 mg/kg, and an increase in the severity of nephropathy in male 
rats, as compared to controls at 30 mg/kg.  NTP (1993) noted that the renal hyperplasia was part of the 
continuum with renal adenomas; thus, this lesion could be considered precancerous.  No renal effects 
were observed in mice chronically administered doses as high as 60 mg/kg 5 days/week (NTP 1993). 
 
Limited information is available on the renal toxicity of 1,2,3-trichloropropane following oral 
administration.  Discolored kidneys and hematuria were observed in rabbits exposed to lethal dermal 
doses of 1,2,3-trichloropropane (Alpert 1982; Union Carbide 1958).  These macroscopic alterations are 
consistent with oral and inhalation evidence of renal toxicity.  
 
2.11   DERMAL 
 
No studies were located regarding dermal or ocular effects in humans after exposure to 1,2,3-trichloro-
propane.  Daily gavage administration of 1,2,3-trichloropropane at doses ≥63 mg/kg for up to 17 weeks 
caused alopecia but no gross eye irritation in rats (NTP 1993).  Mice that were similarly treated with up to 
250 mg/kg 1,2,3-trichloropropane had no macroscopic skin lesions or gross eye irritation (NTP 1993). 
 
Dermal application of 1,2,3-trichloropropane causes severe skin irritation in rabbits.  Evidence suggests 
that prolonged exposure (e.g., for 24 hours) or repeated daily application (e.g., for 2 weeks) may be 
necessary to cause irritation (Clark 1977; McOmie and Barnes 1949).  The results of one study suggest 
that 1,2,3-trichloropropane in corn oil vehicle was a very mild skin sensitizer in guinea pigs (Clark 1977).  
Another study that used a less sensitive procedure found no evidence of skin sensitization by undiluted 
1,2,3-trichloropropane in guinea pigs (Alpert 1982).  This study also found that corn oil itself was a mild 
skin sensitizer in guinea pigs, indicating that there is a possibility that the vehicle may enhance the weak 
effect observed by Clark (1977). 
 
2.12   OCULAR 
 
Limited information indicates that brief (15-minute) exposure to 100 ppm 1,2,3-trichloropropane vapor 
causes eye irritation in humans (Silverman et al. 1946).  A single 4-hour exposure to vapor concentrations 
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as low as 126 ppm 1,2,3-trichloropropane (Gushow and Quast 1984) caused eye irritation in rats and 
mice.  Repeated intermittent exposure to vapor concentrations as low as 15 ppm for 13 weeks (Johannsen 
et al. 1988) caused eye irritation in rats.  Ocular application of 1,2,3-trichloropropane caused eye irritation 
in rabbits (Alpert 1982; Clark 1977). 
 
2.13   ENDOCRINE 
 
No studies were located regarding endocrine effects in humans after exposure to 1,2,3-trichloropropane.  
Two studies have reported effects in endocrine tissues in rats.  A 13-week drinking water study reported 
histological alterations in the thyroid of rats exposed to 113 mg/kg/day (Villeneuve et al. 1985); 
alterations included reduced colloid density, increased epithelial height, and angular collapse of some 
follicles.  NTP (1993) reported focal hyperplasia of pancreatic acini in rats administered ≥3 mg/kg 
1,2,3-trichloropropane by gavage 5 days/week for 2 years.  The endocrine system does not appear to be a 
sensitive target of 1,2,3-trichloropropane toxicity based on the inconsistency of affected tissues in the 
studies finding effects and that most studies examining the endocrine system including a 2-week rat 
inhalation study identifying a NOAEL of 132 ppm (Miller et al. 1986a), 17-week gavage studies in rats 
and mice both identifying a NOAEL value of 125 ppm (NTP 1993), and a 2-year gavage study in mice 
with a NOAEL of 60 mg/kg (NTP 1993) have not found effects.  
 
2.14   IMMUNOLOGICAL 
 
No studies were located regarding immunological effects in humans after exposure to 1,2,3-trichloro-
propane.  Information on the potential effect of 1,2,3-trichloropropane on immune function is limited to 
an in vitro assay that reported weak inhibition of B-cell lymphocyte mitogenesis and no inhibition of 
T-cell lymphocyte mitogenesis in C3H/He mouse splenic cells (Sakazaki et al. 2001). 
 
There were no histopathological alterations in the thymus, spleen, lymphoid tissue, or bone marrow of 
rats and mice that were intermittently exposed to concentrations as high as 132 ppm 1,2,3-trichloro-
propane for 11 days (Miller et al. 1986a) or rats that were similarly exposed to up to 49 ppm for 13 weeks 
(Johannsen et al. 1988).  Intermittent exposure to a higher (lethal) concentration (579 ppm) for 4 weeks 
caused decreased spleen weight in rats (Johannsen et al. 1988).  Due to the lack of histological 
examinations and immunoassays, the immunological significance of the decreased spleen weight cannot 
be determined.  
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Merrick et al. (1991) reported diffuse thymic atrophy in rats administered 188 mg/kg/day for 10 days and 
plasma cell hyperplasia in the mandibular lymph nodes of rats administered 58.9 mg/kg/day for 90 days.  
NTP (1993) reported lymphoid depletion in the spleen and thymus of rats administered 1,2,3-trichloro-
propane at doses ≥63 mg/kg/day over 17 weeks and dying early (NTP 1993); the incidence of these 
lesions were not reported.  Mice that were similarly treated with lethal doses (250 mg/kg) showed splenic 
lymphoid depletion with occasional lymphoid necrosis and increased thymus weight (incidences were not 
reported) (NTP 1993).  The immunological significance of these effects are not known.  
 
As indicated in the discussion of dermal effects (Section 2.11), one study provides limited evidence that 
1,2,3-trichloropropane may be a very weak dermal sensitizer in animals (Clark 1977). 
 
2.15   NEUROLOGICAL 
 
There are limited data on the neurotoxicity of 1,2,3-trichloropropane in humans.  Case reports describe 
neurological signs in individuals exposed to airborne 1,2,3-trichloropropane (Mi et al. 2013) or ingesting 
1,2,3-trichloropropane (Han 2010).  In both cases, exposure to 1,2,3-trichloropropane was assumed based 
on elevated levels in the blood; it was not known if they were exposed to other compounds.  Observed 
signs included confusion and agitation (Han 2010) and headache, and intermittent drowsiness (Mi et al. 
2013).   
 
Data on the effects of 1,2,3-trichloropropane on the nervous system is limited to studies examining 
histopathology; no studies tested for neurofunction.  Clinical signs were observed in animals exposed to 
lethal airborne concentrations of 1,2,3-trichloropropane; prostration was observed in rats exposed to 
888 ppm for 6 hours (Johannsen et al. 1988) and hypoactivity was observed in rats exposed to 579 ppm 
6 hours/day for 4 weeks (Johannsen et al. 1988).  Histopathological examination of nervous tissue was 
not conducted for either groups of rats.   
 
No histopathological effects were observed in the brain, spinal cord, and peripheral nerves of rats and 
mice that were intermittently exposed to concentrations as high as 132 ppm 1,2,3-trichloropropane for 
2 weeks (Miller et al. 1986a).  No effect was observed on brain and spinal cord histology and brain 
weight in rats that were intermittently exposed to up to 49 ppm for 13 weeks (Johannsen et al. 1988).  
There were no treatment-related changes in brain weight or brain histology in rats and mice that were 
administered 1,2,3-trichloropropane doses as high as 250 mg/kg/day for periods as long as 17 weeks 
(NTP 1983a, 1983b).  
1,2,3-TRICHLOROPROPANE  47 
 
2.  HEALTH EFFECTS 
 
 
 
 
 
 
***DRAFT FOR PUBLIC COMMENT*** 
 
2.16   REPRODUCTIVE 
 
No studies were located regarding reproductive effects in humans after exposure to 1,2,3-trichloro-
propane.  In the only inhalation reproductive study of 1,2,3-trichloropropane, male and female rats were 
intermittently exposed to concentrations of 0.49–15 ppm prior to mating, during mating, and during 
gestation (Johannsen et al. 1988).  There were no effects on mating performance or fertility in either sex, 
but the data for the males at ≥4.5 ppm concentrations are inconclusive because the control group for these 
males had low mating performance compared to another male control group.  No effects on mating or 
fertility were found in male rats administered by gavage 80 mg/kg/day 1,2,3-trichloropropane for 5 days 
in a dominant lethal mutation study (Saito-Suzuki et al. 1982).  In a continuous breeding study, decreases 
in the number of litters produced and decreases in the number of live pups per litter were observed in rats 
administered ≥60 mg/kg/day for five litters (approximately 98 days) (NTP 1990).  An increase in the days 
to litter was also observed at 120 mg/kg/day.  To assess whether the observed effects were due to effects 
in the male or female animals, a cross-over mating study was conducted after the fifth litter was born 
(NTP 1990).  A decrease in the number of live pups were observed when females administered 
120 mg/kg/day were mated with control males.  In the cross-over mating study, no alterations in 
epididymal sperm motility, count, or morphology or estrous cycle length were observed (NTP 1990). 
 
Other inhalation and oral studies have examined potential histological alterations in reproductive tissues.  
Intermittent inhalation exposure to ≤132 ppm for 2 weeks (Miller et al. 1986b) or ≤49 ppm 1,2,3-tri-
chloropropane for 13 weeks (Johannsen et al. 1988) had no effect on the weights or histology of the 
reproductive organs of male and female rats.  In gavage studies, no histological alterations were observed 
in the testes of rats administered 80 mg/kg/day 1,2,3-trichloropropane for 5 days (Saito-Suzuki et al. 
1982); no alterations were observed in male or female reproductive tissues in rats or mice administered 
≤125 mg/kg (5 days/week) for 17 weeks (NTP 1993), rats administered ≤30 mg/kg 5 days/week for 
2 years (NTP 1993), or in mice administered ≤60 mg/kg 5 days/week for 2 years (NTP 1993).  In the 
cross-over mating study (NTP 1990), amyloidosis was observed in the ovaries of rats administered 
120 mg/kg/day for at least 98 days.   
 
2.17   DEVELOPMENTAL 
 
One epidemiology study examined the possible association between 1,2,3-trichloropropane exposure and 
birth defects (Brender et al. 2014).  Using data from the Texas Birth Defect Registry, the study found 
associations for several birth defects, including any neural tube defect, spina bifida, and septal heart 
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defects; the odds ratios (OR) and confidence intervals (CI) are presented in Table 2-4.  Exposure was 
quantified based on maternal residential proximity and estimated pounds of chemical emitted.  For spina 
bifida and cleft palate, associations were only found at the highest exposure intensity (OR 2.62, 95% CI 
1.55–4.46 and OR 1.91, 95% CI 1.01–3.63, respectively).  For septal heart defects, an association was 
found in the medium-intensity group (OR 1.31, 95% CI 1.12–1.52), but not in the high-intensity group 
(OR 1.02, 95% CI 0.86–1.21).  Although the study found associations, it does not establish causality; it is 
also noted that the study found associations for a number of chemicals. 
 
Table 2-4.  Possible Associations Between Maternal Residential Proximity to 
1,2,3-Trichloropropane Air Emissions and Birth Defects 
 
Defect Adjusted odds ratioa 95% Confidence interval 
Any neural tube defect 1.49  1.08–2.06 
Anencephaly 1.15 0.56–2.36 
Spina bifida 1.78 1.22–2.59 
Any oral cleft defect 1.16 0.89–1.51 
Cleft palate alone 1.48 0.97–2.25 
Cleft lip without cleft palate 1.03 0.73–1.44 
Conotruncal heart defects 1.01 0.74–1.37 
Obstructive heart defects 1.06 0.79–1.42 
Septal heart defects 1.13 1.02–1.24 
Any type of limb deficiency 1.10 0.72–1.67 
Longitudinal limb deficiency 1.08 0.58–1.99 
Transverse limb deficiency 0.95 0.53–1.71 
 
aAdjustments for birth year and maternal age, education, race/ethnicity, and public health region of residence. 
 
Source:  Brender et al. 2014 
 
Limited information regarding developmental effects of inhaled 1,2,3-trichloropropane in animals is 
available from a reproduction study in which male and female rats were intermittently exposed to 
concentrations as high as 15 ppm prior to mating, during mating, and during gestation (Johannsen et al. 
1988).  There were no effects on gestation length, and pup viability and weight at birth and during 
lactation were normal.  In an oral developmental toxicity study utilizing the offspring of rats tested in the 
continuous breeding study (NTP 1990, see Section 2.16), decreases in mating and fertility indices were 
observed at 120 mg/kg/day.  No alterations in the number of live pups, sex ratio, or pup body weight were 
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observed at a dose of ≤120 mg/kg/day (NTP 1990).  Increases in average estrous cycle length was 
observed at 30, 60, and 120 mg/kg, but the increase was not dose-related. 
 
2.18   OTHER NONCANCER 
 
No studies were located regarding other noncancer effects in humans or animals after exposure to 
1,2,3-trichloropropane. 
 
2.19   CANCER 
 
No studies were located regarding carcinogenicity in humans after exposure to 1,2,3-trichloropropane. 
 
Information on the carcinogenicity of 1,2,3-trichloropropane is based on chronic duration gavage studies 
in rats and mice (NTP 1993).  Increases in the incidence of neoplastic lesions were observed at all doses 
tested.  In rats administered ≥3 mg/kg (5 days/week), squamous cell papillomas or squamous cell 
carcinomas were observed in the forestomach and adenomas were observed in the pancreas.  At 
≥10 mg/kg, squamous cell papillomas or squamous cell carcinomas in the oral mucosa, adenomas in renal 
tubules, adenoma or carcinoma of the clitoral gland, and adenocarcinomas of the mammary gland were 
observed.  At the highest dose tested (30 mg/kg), adenoma or carcinoma in the preputial gland, and 
carcinoma in the Zymbal’s gland (males only) were also observed.  Clear evidence of carcinogenicity was 
also found in male and female mice treated with ≥6 mg/kg (NTP 1993).  The evidence consisted of 
increased incidences of squamous cell papilloma or carcinoma in the forestomach and hepatocellular 
adenoma or carcinoma (males only) at 6 mg/kg; harderian gland adenoma in males at 20 mg/kg; and 
squamous cell papilloma or carcinoma of the oral mucosa (females only), harderian gland adenoma 
(females only), and uterine stromal polyps and endometrial adenoma or adenocarcinoma at 60 mg/kg.   
 
The Department of Health and Human Services has determined that 1,2,3-trichloropropane is reasonably 
anticipated to be a human carcinogen (NTP 2016).  EPA concluded that it is likely to be carcinogenic to 
humans (EPA 2009b), and IARC considers is to be a suspected human carcinogen (IARC 2017). 
 
2.20   GENOTOXICITY 
 
The genotoxicity of 1,2,3-trichloropropane has been investigated in a small number of in vitro studies, 
which are summarized in Table 2-5.  1,2,3-Trichloropropane was mutagenic in certain strains of 
Salmonella typhimurium when assayed with exogenous metabolic activation preparation (Haworth et al. 
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1983; Kubo et al. 2002; Låg et al. 1994; Mersch-Sundermann et al. 1994; NTP 1993; Ratpan and 
Plaumann 1988; Stolzenberg and Hine 1980).  It did not induce gene mutations in Escherichia coli 
(Mersch-Sundermann et al. 1994).  In eukaryotic organisms, 1,2,3-trichloropropane induced gene 
mutations in mouse lymphoma cells (NTP 1994), DNA damage in human lymphocytes (Tafazoli and 
Kirsch-Volders 1996), sister chromatid exchange in Chinese hamster V79 and ovary cells (NTP 1993; 
Von Der Hude et al. 1987), and chromosomal aberrations in Chinese hamster ovary cells (NTP 1993).  In 
most cases, the positive results were only observed with activation.  1,2,3-Trichloropropane did not 
increase micronuclei formation in human lymphocytes (Tafazoli and Kirsch-Volders 1996). 
 
Table 2-5.  Genotoxicity of 1,2,3-Trichloropropane In Vitro 
 
Species (test system) Endpoint 
Results 
Reference 
Activation 
With Without 
Prokaryotic organisms 
 Salmonella typhimurium (plate 
incorporation test) 
Gene mutation + – Stolzenberg and 
Hine 1980 
 S. typhimurium strains (liquid 
preincubation test) 
Gene mutation + – Haworth et al. 1983 
 S. typhimurium TA97, TA98, 
TA100, and TA1535, (liquid 
preincubation test) 
Gene mutation + – NTP 1993 
 S. typhimurium TA1537 (liquid 
preincubation test) 
Gene mutation – – NTP 1993 
 S. typhimurium (plate 
incorporation test) 
Gene mutation + – Ratpan and 
Plaumann 1988 
 S. typhimurium TA98 (Ames 
assay) 
Gene mutation – – Kubo et al. 2002 
 S. typhimurium TA100 (Ames 
assay) 
Gene mutation + – Kubo et al. 2002 
 S. typhimurium TA100 (Ames 
assay) 
Gene mutation + – Låg et al. 1994 
 S. typhimurium TA100 (Ames 
assay) 
Gene mutation + – Mersch-Sundermann 
et al. 1994 
 Escherichia coli (SOS chromotest) Gene mutation – – Mersch-Sundermann 
et al. 1994 
Eukaryotic organisms 
 L5178Y mouse lymphoma cells Gene mutation + – NTP 1993 
 Human lymphocytes (comet 
assay) 
DNA damage + + Tafazoli and Kirsch-
Volders 1996 
 Human lymphocytes  Micronuclei formation – – Tafazoli and Kirsch-
Volders 1996 
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Table 2-5.  Genotoxicity of 1,2,3-Trichloropropane In Vitro 
 
Species (test system) Endpoint 
Results 
Reference 
Activation 
With Without 
 Chinese hamster V79 cells Sister chromatid 
exchange 
+ – Von Der Hude et al. 
1987 
 Chinese hamster ovary cells Sister chromatid 
exchange 
+ – NTP 1993 
 Chinese hamster ovary cells Chromosomal 
aberrations 
+ – NTP 1993 
 
+ = positive results; – = negative results 
 
A small number of studies have evaluated the in vivo genotoxicity (Table 2-6).  In Drosophila, exposure 
to 1,2,3-trichloropropane increased the frequency of somatic mutations and recombinations (Chroust et al. 
2007).  In mammalian species, 1,2,3-trichloropropane did not induce dominant lethal mutations when 
administered orally to rats (Saito-Suzuki et al. 1982) (see Section 2.16) or increase the frequency of 
micronucleated polychromatic erythrocytes in mice (Crebelli et al. 1999). 
 
Table 2-6.  Genotoxicity of 1,2,3-Trichloropropane In Vivo 
 
Species (exposure route) Endpoint Results Reference 
Drosophila melanogaster Somatic mutation and recombination  + Chroust et al. 2007 
CD-1 mice (intraperitoneal) Micronucleated polychromatic erythrocytes – Crebelli et al. 1999 
 
– = negative result; + = positive result 
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CHAPTER 3.  TOXICOKINETICS, SUSCEPTIBLE POPULATIONS, 
BIOMARKERS, CHEMICAL INTERACTIONS 
 
3.1   TOXICOKINETICS  
 
No studies were located regarding 1,2,3-trichloropropane toxicokinetics in humans, but there are limited 
data from studies in animals.  These data are summarized below. 
• Approximately 80% of an oral dose is absorbed through the gastrointestinal tract.  No absorption 
data are available for inhalation or dermal routes although absorption is presumed based on 
remote toxicity.   
• Absorbed 1,2,3-trichloropropane is widely distributed throughout the body.   
• 1,2,3-Trichloropropane is rapidly and extensively metabolized.  It likely undergoes cytochrome 
P450-catalyzed dehalogenation reactions. 
• 1,2,3-Trichloropropane and its metabolites are excreted via urine, feces, and exhaled breath.  It is 
excreted within 2 days of a single exposure. 
 
3.1.1   Absorption  
 
No quantitative information was located regarding absorption of 1,2,3-trichloropropane following 
inhalation exposure; however, since liver and hematological toxicity has been reported in animals 
exposed by the inhalation route (Johannsen et al. 1988; Miller et al. 1986a), it can be concluded that 
absorption occurs to some extent.  The results of studies performed in rats indicate that near complete 
absorption (>80%) from the gastrointestinal tract occurs within the first day following oral exposure 
(Mahmood et al. 1991; Sipes et al. 1982; Volp et al. 1984).  As with inhalation exposure, dermal 
absorption can be implied based on the lethality study conducted by Smyth et al. (1962) in which the 
dermal application site was protected by an impervious membrane. 
 
3.1.2   Distribution  
 
Muscle, blood, liver, skin, and adipose tissue contained the largest amounts of 1,2,3-trichloropropane 
following oral exposure in rats (Sipes et al. 1982).  Retention in all tissues was low, however, as 
elimination of 1,2,3-trichloropropane-derived radioactivity from tissues was nearly complete (>97%) 
within 8 days after oral exposure in rats (Sipes et al. 1982).  Another study found that 6 hours after 
receiving a gavage dose of radiolabeled 1,2,3-trichloropropane, the highest concentrations of radioactivity 
were found in the gastrointestinal tract (in decreasing concentration: forestomach, glandular stomach, 
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small intestine, large intestine), adipose, kidney, and liver (Mahmood et al. 1991).  After 60 hours, the 
highest concentrations were found in the liver, kidneys, and forestomach.  In mice, the highest 
concentrations were found in the forestomach, liver, and kidney 60 hours post-dosing (Mahmood et al. 
1991).  The 1,2,3-trichloropropane remaining in the forestomach, liver, and kidney was non-extractable 
metabolites, suggesting that it was covalently bound to tissue macromolecules. 
 
Distribution studies of intravenously injected 1,2,3-trichloropropane in rats have provided a quantitative 
description of the distribution kinetics from which predictions can be made regarding other routes of 
exposure (Sipes et al. 1982; Volp et al. 1984).  Intravenously injected 1,2,3-trichloropropane rapidly 
distributes to many tissues.  The major sites of accumulation are liver, kidney, small and large intestine, 
adipose tissue, muscle, and skin.  Peak concentrations are achieved within l–2 hours after intravenous 
injection.  Elimination of 1,2,3-trichloropropane from tissues in the rat is also rapid and a two-phase 
process (Volp et al. 1984).  Elimination half-times for >90% of the 1,2,3-trichloropropane in tissues 
ranged from 20 minutes in kidney to 2 hours in adipose tissue (first phase).  A small fraction of the 
1,2,3-trichloropropane in these tissues (<10%) was eliminated more slowly, with half-times ranging from 
23 to 45 hours (second phase).  Elimination of total radioactivity from the tissues after intravenous 
injection of radiolabeled 1,2,3-trichloropropane (phase one half-times between 2 and 5 hours, phase two 
half-times between 87 and 182 hours) is slower than elimination of parent 1,2,3-trichloropropane.  This 
suggests that metabolites of 1,2,3-trichloropropane are eliminated slower than the parent compound.  
Based on the results of studies in the rat, it can be concluded that 1,2,3-trichloropropane absorbed by any 
route is likely to be widely distributed in the body.  Most of the 1,2,3-trichloropropane that enters tissues 
is eliminated within hours to days.  
 
3.1.3   Metabolism  
 
Gavage administered or intravenously injected 1,2,3-trichloropropane is extensively metabolized within 
hours in rats.  Metabolic products in rats include carbon dioxide, which is expired, and numerous 
metabolites that are excreted in urine and enter the bile to be excreted in feces or absorbed in the 
intestines (Mahmood et al. 1991; Sipes et al. 1982; Volp et al. 1984).  Many of the metabolites of 
1,2,3-trichloropropane that are formed in the rat have not been identified; based on the metabolic 
pathways that have been identified for other halogenated alkanes, dehalogenation products, glutathione 
conjugates, and their subsequent metabolites, mercapturic acids, can be anticipated.  Chloroalkanes such 
as 1,2,3-trichloropropane undergo dehalogenation reactions catalyzed by cytochrome P450 (Ivanetich et 
al. 1978; Salmon et al. 1981; Van Dyke et al. 1971).  Depending on the reaction mechanism, highly 
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reactive intermediates (e.g., radicals) can be formed from these reactions, leading to protein and DNA 
adducts or lipid peroxidation.  Conjugation with glutathione could result in formation of sulfur mustard-
like compounds that are potential alkylating agents. 
 
Mahmood et al. (1991) proposed three possible metabolic pathways for 1,2,3-trichloropropane, which 
involve cytochrome P450 metabolism or glutathione conjugation.  The possible pathways are summarized 
below and illustrated in Figure 3-1: 
1. Nucleophilic displacement of chlorine at the C1 or C2 position, possibly by glutathione 
transferase, to form a β-chlorothio ether.  Displacement of the β-chlorine could result in the 
formation of a reactive episulfonium ion.  The episulfonium ion could react with water to form 
glutathione conjugates at the C1 or C2 position.   
a. Cleavage of the glutathione conjugate at the C2 position could ultimately result in the 
formation of N-acetyl-S-(3-chloro-2-hydroxypropyl)-L-cysteine (ACPC) or S-(3-chloro-
2-hydroxypropyl)-L-cysteine (CPC).   
b. The episulfonium ion could also react with water at the C1 position to form another 
episulfonium ion.  The second episulfonium ion could react with water at the C3 position 
to form a 1,3-dihydroxypropyl glutathione conjugate which could oxidize to form 
2-(S-glutathionyl)malonic acid (GMA). 
2. Oxidation of 1,2,3-trichloropropane at the C2 position, possibly by cytochrome P450, would 
result in the formation of 1,3-dichloroacetone.  1,3-Dichloroacetone could undergo chlorine 
displacement by glutathione and reduction of the keto group to form ACPC and CPC.   
3. Oxidation of 1,2,3-trichloropropane at the C1 position, possibly by cytochrome P450, to form the 
α-chlorohydrin, 2,3-dichloropropanal.  Loss of HCl from 2,3-dichlorpropanal would form 
chloroacrolein, which could react with glutathione to form an episulfonium ion.  The 
episulfonium ion could react with water at the C3 position to form GMA after oxidation of the C2 
and C3 atoms to carboxylic acids. 
 
The results of an in vitro study (Weber and Sipes 1992) in rat hepatic microsomes suggest two similar 
possible metabolic pathways for 1,2,3-trichloropropane:  oxidation at the C2 position to form the unstable 
compound gem-chlorohydrin, which is dehalogenated to form 1,3-dichloroacetone and oxidation at the C1 
position to form gem-chlorohydrin, which is dehalogenated to form 2,3-dichloropropanal, which is 
subsequently reduced to 2,3-dichloropropanol.  
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Figure 3-1.  Possible Metabolic Pathways for the Formation of ACPC, CPC, and 
GMA from 1,2,3-Trichloropropane 
  
 
 
 
ACPC = N-Acetyl-S-(3-chloro-2-hydroxypropyl)-L-cysteine; CPC = S-(3-chloro-2-hydroxypropyl)-
L-cysteine; GMA = 2-(S-glutathionyl)malonic acid 
 
Source: Mahmood et al. 1991 
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3.1.4   Excretion  
 
Studies conducted with rats showed that 1,2,3-trichloropropane and its metabolites were excreted in urine, 
feces, and exhaled breath after oral exposure (Sipes et al. 1982).  Excretion was nearly complete (95–
96%) within 2 days.  Most of the dose was excreted in the urine and feces (up to 56 and 25%, 
respectively), with the remainder in the breath.  Mahmood et al. (1991) demonstrated that ≥90% of the 
radioactivity was excreted 60 hours following a gavage dose of radiolabeled 1,2,3-trichloropropane in rats 
and mice.  Urine was the primary route of excretion, accounting for 50–57% of the dose in rats and 65% 
of the dose in mice.  In the urine, the radiolabel was primarily found in the form of N-acetyl-S-(3-chloro-
2-hydroxypropl)-L-cysteine.  Excretion as carbon dioxide or in the feces accounted for 20 and 20% of the 
radiolabel, respectively, in rats and 20 and 15% of the label, respectively, in mice.  Comparison of 
excretion data from rats and mice suggest that at a given dose, male mice appear to eliminate 1,2,3-tri-
chloropropane faster and retain less radioactivity than male (or female) rats (Mahmood et al. 1991).   
 
Studies of the excretion of intravenously injected 1,2,3-trichloropropane in rats have provided a 
quantitative description of the excretion kinetics from which predictions can be made about other routes 
of exposure (Sipes et al. 1982; Volp et al. 1984).  Excretion of intravenously injected 1,2,3-trichloro-
propane and metabolites is nearly complete within 2 days.  Unchanged 1,2,3-trichloropropane and its 
major metabolite, carbon dioxide, are expired in exhaled breath.  Nonvolatile metabolites are excreted in 
the urine.  Extensive biliary excretion of nonvolatile metabolites also occurs, resulting in fecal excretion 
as well as reabsorption of metabolites from the gastrointestinal tract.  Based on the results of studies in 
rats, exhaled breath, urine, and feces are likely to be significant routes of excretion of absorbed 1,2,3-tri-
chloropropane and its metabolites in humans. 
 
3.1.5   Physiologically Based Pharmacokinetic (PBPK)/Pharmacodynamic (PD) Models  
 
PBPK models use mathematical descriptions of the uptake and disposition of chemical substances to 
quantitatively describe the relationships among critical biological processes (Krishnan et al. 1994).  PBPK 
models are also called biologically based tissue dosimetry models.  PBPK models are increasingly used in 
risk assessments, primarily to predict the concentration of potentially toxic moieties of a chemical that 
will be delivered to any given target tissue following various combinations of route, dose level, and test 
species (Clewell and Andersen 1985).  Physiologically based pharmacodynamic (PBPD) models use 
mathematical descriptions of the dose-response function to quantitatively describe the relationship 
between target tissue dose and toxic endpoints.   
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Volp et al. (1984) developed a PBPK model in male rats to investigate the time course of 1,2,3-trichloro-
propane is tissues.  The flow-limited model consisted of seven compartments:  blood, liver, kidney, fat, 
muscle, skin, and remaining distribution volume.  The model, with some adjustments of pharmacokinetic 
parameters, predicted the concentration versus time curves for the selected tissues.   
 
3.1.6   Animal-to-Human Extrapolations  
 
The limited available toxicokinetic data do not allow for an assessment of potential species 
differences.  Most of the toxicity studies were conducted in rats; two studies tested rats and mice, which 
allow for a comparison across species.  In an 11-day inhalation study, Miller et al. (1986a) found similar 
targets of toxicity, but differences in sensitivity between rats and mice.  In rats, exposure to 3 ppm 
resulted in thickening of the nasal olfactory epithelium.  In mice, 3 ppm was a NOAEL for nasal effects; 
at 10 ppm, nasal olfactory inflammation was observed.  Similar findings were observed in intermediate- 
and chronic-duration studies (NTP 1993).  In rats, increases in liver weight were observed at ≥16 mg/kg 
(5 days/week) and hepatocellular necrosis and bile duct hyperplasia were observed at 125 ppm.  In 
contrast, increases in liver weight was not observed in mice at doses lower than 125 ppm and 
hepatocellular necrosis was observed at 250 ppm.  Chronic-duration exposure resulted in differences in 
the types of effects (e.g., bile duct hyperplasia in rats and hepatocellular necrosis in mice) and 
sensitivity.  Collectively, these studies suggest species differences in the toxicity of 1,2,3-trichloro-
propane.  There are insufficient data to assess whether rats or mice would be a better model for human 
toxicity.  In the absence of these data, it was assumed that the most sensitive species would be appropriate 
for MRL derivation. 
 
3.2   CHILDREN AND OTHER POPULATIONS THAT ARE UNUSUALLY SUSCEPTIBLE 
 
This section discusses potential health effects from exposures during the period from conception to 
maturity at 18 years of age in humans.  Potential effects on offspring resulting from exposures of parental 
germ cells are considered, as well as any indirect effects on the fetus and neonate resulting from maternal 
exposure during gestation and lactation.  Children may be more or less susceptible than adults to health 
effects from exposure to hazardous substances and the relationship may change with developmental age.   
 
This section also discusses unusually susceptible populations.  A susceptible population may exhibit 
different or enhanced responses to certain chemicals than most persons exposed to the same level of these 
chemicals in the environment.  Factors involved with increased susceptibility may include genetic 
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makeup, age, health and nutritional status, and exposure to other toxic substances (e.g., cigarette smoke).  
These parameters can reduce detoxification or excretion or compromise organ function.   
 
Populations at greater exposure risk to unusually high exposure levels to 1,2,3-trichloropropane are 
discussed in Section 5.7, Populations with Potentially High Exposures. 
 
There are limited data on the susceptibility of children to the toxicity of 1,2,3-trichloropropane; in the 
absence of data to the contrary, it is assumed that it would be the same as in adults.  The developmental 
toxicity of 1,2,3-trichloropropane has not been thoroughly investigated.  A 2-generation study found 
decreases in fertility in F1 mice (NTP 1990); however, it is not known if this was due to impaired 
development of the reproductive system as similar effects were observed in the P0 animals. 
 
No populations with unusual susceptibility to health effects of 1,2,3-trichloropropane have been 
identified.  The respiratory tract, blood, liver, and kidneys are principal targets of 1,2,3-trichloropropane 
in animals (see Section 2.4).  It is therefore possible that people with chronic respiratory, liver, or kidney 
disease, or possibly people with compromised pulmonary, hepatic, or renal function (e.g., alcoholics), 
might be unusually susceptible to 1,2,3-trichloropropane. 
 
3.3   BIOMARKERS OF EXPOSURE AND EFFECT  
 
Biomarkers are broadly defined as indicators signaling events in biologic systems or samples.  They have 
been classified as biomarkers of exposure, biomarkers of effect, and biomarkers of susceptibility 
(NAS/NRC 1989). 
 
A biomarker of exposure is a xenobiotic substance or its metabolite(s) or the product of an interaction 
between a xenobiotic agent and some target molecule(s) or cell(s) that is measured within a compartment 
of an organism (NAS/NRC 1989).  The preferred biomarkers of exposure are generally the substance 
itself, substance-specific metabolites in readily obtainable body fluid(s), or excreta.  Biomarkers of 
exposure to 1,2,3-trichloropropane are discussed in Section 3.3.1.  The National Report on Human 
Exposure to Environmental Chemicals provides an ongoing assessment of the exposure of a generalizable 
sample of the U.S. population to environmental chemicals using biomonitoring (see 
http://www.cdc.gov/exposurereport/).  If available, biomonitoring data for 1,2,3-trichloropropane from 
this report are discussed in Section 5.6, General Population Exposure.   
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Biomarkers of effect are defined as any measurable biochemical, physiologic, or other alteration within an 
organism that (depending on magnitude) can be recognized as an established or potential health 
impairment or disease (NAS/NRC 1989).  This definition encompasses biochemical or cellular signals of 
tissue dysfunction (e.g., increased liver enzyme activity or pathologic changes in female genital epithelial 
cells), as well as physiologic signs of dysfunction such as increased blood pressure or decreased lung 
capacity.  Note that these markers are not often substance specific.  They also may not be directly 
adverse, but can indicate potential health impairment (e.g., DNA adducts).  Biomarkers of effect caused 
1,2,3-trichloropropane are discussed in Section 3.3.2. 
 
A biomarker of susceptibility is an indicator of an inherent or acquired limitation of an organism's ability 
to respond to the challenge of exposure to a specific xenobiotic substance.  It can be an intrinsic genetic or 
other characteristic or a preexisting disease that results in an increase in absorbed dose, a decrease in the 
biologically effective dose, or a target tissue response.  If biomarkers of susceptibility exist, they are 
discussed in Section 3.2, Children and Other Populations that are Unusually Susceptible. 
 
3.3.1   Biomarkers of Exposure 
 
Biomarkers of exposure to 1,2,3-trichloropropane cannot be identified because information on levels of 
1,2,3-trichloropropane or its metabolites in human tissues, fluids, or excreta or information on effects 
specific for 1,2,3-trichloropropane is not available.  Studies with rats indicate that excretion of 1,2,3-tri-
chloropropane in the breath or urine may be sufficient for monitoring purposes (see Section 3.1.4).  
 
3.3.2   Biomarkers of Effect 
 
Effects in humans that are specifically attributable to 1,2,3-trichloropropane exposure are not known.  
Principal targets of 1,2,3-trichloropropane in animals are the respiratory tract, blood, liver, and kidneys.  
One study with rats suggests that alterations of serum enzymes (e.g., decreased serum pseudo-
cholinesterase activity) and anemia might be useful biomarkers for hepatic and hematologic effects, 
respectively, of 1,2,3-trichloropropane.  Insufficient data exist, however, to determine whether 1,2,3-tri-
chloropropane is likely to cause anemia in humans, and substances other than 1,2,3-trichloropropane 
could also cause similar hematologic and hepatic effects.  
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3.4   INTERACTIONS WITH OTHER CHEMICALS  
 
Rats were exposed by inhalation to 500 ppm trichloropropane and 1,000 ppm dichloropropane alone and 
in combination for 4 hours (Drew et al. 1978).  Activities of liver-associated serum enzymes (serum 
glutamicoxaloacetic transaminase, serum glutamic-pyruvic transaminase, ornithine carbamyl transferase) 
were increased 24–48 hours following exposure to each chemical alone.  The combined exposure resulted 
in higher enzyme activities than with either chemical alone, but the increases were less than additive. 
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CHAPTER 4.  CHEMICAL AND PHYSICAL INFORMATION 
 
4.1   CHEMICAL IDENTITY 
 
Data pertaining to the chemical identity of 1,2,3-trichloropropane are listed in Table 4-1. 
 
Table 4-1.  Chemical Identity of 1,2,3-Trichloropropane 
 
Characteristic Information Reference 
Chemical name 1,2,3-Trichloropropane CAS 1989 
Synonym(s) and registered trade 
name(s) 
Allyl trichloride; glycerol 
trichlorohydrin; trichlorohydrin 
CAS 1989 
Chemical formula C3H5Cl3 CAS 1989 
Chemical structure 
 
 
CAS Registry Number  96-18-4 CAS 1989 
 
CAS = Chemical Abstracts Service  
 
4.2   PHYSICAL AND CHEMICAL PROPERTIES  
 
The physical and chemical properties of 1,2,3-trichloropropane are presented in Table 4-2. 
  
CH2 C
H
C
H2
Cl Cl Cl
1,2,3-TRICHLOROPROPANE  62 
 
4.  CHEMICAL AND PHYSICAL INFORMATION 
 
 
 
 
 
 
***DRAFT FOR PUBLIC COMMENT*** 
Table 4-2.  Physical and Chemical Properties of 1,2,3-Trichloropropane 
 
Property Information Reference 
Molecular weight 147.43 Weast 1985 
Color Colorless Hawley 1981 
Physical state Liquid Hawley 1981 
Melting point -14.7°C Williams 1949 
Boiling point 156.8°C Ruddick et al. 1986 
Density at 20 °C 1.3888 g/cm2 Ruddick et al. 1986 
Odor Strong, acrid; trichloroethylene-like; 
“sweet smelling” 
HSDB 1989; McNeill 1979; Ruth 
1986 
Odor threshold:   
 Water No data  
 Air No data  
Solubility:   
 Water at 20 °C 1,750 mg/L Ruddick et al. 1986 
 Organic solvents Soluble in ethyl alcohol and higher 
alcohols, chloroform and other 
chlorinated hydrocarbons, ethyl 
ether, benzene 
Weast 1985; Williams 1949 
Partition coefficients:   
 Log Kow 1.98 EPA 1988b 
 Log Koca 1.99 (estimated) Lyman et al. 1982 
Bioconcentration factorb 9.2 (estimated) Lyman et al. 1982 
Vapor pressure at 20°C 3.1 mmHg Mackay et al. 1982 
Henry's law constant at 25°C 3.17x10-4 atm-m3/mol (calculated) Lyman et al. 1982 
Autoignition temperature 304°C (580°F) Hawley 1981 
Flashpoint   
 Open cup 82.2°C Hawley 1981 
 Open cup 78.9°C Williams 1949 
 Closed cup 73.3°C Williams 1949 
Flammability limits No data  
Conversion factors 1 ppm (v/v)x6.03 =mg/m2 
1 mg/m3x0.166 = ppm (v/v) 
 
Explosive limits No data  
 
aCalculated from water solubility using equation 4-7 (Lyman et al. 1982). 
bCalculated from log Kow using equation 5-2 (Lyman et al. 1982). 
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CHAPTER 5.  POTENTIAL FOR HUMAN EXPOSURE 
 
5.1   OVERVIEW  
 
1,2,3-Trichloropropane has been identified in at least 25 of the 1,854 hazardous waste sites that have been 
proposed for inclusion on the EPA National Priorities List (NPL) (ATSDR 2017).  However, the number 
of sites in which 1,2,3-trichloropropane has been evaluated is not known.  The number of sites in each 
state is shown in Figure 5-1.  Of these sites, 25 are located within the United States. 
 
Figure 5-1.  Number of NPL Sites with 1,2,3-Trichloropropane Contamination 
 
 
• The most likely route of exposure for the general population is through ingestion of contaminated 
water.  Additional exposure may occur through the inhalation of contaminated air, especially for 
those who live near facilities that manufacture or use 1,2,3-trichloropropane or at treatment or 
disposal facilities. 
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• Releases to the environment are likely to occur as a result of its manufacture, formulation, and 
use as a solvent and extractive agent, paint- and varnish-remover, cleaning and degreasing agent, 
cleaning and maintenance reagent, and chemical intermediate. 
 
• In ambient air, the primary removal process is expected to be the vapor phase reaction with 
photochemically generated hydroxyl radicals.  In surface waters, the primary removal process is 
likely to be volatilization.  In soil, the primary removal processes are volatilization from near-
surface soil and leaching to groundwater.  Aerobic biodegradation is probably a slow process in 
natural waters and soil.   
 
5.2   PRODUCTION, IMPORT/EXPORT, USE, AND DISPOSAL 
 
5.2.1   Production 
 
Recent data regarding production volumes for 1,2,3-trichloropropane are not available.  The estimated 
1977 production volume for the chemical ranged from 21 to 110 million pounds (EPA 1989b).  
Manufacturers of 1,2,3-trichloropropane in 1989 included Dow Chemical U.S.A., Freeport, Texas, and 
Shell Oil Company, Deer Park, Texas (SRI 1989).  In 1977, two additional manufacturing locations were 
Dow Chemical U.S.A., a major producer in Midland, Michigan, and Columbia Organic Chemicals Co., a 
minor producer in Columbia, South Carolina (EPA 1989b).  1,2,3-Trichloropropane can be produced via 
the chlorination of propylene (Hawley 1981).  Other reported methods for producing 1,2,3-trichloro-
propane include the addition of chlorine to allyl chloride, reaction of thionyl chloride with glycerol, and 
the reaction of phosphorus pentachloride with either 1,3- or 2,3-dichloropropanol (NIOSH 1981; 
Williams 1949).  1,2,3-Trichloropropane also may be produced in potentially significant amounts as a 
byproduct of processes primarily used to produce other chemicals, including dichloropropene (a soil 
fumigant and nematocide), propylene chlorohydrin, propylene oxide, dichlorohydrin, and glycerol (Baier 
et al. 1987; NIOSH 1981).  Technical-grade 1,2,3-trichloropropane reportedly varies between 97.5 and 
99.4% purity (Alberti 1982; NTP 1983a).  The material tested by the NTP (1983a) contains the following 
impurities: 0.066% water, 0.14% unspecified chlorohexene, two unspecified chlorohexadienes (0.24 and 
0.13%), and total acidity of 48 ppm (as HCl).  Table 5-1 summarizes information on U.S. companies that 
reported the manufactured or used 1,2,3-trichloropropane in 2016 (TRI16 2017).   
 
5.2.2   Import/Export 
 
No data concerning the import or export of 1,2,3-trichloropropane were located. 
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Table 5-1.  Facilities that Produce, Process, or Use 1,2,3-Trichloropropane 
 
Statea 
Number of 
facilities 
Minimum 
amount on site 
in poundsb 
Maximum 
amount on site 
in poundsb Activities and usesc 
LA 2 0 9,999,999 1, 5, 6, 12, 13, 14 
TX 4 1,000 999,999 1, 4, 5, 6, 12, 13 
 
aPost office state abbreviations used. 
bAmounts on site reported by facilities in each state. 
cActivities/Uses: 
1.  Produce 
2.  Import 
3.  Used Processing 
4.  Sale/Distribution 
5.  Byproduct 
6.  Reactant 
7.  Formulation Component 
8.  Article Component 
9.  Repackaging 
10.  Chemical Processing Aid 
11.  Manufacture Aid 
12.  Ancillary 
13.  Manufacture Impurity 
14.  Process Impurity 
 
Source:  TRI16 2017 (Data are from 2016) 
 
5.2.3   Use 
 
1,2,3-Trichloropropane has, in the past, been used mainly as a solvent and extractive agent.  No current 
information is available that indicates that the compound is still used for these purposes today.  It 
dissolves a variety of resins, oils, waxes, and other materials while having a low solubility in water 
(Williams 1949).  Common uses have included use as a paint- and varnish remover, a cleaning and 
degreasing agent, and a cleaning and maintenance reagent (Hawley 1981; NIOSH 1981).  It is used as a 
chemical intermediate; for example, in the production of polysulfone liquid polymers and 
dichloropropene, synthesis of hexafluoropropylene, and as a crosslinking agent in the synthesis of 
polysulfides (Baier et al. 1987; Ellerstein and Bertozzi 1982; Gangal 1980; HSDB 1989).  No data were 
found concerning the approximate amounts currently used for particular purposes. 
 
5.2.4   Disposal 
 
1,2,3-Trichloropropane has been identified as a hazardous waste by the EPA, and the disposal of this 
compound is regulated under the Resource Conservation and Recovery Act (RCRA).  Specific 
information regarding the federal regulations of land disposal of 1,2,3-trichloropropane is available (EPA 
1988a).  1,2,3-Trichloropropane can be disposed of via atomization in a suitable incinerator equipped 
with appropriate effluent gas scrubbers (HSDB 1989).  In case of accidental spills, the chemical may be 
disposed of by absorption onto vermiculite, dry sand, earth, or similar material followed by disposal in a 
secured landfill (HSDB 1989); however, land disposal may no longer be allowed by the disposal 
regulations discussed above.  Significant removal of 1,2,3-trichloropropane from waste water and sewage 
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may be accomplished through the use of activated sludge treatment processes (Matsui et al. 1975).  No 
data were found concerning the approximate amounts disposed by the various methods. 
 
5.3   RELEASES TO THE ENVIRONMENT  
 
The Toxics Release Inventory (TRI) data should be used with caution because only certain types of 
facilities are required to report (EPA 2005).  This is not an exhaustive list.  Manufacturing and processing 
facilities are required to report information to the TRI only if they employ ≥10 full-time employees; if 
their facility is included in Standard Industrial Classification (SIC) Codes 10 (except 1011, 1081, and 
1094), 12 (except 1241), 20–39, 4911 (limited to facilities that combust coal and/or oil for the purpose of 
generating electricity for distribution in commerce), 4931 (limited to facilities that combust coal and/or 
oil for the purpose of generating electricity for distribution in commerce), 4939 (limited to facilities that 
combust coal and/or oil for the purpose of generating electricity for distribution in commerce), 4953 
(limited to facilities regulated under RCRA Subtitle C, 42 U.S.C. section 6921 et seq.), 5169, 5171, and 
7389 (limited S.C. section 6921 et seq.), 5169, 5171, and 7389 (limited to facilities primarily engaged in 
solvents recovery services on a contract or fee basis); and if their facility produces, imports, or processes 
≥25,000 pounds of any TRI chemical or otherwise uses >10,000 pounds of a TRI chemical in a calendar 
year (EPA 2005). 
 
5.3.1   Air  
 
Estimated releases of 2,717 pounds (~1.23 metric tons) of 1,2,3-trichloropropane to the atmosphere from 
6 domestic manufacturing and processing facilities in 2016, accounted for about 53.9% of the estimated 
total environmental releases from facilities required to report to the TRI (TRI16 2017).  These releases are 
summarized in Table 5-2. 
 
Data on releases of 1,2,3-trichloropropane to the atmosphere are lacking.  Based on the few data 
available, current releases to the air are expected to be relatively small.  Minor releases may have 
occurred as exhaust, stack, and fugitive emissions from its manufacture, formulation, and use as a solvent 
(HSDB 1989).  1,2,3-Trichloropropane may have been released in the past into the air as a result of its use 
as a paint and varnish remover, a degreasing agent, and a cleaning and maintenance reagent (Hawley 
1981; NIOSH 1981).  No information was found that indicates that 1,2,3-trichloropropane is still used for 
these purposes today.  Very small amounts may be released during its use as a chemical intermediate and 
as a result of its formation during the synthesis of other organic chemicals.  Volatilization from 
contaminated surface waters, effluent waters, and near surface soils may also be minor atmospheric 
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sources of this compound.  This includes volatilization from identified and unidentified hazardous waste 
dumps that contain 1,2,3-trichloropropane and from farmland treated with 1,2,3-trichloropropane-
contaminated fumigants and nematocides (no information is available to determine whether or not the soil 
fumigants and nematocides currently manufactured contain 1,2,3-trichloropropane).  Small amounts may 
be released to the air during treatment of water containing 1,2,3-trichloropropane, because some of the 
chemical may be removed via evaporative stripping from the water. 
 
Table 5-2.  Releases to the Environment from Facilities that Produce, Process, or 
Use 1,2,3-Trichloropropanea 
 
 Reported amounts released in pounds per yearb 
Statec RFd Aire Waterf UIg Landh Otheri 
Total release 
On-sitej Off-sitek 
On- and 
off-site 
LA 2 1,554 0 0 0 0 1,554 0 1,554 
TX 4 1,163 2,218 0 105 0 3,384 102 3,486 
Total 6 2,717 2,218 0 105 0 4,938 102 5,040 
 
aThe TRI data should be used with caution since only certain types of facilities are required to report.  This is not an 
exhaustive list.  Data are rounded to nearest whole number. 
bData in TRI are maximum amounts released by each facility. 
cPost office state abbreviations are used. 
dNumber of reporting facilities. 
eThe sum of fugitive and point source releases are included in releases to air by a given facility. 
fSurface water discharges, waste water treatment-(metals only), and publicly owned treatment works (POTWs) (metal 
and metal compounds). 
gClass I wells, Class II-V wells, and underground injection. 
hResource Conservation and Recovery Act (RCRA) subtitle C landfills; other onsite landfills, land treatment, surface 
impoundments, other land disposal, other landfills. 
iStorage only, solidification/stabilization (metals only), other off-site management, transfers to waste broker for 
disposal, unknown 
jThe sum of all releases of the chemical to air, land, water, and underground injection wells. 
kTotal amount of chemical transferred off-site, including to POTWs. 
 
RF = reporting facilities; UI = underground injection 
 
Source:  TRI16 2017 (Data are from 2016) 
 
5.3.2   Water  
 
Estimated releases of 2,218 pounds (~1 metric ton) of 1,2,3-trichloropropane to surface water from 
6 domestic manufacturing and processing facilities in 2016, accounted for about 44% of the estimated 
total environmental releases from facilities required to report to the TRI (TRI16 2017).  These releases are 
summarized in Table 5-2. 
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Data on the release of 1,2,3-trichloropropane to environmental waters are lacking.  Based on the few data 
available, current releases to environmental waters are expected to be relatively small.  Releases to 
surface water may have occurred through runoff of waste water from hazardous waste sites containing 
1,2,3-trichloropropane and runoff from farmland treated with certain soil fumigants and nematocides that 
contain 1,2,3-trichloropropane.  Releases to surface and groundwater may have occurred as a result of the 
improper disposal of 1,2,3-trichloropropane-containing industrial wastes or wastes from its use in paint- 
and varnish-removers, cleaning and degreasing agents, and maintenance reagents.  Releases to 
groundwater may have occurred as a result of the chemical leaching through soil at waste sites and 
agricultural soil treated with fumigants that contain the chemical.  Small amounts of the chemical may 
have entered surface waters as a result of washout from 1,2,3-trichloropropane-contaminated air; 
however, some of the 1,2,3-trichloropropane removed from the atmosphere by washout is likely to have 
re-entered the atmosphere by volatilization.   
 
5.3.3   Soil  
 
Estimated releases of 105 pounds (~0.05 metric tons) of 1,2,3-trichloropropane to soils from 6 domestic 
manufacturing and processing facilities in 2016, accounted for about 2.1% of the estimated total 
environmental releases from facilities required to report to the TRI (TRI16 2017).  No 1,2,3-trichloro-
propane was released via underground injection (TRI16 2017).  These releases are summarized in 
Table 5-2. 
 
Data on releases of 1,2,3-trichloropropane to soils are sparse, which makes a quantitative estimation of 
the magnitude of such releases impossible.  However, releases to soils are expected to be relatively small 
based upon the available data.  Releases to farmland soil have occurred as a result of the use of certain 
soil fumigants and nematocides known to contain 1,2,3-trichloropropane as an impurity.  No current 
information is available, however, that indicates that these soil fumigants and nematocides still contain 
1,2,3-trichloropropane.  Releases of the chemical to soil may have occurred as a result of disposal of 
1,2,3-trichloropropane-containing sewage sludge from municipal sewage treatment plants (Jacobs and 
Zabik 1983).  Very small amounts of the chemical may be brought to the surface of the earth as a result of 
washout from 1,2,3-trichloropropane-containing air; however, much of the 1,2,3-trichloropropane 
removed from the atmosphere by washout may re-enter the atmosphere by volatilization from near-
surface soil.  Land disposal of wastes from its use in paint and varnish removers, cleaning and degreasing 
agents, and cleaning and maintenance reagents may have released 1,2,3-trichloropropane to soil.   
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5.4   ENVIRONMENTAL FATE  
 
5.4.1   Transport and Partitioning  
 
No experimental or predictive data were located in the literature regarding the transport of 1,2,3-trichloro-
propane in the atmosphere.  1,2,3-Trichloropropane is expected to exist in the atmosphere predominantly 
in the vapor phase, based on its vapor pressure (Table 4-2) (Eisenreich et al. 1981; MacKay et al. 1982).  
The speculation that substantial amounts of 1,2,3-trichloropropane are not likely to be present in the 
particulate phase indicates that dry deposition to the earth's surface will not be an important removal 
process.  Based upon its low water solubility and moderate vapor pressure (Table 4-2), very small 
amounts of 1,2,3-trichloropropane present in air may be removed by wet deposition; however, much of 
the 1,2,3-trichloropropane removed from the atmosphere by washout is likely to re-enter the atmosphere 
by volatilization.  Based upon an estimated soil organic carbon partition coefficient (Koc) of 98 (calculated 
from water solubility) (Lyman et al. 1982; Riddick et al. 1986), 1,2,3-trichloropropane is expected to 
display high mobility in soil (Swann et al. 1983); therefore, it has the potential to leach into groundwater.  
This predicted mobility is confirmed by the detection of 1,2,3-trichloropropane in groundwater from 
various locations.  The vapor pressure of 1,2,3-trichloropropane (3.1 mmHg at 25°C) (MacKay et al. 
1982) and the calculated Henry's law constant (3.17x10-4 atm-m3/mol at 25°C) (Lyman et al. 1982) 
suggest that volatilization from either dry or moist soil to the atmosphere will be a significant 
environmental process.  1,2,3-Trichloropropane in surface water is expected to volatilize rapidly to the 
atmosphere.  An experimental half-life of 56.1 minutes has been measured for evaporation of 1,2,3-tri-
chloropropane from a 1 ppm solution, with a depth of 6.5 cm, stirred with a shallow pitch propeller at 
200 rpm at 25°C under still air (<0.2 mph air currents) (Dilling 1977).  Using the Henry's law constant, a 
half-life of 6.9 hours was calculated for evaporation from a model river 1 m deep, flowing at 1 m/second, 
with a wind velocity of 3 m/second, and neglecting adsorption to sediment (Lyman et al. 1982).  A 
volatilization half-life of 3.5 days from a model pond can be estimated (EPA 1985).  1,2,3-Trichloro-
propane is not expected to significantly adsorb to sediment and suspended organic matter based upon the 
estimated Koc of 98 (calculated from water solubility) (Lyman et al. 1982; Riddick et al. 1986).  It is also 
not expected to significantly bioconcentrate in fish and aquatic organisms based upon an estimated 
bioconcentration factor (BCF) of 9.2 (calculated from log octanol-water partition coefficient (Kow) (EPA 
1988b; Lyman et al. 1982).  No data were located to indicate a potential for 1,2,3-trichloropropane to 
biomagnify from lower to higher trophic states of the food chain, but based upon the estimated BCF, this 
is not likely. 
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5.4.2   Transformation and Degradation  
 
Air.    The primary degradation process for 1,2,3-trichloropropane in the atmosphere is expected to occur 
via gas-phase reaction with photochemically produced hydroxyl radicals.  The rate constant for this 
process is an estimated 1.0475x10-12 cm3/molecule-second (Atkinson 1987).  This corresponds to a half-
life of 15.3 days at an estimated atmospheric concentration of 5x105 hydroxyl radicals/cm3.  Direct 
photolysis of 1,2,3-trichloropropane is not expected to occur in the atmosphere because the chemical 
lacks a chromophore that absorbs light at environmentally significant wavelengths (>290 nm) (Silverstein 
et al. 1974). 
 
Water.    Degradation of 1,2,3-trichloropropane in natural waters is expected to be a slow process.  The 
chemical should volatilize from surface waters before significant degradation can occur.  Hydrolysis of 
1,2,3-trichloropropane in natural waters is not expected to be a significant removal process.  The 
measured neutral and base hydrolysis rate constants at 25°C are 1.8x10-6 hour-l and 9.9x10-4 M-1 hour-l, 
respectively (EPA 1988c).  These rate constants correspond to a hydrolysis half-life of 44 years over a pH 
range of 5–9.  Direct photolysis of 1,2,3-trichloropropane is not expected to occur in environmental 
waters because the chemical lacks a chromophore that absorbs light at environmentally significant 
wavelengths (>290 nm) (Silverstein et al. 1974). 
 
No studies were located regarding the biodegradation of 1,2,3-trichloropropane in natural waters.  An 
aqueous screening study with activated sewage sludge has indicated that 1,2,3-trichloropropane can be 
removed by biological treatment processes and that at least part of the removal was due to volatilization.  
However, this study cannot be used to predict the biodegradability of this compound under natural 
conditions.  Other authors have observed that halogenated hydrocarbons, in general, and especially those 
with multiple chlorine substitution, such as 1,1,2-trichloroethane and 1,1,2,2-tetrachloroethane, are 
recalcitrant towards biodegradation (Kawasaki 1980; Tabak et al. 1981).  No data concerning the potential 
for anaerobic aqueous biodegradation of 1,2,3-trichloropropane were found. 
 
Sediment and Soil.    No data specifically regarding the degradation of 1,2,3-trichloropropane in soil 
were found.  However, it has been observed that 1,2-dichloropropane will not significantly biodegrade in 
soil (Roberts and Stoydin 1976).  Therefore, 1,2,3-trichloropropane is expected to be even less 
biodegradable because it contains an additional chlorine.  The rate of 1,2,3-trichloropropane loss from soil 
due to biodegradation may not be significant when compared with its loss by volatilization and leaching 
from soil.  1,2,3-Trichloropropane will be lost from the soil by evaporation (from both moist and dry 
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near-surface soil) and by leaching to groundwater before 1,2,3-trichloropropane will hydrolyze in soil.  
Direct photolysis on the surface of soil will not occur. 
 
5.5   LEVELS IN THE ENVIRONMENT  
 
Reliable evaluation of the potential for human exposure to 1,2,3-trichloropropane depends, in part, on the 
reliability of supporting analytical data from environmental samples and biological specimens.  
Concentrations of 1,2,3-trichloropropane in unpolluted atmospheres and in pristine surface waters are 
often so low as to be near the limits of current analytical methods.  In reviewing data on 1,2,3-trichloro-
propane levels monitored or estimated in the environment, it should also be noted that the amount of 
chemical identified analytically is not necessarily equivalent to the amount that is bioavailable. 
 
Table 5-3 shows the lowest limit of detections that are achieved by analytical analysis in environmental 
media.  An overview summary of the range of concentrations detected in environmental media is 
presented in Table 5-4. 
 
Table 5-3.  Lowest Limit of Detection Based on Standardsa 
 
Media Detection limit Reference 
Air 0.3 mg/sample NIOSH 1987 
Drinking water 0.03 µg/L EPA 1986a; Ho 1989 
Surface water and 
groundwater 
No data E{PA 1986b 
Soil No data Lopez-Avila et al. 1987 
 
aDetection limits based on using appropriate preparation and analytics.  These limits may not be possible in all 
situations. 
 
Table 5-4.  Summary of Environmental Levels of 1,2,3-Trichloropropane 
 
Media Low High For more information 
Outdoor air (ppbv) No monitoring data identified 
Indoor air (ppbv) No monitoring data identified 
Surface water (ppb) No monitoring data identified 
Ground water (ppb) 0.1 µg/L 5.0 µg/L Section 5.5.2 
Drinking water (ppb) No monitoring data identified 
Food (ppb) No monitoring data identified 
Soil 0.2 ppb 2 ppb See Section 5.5.3 
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Detections of 1,2,3-trichloropropane in air, water, and soil at NPL sites are summarized in Table 5-5.   
 
Table 5-5.  1,2,3-Trichloropropane Levels in Water, Soil, and Air of National 
Priorities List (NPL) Sites 
 
Medium Mediana 
Geometric 
meana 
Geometric 
standard 
deviationa 
Number of 
quantitative 
measurements NPL sites 
Water (ppb) 0.8 7.2 283,000 11 8 
Soil (ppb) 12,500,000 79,100 3,430,000 2 1 
 
aConcentrations found in ATSDR site documents from 1981 to 2017 for 1,854 NPL sites (ATSDR 2017).  Maximum 
concentrations were abstracted for types of environmental media for which exposure is likely.  Pathways do not 
necessarily involve exposure or levels of concern. 
 
5.5.1   Air  
 
No data were located regarding the detection of 1,2,3-trichloropropane in ambient air in the United States.  
Therefore, no estimate of U.S. atmospheric levels of the chemical, including background levels, is 
possible. 
 
5.5.2   Water  
 
Limited data are available regarding the detection of 1,2,3-trichloropropane in environmental waters.  It 
has been detected by one of the sampling techniques at <0.2 μg/L in drinking water from the Carrollton 
Water Plant in New Orleans, Louisiana, sampled during August, 1974; however, since two of the three 
sampling techniques failed to detect the compound, the significance of this detection is in question (Keith 
et al. 1976).  1,2,3-Trichloropropane has been qualitatively detected in the drinking water of Cincinnati, 
Ohio, sampled during 1978 (EPA 1984), and Ames, Iowa, on an unspecified date (EPA 1987).  Data from 
the EPA STORET database indicate that 1,2,3-trichloropropane was found in 39% of 941 samples of 
groundwater at a median concentration of 0.69 μg/L, at an average concentration of 1.0 μg/L, and a range 
of trace (below unspecified detection limit) to 2.5 μg/L (STORET 1989).  It has been found at 
concentrations ranging from 0.1 to 5.0 μg/L in groundwater samples from California and Hawaii during 
small- and large-scale retrospective studies of farmlands possibly treated with fumigants and nematocides 
that contained 1,2,3-trichloropropane as an impurity (Cohen et al. 1986, 1987).  The locations that had 
1,2,3-trichloropropane-contaminated wells included the island of Oahu, Hawaii, and the Central Valley of 
California.  Typical concentrations ranged from 0.2 to 2 μg/L.  1,2,3-Trichloropropane was found in water 
from nine of nine wells in Oahu, Hawaii, sampled in 1983 and 1984 at maximum concentrations ranging 
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from 0.30 to 2.8 μg/L (Oki and Giambelluca 1987).  The wells had been closed previously to drinking 
water use due to contamination with other halogenated hydrocarbons.  1,2,3-Trichloropropane has been 
detected in groundwater from 2 of 10 sites in an agricultural community in Suffolk County, New York, at 
concentrations of 6 and 10 μg /L (Lykins and Baier 1985). 
 
1,2,3-Trichloropropane was qualitatively found in 1 of 30 water samples from the Delaware, Schuylkill, 
and Lehigh Rivers, taken February 17–20, 1976 (DeWalle and Chian 1978).  1,2,3-Trichloropropane was 
qualitatively found in water from Narragansett Bay, Rhode Island, sampled during the summers of 1979 
and 1980, and the winters of 1980 and 1981 (Wakeham et al. 1983).  Some samples reportedly contained 
significant levels of the chemical.  The chemical was qualitatively detected in effluent from an advanced 
waste treatment plant in Lake Tahoe, California, in 1974 (EPA 1984).   
 
5.5.3   Sediment and Soil  
 
Limited data are available regarding the detection of 1,2,3-trichloropropane in soil samples.  It has been 
found in soil samples from California and Hawaii during small- and large-scale retrospective studies at 
levels typically ranging from 0.2 to 2 ppb (Cohen et al. 1987).  It was found at least 10 feet down in the 
soil profiles in Hawaii.  1,2,3-Trichloropropane may be present in these soils as a result of the use of 
dichloropropene (a soil fumigant and nematocide).  1,2,3-Trichloropropane is used in the preparation of 
this nematocide and is an impurity in the formulation of it (Baier et al. 1987).   
 
5.5.4   Other Media  
 
1,2,3-Trichloropropane has been qualitatively identified as a component of ethylene dichloride-tar, a 
tarlike, oily waste byproduct of vinyl chloride production that had been disposed of by dumping into the 
sea (Jensen et al. 1975).  The chemical has been found in the volatile products from the thermal oxidative 
degradation of the flame-retardant plasticizer, tris(dichloropropy1) phosphate (Christos et al. 1977).  No 
information was found that indicated that 1,2,3-trichloropropane has been found in food.  Because of the 
lack of recent comprehensive monitoring data, the average daily intake of 1,2,3-trichloropropane and the 
relative significance of each source of exposure cannot be determined. 
 
5.6   GENERAL POPULATION EXPOSURE  
 
There are not enough measured data to assess the general population's exposure to this compound.  The 
paucity of data may be the result of either a lack of 1,2,3-trichloropropane contamination in the 
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environment or a lack of studies that attempt to identify and quantify the compound in the environment 
using sufficiently sensitive techniques.  Based upon the few data available, the estimated transport and 
partitioning properties of the compound, and information on production and use, the following 
estimations concerning exposure can be made.  A small part of the population may be exposed to very 
low levels of 1,2,3-trichloropropane through the ingestion of contaminated drinking water.  Exposure to 
very low levels of 1,2,3-trichloropropane also may occur through the inhalation of contaminated air; 
however, no monitoring data regarding the presence of 1,2,3-trichloropropane in the atmosphere in the 
United States were located.  General exposure to air containing low levels may occur near chemical 
manufacturing facilities that produce 1,2,3-trichloropropane and certain other chemicals, near 1,2,3-tri-
chloropropane-containing hazardous waste dumps, and farmlands treated with fumigants and nematocides 
that contain 1,2,3-trichloropropane.  No current information is available, however, that indicates that 
1,2,3-trichloropropane is still present in soil fumigant formulations, and commercial manufacturing 
processes generally occur in closed and tightly sealed systems (NIOSH 1981).  Inhalation and dermal 
exposure may occur during the use of 1,2,3-trichloropropane as a solvent and extractive agent, in paint 
and varnish removers, in cleaning and degreasing agents, and in cleaning and maintenance reagents, 
although there is no current information that indicates that the compound is still used for these purposes 
(Hawley 1981; NIOSH 1981).  No data regarding the detection of 1,2,3-trichloropropane in humans in the 
United States were located. 
 
According to the NOES conducted by NIOSH from 1981 to 1983, 492 workers (of which 9 were women) 
were potentially exposed to 1,2,3-trichloropropane in the workplace in 1980 (NIOSH 1989); however, no 
report of actual measured exposure levels in any occupational situation in the United States was located.  
The NOES database does not contain information on the frequency, concentration, or duration of 
exposure of workers to any of the chemicals therein.  This survey provides only an estimate of the number 
of workers potentially exposed to chemicals in the workplace.  Occupational exposure to 1,2,3-trichloro-
propane is expected to be higher in facilities where the chemical or products containing the chemical are 
used than in facilities that produce 1,2,3-trichloropropane either directly or as a byproduct, since the 
commercial manufacturing processes generally occur in closed and tightly sealed systems (NIOSH 1981).  
Furthermore, exposure may result from procedures that require direct handling of the material; these 
include purification, formulation of products, sampling and quality control, packaging and storage, 
leakage of equipment, startup and shutdown procedures, maintenance, cleanup, spills, and other plant 
emergencies (NIOSH 1981). 
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5.7   POPULATIONS WITH POTENTIALLY HIGH EXPOSURES  
 
Data regarding the presence of 1,2,3-trichloropropane in the environment are lacking, which prevents the 
thorough assessment of the potential for high exposure in various populations.  Populations with 
potentially high exposure to 1,2,3-trichloropropane will generally include those that may be exposed to 
environmental contamination over long periods of time.  These may include populations exposed to low 
levels of 1,2,3-trichloropropane via inhalation of contaminated air at or near both identified and 
unidentified 1,2,3-trichloropropane-containing waste disposal sites and landfills.  Children playing in and 
around these sites may also be dermally exposed to soil containing 1,2,3-trichloropropane, although any 
1,2,3-trichloropropane in surface soil would be expected to volatilize or leach through the soil.  Persons 
whose drinking water is derived from 1,2,3-trichloropropane-contaminated groundwater or surface water 
for a long period of time may be exposed to relatively high levels of 1,2,3-trichloropropane.  Workers 
involved in the manufacture or use of 1,2,3-trichloropropane or 1,2,3-trichloropropane-containing 
products may have the highest potential for exposure to 1,2,3-trichloropropane.  Potentially high general 
population exposure may occur during the use of 1,2,3-trichloropropane-containing products, such as 
paint and varnish removers and cleaners, especially when they are used in poorly ventilated areas such as 
in the cleaning of reactors.  Exposure through the manufacture or use of 1,2,3-trichloropropane-containing 
products may not be significant, however, since current manufacturing processes generally occur in 
closed and tightly sealed systems (NIOSH 1981) and no current information indicates that 1,2,3-trichloro-
propane is still used for those purposes listed. 
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CHAPTER 6.  ADEQUACY OF THE DATABASE 
 
Section 104(i)(5) of CERCLA, as amended, directs the Administrator of ATSDR (in consultation with the 
Administrator of EPA and agencies and programs of the Public Health Service) to assess whether 
adequate information on the health effects of 1,2,3-trichloropropane is available.  Where adequate 
information is not available, ATSDR, in conjunction with NTP, is required to assure the initiation of a 
program of research designed to determine the adverse health effects (and techniques for developing 
methods to determine such health effects) of 1,2,3-trichloropropane. 
 
Data needs are defined as substance-specific informational needs that, if met, would reduce the 
uncertainties of human health risk assessment.  This definition should not be interpreted to mean that all 
data needs discussed in this section must be filled.  In the future, the identified data needs will be 
evaluated and prioritized, and a substance-specific research agenda will be proposed.  
 
6.1   Information on Health Effects 
 
Studies evaluating the health effects of inhalation, oral, and dermal exposure of humans and animals to 
1,2,3-trichloropropane that are discussed in Chapter 2 are summarized in Figure 6-1.  The purpose of this 
figure is to illustrate the information concerning the health effects of 1,2,3-trichloropropane.  The number 
of human and animal studies examining each endpoint is indicated regardless of whether an effect was 
found and the quality of the study or studies.   
 
As illustrated in Figure 6-1, most of the data on the toxicity of 1,2,3-trichloropropane come from studies 
in experimental animals.  The most commonly examined endpoints were liver, body weight, respiratory, 
and kidneys.  Information of the toxicity of 1,2,3-trichloropropane in humans is limited to three studies, 
one being a case report.  Approximately half of the experimental animal studies involved oral exposure; 
the remaining studies were equally split between inhalation and dermal/ocular exposure routes. 
 
6.2   Identification of Data Needs  
 
Missing information in Figure 6-1 should not be interpreted as a “data need”.  A data need, as defined in 
ATSDR’s Decision Guide for Identifying Substance-Specific Data Needs Related to Toxicological 
Profiles (ATSDR 1989), is substance-specific information necessary to conduct comprehensive public 
health assessments.  Generally, ATSDR defines a data gap more broadly as any substance-specific 
information missing from the scientific literature.   
1,2,3-TRICHLOROPROPANE   
 
6.  ADEQUACY OF THE DATABASE 
 
 
 
 
 
 
***DRAFT FOR PUBLIC COMMENT*** 
Figure 6-1.  Summary of Existing Health Effects Studies on 
1,2,3-Trichloropropane By Route and Endpoint* 
   
Potential hepatic, respiratory, body weight, and renal effects were the most studied endpoints  
The majority of the studies examined oral exposure in animals (versus humans) 
 
 
 
 
 
*Includes studies discussed in Chapter 2; the number of studies include those 
finding no effect.   
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Acute-Duration MRLs.  The available acute inhalation database was considered adequate for 
derivation of a provisional MRL.  Although several studies have evaluated the acute oral toxicity of 
1,2,3-trichloropropane, the database was not considered adequate for derivation of an MRL.  Several 
limitations were identified, including the lack of support for categorizing the increase in liver weight 
observed in the Merrick et al. (1991) study as adverse and support for the observed cardiovascular lesions 
(Merrick et al. 1991).  Additionally studies that included examination of the liver and heart would provide 
valuable information for identifying critical effects and establishing dose-response relationships. 
 
Intermediate-Duration MRLs.  Several studies have evaluated the intermediate-duration toxicity of 
inhaled 1,2,3-trichloropropane in experimental animals (Johannsen et al. 1988); several adverse effects 
were identified including peribronchial hyperplasia, hepatocellular hypertrophy, and splenic 
extramedullary hematopoiesis.  However, derivation of an MRL based on these endpoints resulted in a 
value that was about 10 times higher than the acute-duration inhalation MRL.  One limitation of the 
intermediate-duration database is the lack of a study examining the nasal cavity, which was the most 
sensitive effect following acute exposure.  Intermediate-duration studies examining a wide range of 
endpoints, particularly the nasal cavity, would be useful for identifying the most sensitive effect and 
derivation of an MRL.  The oral exposure database was considered adequate for derivation of an oral 
MRL. 
 
Chronic-Duration MRLs.  No chronic-duration inhalation studies were identified for 1,2,3-trichloro-
propane, precluding the derivation of an MRL.  Chronic-duration studies examining a wide range of 
endpoints, particularly the nasal cavity, which was the most sensitive target following acute-duration 
exposure, would be useful for identifying the most sensitive effect, establishing concentration-response 
relationships and derivation of an MRL.  The chronic-duration oral database was considered adequate for 
deriving a provisional MRL. 
 
Health Effects.   
 
Respiratory.  Acute inhalation studies have identified the nasal olfactory epithelium as a 
sensitive target of 1,2,3-trichloropropane toxicity in rats and mice (Miller et al. 1986a, 1986b).  
Nasal effects have also been observed in following oral exposure (NTP 1993).  However, nasal 
effects have not been examined in longer-term inhalation studies.  Longer-term studies examining 
the nasal cavity would allow for a better understanding of the toxicity of inhaled 1,2,3-trichloro-
propane. 
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Cardiovascular.  Inflammation, degeneration, and necrosis have been observed in rats 
following acute and intermediate oral exposure (Merrick et al. 1991).  However, other 
investigators have not reported adverse effects in rats administered similar or higher doses.  
Additional studies are needed to support this finding. 
 
Immune.  Effects such as lymphoid depletion and decreased weight of the spleen of rats and 
mice exposed orally and by inhalation to near-lethal levels of 1,2,3-trichloropropane for several 
weeks could have immunological significance (Johannsen et al. 1988; Merrick et al. 1991; NTP 
1993).  However, these effects could also be secondary to the observed decreases in body weight.  
Limited evidence from one study suggests that 1,2,3-trichloropropane may be a weak dermal 
sensitizer in guinea pigs (Clark 1977).  Studies examining immune function are needed to 
evaluate the potential immunotoxicity of 1,2,3-trichloropropane. 
 
Developmental.  There were no effects on growth or viability of offspring of rats exposed by 
inhalation to low concentrations of 1,2,3-trichloropropane prior to mating and during gestation, 
(Johannsen et al. 1988).  In a 2-generation study, decreases in reproductive function was observed 
in F1 rats (NTP 1990).  Both studies were of limited scope.  Given the genotoxicity of 1,2,3-tri-
chloropropane, there is potential for developmental effects.  Single and 2-generation studies 
examining a wide range of endpoints are needed; the developmental studies should also include 
neurological and cognitive endpoints. 
 
Carcinogenicity.  Although animal studies provide evidence of the carcinogenicity of 
1,2,3-trichloropropane, very little information is available on the mechanisms of action for 
carcinogenicity and the causative agent.  Mechanistic studies would provide valuable information 
to the understanding of the carcinogenic potential in humans. 
 
Epidemiology and Human Dosimetry Studies.  A small number of human studies have been 
examined the toxicity 1,2,3-trichloropropane (Brender et al. 2014; Han 2010; Silverman et al. 1946).  
Only one of these provided exposure data (Silverman et al. 1946), but only examined sensory responses.  
Studies of populations exposed to 1,2,3-trichloropropane could provide information on whether rodents 
are good models for human toxicity.   
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Biomarkers of Exposure and Effect.  There are no known biomarkers of exposure for 1,2,3-tri-
chloropropane in humans.  Studies with rats suggest that respiratory or urinary excretion of 1,2,3-tri-
chloropropane may be sufficient for monitoring purposes (Sipes et al. 1982).  Additional studies could 
help determine the feasibility of using 1,2,3-trichloropropane in the breath or urine as a biomarker of 
exposure.  
 
There are no known biomarkers of effects for 1,2,3-trichloropropane in humans.  One study with rats 
(NTP 1993) suggests that anemia and alterations of serum enzymes (e.g., decreased serum 
pseudocholinesterase activity) might be sensitive biomarkers for hematologic and hepatic effects of 
1,2,3-trichloropropane, respectively.  Additional animal studies or examination of humans with known 
exposure to 1,2,3-trichloropropane are needed to identify potential biomarkers of exposure, especially 
biomarkers that would be indicative of subclinical alterations. 
 
Absorption, Distribution, Metabolism, and Excretion.  There is limited information on absorption 
and excretion of single oral doses of 1,2,3-trichloropropane in rats (Mahmood et al. 1991; Sipes et al. 
1982; Volp et al. 1984), but no data are available on the toxicokinetics of 1,2,3-trichloropropane in 
animals after inhalation or dermal exposure.  Tissue distribution, metabolism, and excretion of 
intravenously injected 1,2,3-trichloropropane also have been investigated in rats (Volp et al. 1984).  A 
PBPK model describing tissue distribution and excretion was developed using data from this intravenous 
study.  A more complete oral study in animals, as well as animal studies using inhalation and dermal 
exposure, could provide necessary data (e.g., absorption kinetics) for expanding the model to include 
inhalation, oral, and dermal exposure and verifying the model.  It might then be possible to use the model 
to predict the pharmacokinetics of 1,2,3-trichloropropane in humans exposed by these routes.  Studies 
with several dose levels and exposure durations would allow more accurate comparison between routes 
(e.g., assessment of relative rates and extent of absorption, distribution, metabolism, and excretion) as 
well as detection of saturation effects. 
 
Comparative Toxicokinetics.  The toxicokinetics of 1,2,3-trichloropropane have been studied only in 
rats by the oral and intravenous routes (Mahmood et al. 1991; Sipes et al. 1982; Volp et al. 1984).  A 
PBPK model has been proposed based on the intravenous data.  Studies in other species would be useful 
for verifying predictions made from the model about other species, including humans. 
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Children’s Susceptibility.  No information is available on children’s susceptibility; additionally, there 
are limited developmental toxicity studies (see Health Effects section).  Studies examining immature 
animals may provide valuable information on the potential increased sensitivity of children.   
 
Physical and Chemical Properties.  Physical and chemical property data are essential for estimating 
the transport and partitioning of a chemical in the environment.  Many of the physical and chemical 
properties of 1,2,3-trichloropropane are available (Table 4-2) (Hawley 1981; HSDB 1989; Mackay et al. 
1982; McNeill 1979; Riddick et al. 1986; Ruth 1986; Weast 1985; Williams 1949).  However, only 
estimated values are listed for the log Kow, Koc, and BCF (Lyman et al. 1982).  Since the log Kow was used 
to estimate the Koc and BCF, an experimentally determined log Kow would lead to less uncertainty in those 
estimated properties.  Experimentally determined values would clarify the reliability of these data, 
although the techniques used for the estimations appear to be accurate. 
 
Production, Import/Export, Use, Release, and Disposal.  Data regarding the production methods 
for 1,2,3-trichloropropane are available (Bauer et al. 1987; Hawley 1981; NIOSH 1981; SRI 1989; 
Williams 1949); however, data regarding current production, import, and export volumes, and use 
patterns are lacking.  We do know that the chemical is currently produced (SRI 1989), but not in what 
quantities or whether future production levels will increase.  We do not know if the chemical is widely 
used in the home, the environment, or in the workplace, but it does not appear that such widespread use is 
likely.  It has not been found in food, although foods may not have been tested for its presence.  Use, 
release, and disposal information is useful for determining where environmental exposure to 1,2,3-tri-
chloropropane may be high, and may help in estimating whether exposure is likely, and may therefore 
help to determine whether further toxicological studies are warranted.  General data are available 
regarding the methods of disposal of 1,2,3-trichloropropane (HSDB 1989; Matsui et al. 1975), but 
information concerning the efficiencies of these methods, as well as the amount disposed of by each 
method, is lacking.  Specific disposal information, obtainable by polling industries or industry 
organizations, may be useful for determining environmental burden and potential concentrations where 
environmental exposures may be high.  Rules and regulations governing land disposal of 1,2,3-trichloro-
propane are known (EPA 1988a). 
 
Environmental Fate.  The environmental fate of 1,2,3-trichloropropane remains unclear due to a lack 
of experimental data.  We do not know where the chemical partitions in the environment.  However, 
based upon estimated physical properties (Lyman et al. 1982), the chemical is expected to partition into 
the atmosphere and groundwater (Swann et al. 1983).  It has been shown that the chemical leaches 
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through soil (Cohen et al. 1986, 1987; Lykins and Baier 1985; Oki and Giamelluca 1987; STORET 
1989).  It is estimated that it can volatilize, through near-surface soil and water to the atmosphere (EPA 
1985; Lyman et al. 1982).  Nothing definitive is known about the biodegradability of the compound.  The 
rate constant for reaction with hydroxyl radicals in the atmosphere is an estimated value (Atkinson 1987), 
as are significant partition coefficient values used in predicting the environmental fate of the compound 
(EPA 1988b).  Experimental data in these areas would aid in assessing the ultimate environmental fate of 
1,2,3-trichloropropane, which would, in turn, aid in assessing its background levels in the environment 
and levels of human exposure. 
 
Bioavailability from Environmental Media.  Studies have shown that 1,2,3-trichloropropane is 
absorbed through the lungs, gastrointestinal tract, and skin of animals (Alpert 1982; Clark 1977; 
Johannsen et al. 1988; Sipes et al. 1982; Union Carbide 1958; Volp et al. 1984).  This indicates that it 
may be absorbed through the inhalation of contaminated air, ingestion of contaminated water, food, and 
soil, and through dermal contact.  The amount of 1,2,3-trichloropropane that is bioavailable from each 
route is not well documented, and no data were found for humans.  Data on the bioavailability of 1,2,3-tri-
chloropropane would be helpful in assessing the importance of environmental exposure levels. 
 
Food Chain Bioaccumulation.  The estimated BCF for 1,2,3-trichloropropane (EPA 1988b; Lyman 
et al. 1982) indicates that this compound would not significantly bioconcentrate in plants, aquatic 
organisms, or animals.  No experimental data were found to support this conclusion.  Information was 
unavailable on the biomagnification of 1,2,3-trichloropropane in food chains.  Additional information on 
bioconcentration by plants, aquatic organisms, and animals and biomagnification in terrestrial and aquatic 
food chains could be helpful because it might help to indicate whether the chemical biomagnifies in food 
chains and thereby poses a potential for significant exposure.  Biomagnification is not likely, however, 
based upon the estimated BCF. 
 
Exposure Levels in Environmental Media.  Limited data were available regarding the levels of 
1,2,3-trichloropropane in the environment (Baier et al. 1987; Cohen et al. 1986, 1987; Dewalle and Chian 
1978; EPA 1984, 1987; Jacobs and Zabik 1983; Keith et al. 1976; Lykins and Baier 1985; Oki and 
Giambelluca 1987; STORET 1989; Wakeham et al. 1983).  Information on exposure to 1,2,3-trichloro-
propane from environmental media would be useful, especially from drinking water derived from 
groundwater downgradient from 1,2,3-trichloropropane-containing hazardous waste disposal sites and 
other contaminated surface waters, air near facilities that make or use products containing the compound, 
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and soil at waste disposal sites.  Data concerning the presence of 1,2,3-trichloropropane in foods would 
also be useful in assessing potential exposure. 
 
Exposure Levels in Humans.  No data have been found that indicate that 1,2,3-trichloropropane has 
been found in human samples of blood, urine, fat, or breast milk.  Furthermore, no biomarkers of 
exposure or effect have been identified.  Data on both workplace exposure and ambient environmental 
exposure are sparse and outdated (NIOSH 1981, 1989).  A detailed, recent database of exposure would be 
helpful in determining the current exposure levels, thus allowing estimation of the average daily dose 
associated with various scenarios such as living near a hazardous waste disposal site, drinking 
contaminated drinking water, or working in a contaminated workplace.  This database of exposure may be 
very useful if current use patterns, for which information is not available, warrant it. 
 
Exposures of Children.  No monitoring data were identified for children.  General population 
monitoring studies should include children to allow for an assessment of potential differences in exposure 
of children and adults. 
 
Analytical Methods.  Analytical methods for determining 1,2,3-trichloropropane in contaminated air, 
water, soil, liquid and solid waste, sewage sludge, and citrus fruits are available (EPA 1986a, 1986b; Ho 
1989; Lopez-Avila et al. 1987; NIOSH 1987; Tonogai et al. 1986).  No methods were found for the 
determination of 1,2,3-trichloropropane in sediments.  Most of the methods used for environmental 
samples, however, did not report detection limits, recovery, accuracy, or precision for 1,2,3-trichloro-
propane.  Knowledge of these factors, as well as the development of alternative methods of analysis, 
would help in estimating the potential for human exposure to 1,2,3-trichloropropane.  No information was 
found regarding degradation products of 1,2,3-trichloropropane.  Consequently, no comment regarding 
the availability of analytical methods for determining degradation products can be made.  
 
There are methods for analyzing 1,2,3-trichloropropane in most of the biological matrices for the rat, 
although important information such as detection limits and recoveries was not reported (Sipes et al. 
1982).  These methods may be sufficient for the analysis of human biological matrices.   
 
6.3   Ongoing Studies  
  
No ongoing studies were identified for 1,2,3-trichloropropane. 
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CHAPTER 7.  REGULATIONS AND GUIDELINES 
 
Pertinent international and national regulations, advisories, and guidelines regarding 1,2,3-trichloro-
propane in air, water, and other media are summarized in Table 7-1.  This table is not an exhaustive list, 
and current regulations should be verified by the appropriate regulatory agency. 
 
ATSDR develops MRLs which are substance specific guidelines intended to serve as screening levels by 
ATSDR health assessors and other responders to identify contaminants and potential health effects that 
may be of concern at hazardous waste sites.  See Section 1.3 and Appendix A for detailed information on 
the MRLs for 1,2,3-trichloropropane. 
 
Table 7-1.  Regulations and Guidelines Applicable to 1,2,3-Trichloropropane 
 
Agency Description Information Reference 
Air 
EPA RfC 3x10-4 mg/m3 a IRIS 2009 
WHO Air quality guidelines No data WHO 2010 
Water & Food 
EPA Drinking water health advisories   EPA 2012 
 1-Day (10-kg child) 0.6 mg/L  
 10-Day (10-kg child) 0.6 mg/L  
 DWEL 0.1 mg/L  
National primary drinking water regulations No data EPA 2009a 
RfD  4x10-3 mg/kg-dayb IRIS 2009 
WHO Drinking water quality guidelines No data WHO 2017 
FDA EAFUS No datac FDA 2013 
Cancer 
ACGIH Carcinogenicity classification A2d,e ACGIH 2015, 2016 
HHS Carcinogenicity classification Reasonably anticipated 
to be a human 
carcinogenf 
NTP 2016 
EPA Carcinogenicity classification Likely to be 
carcinogenic to 
humansg 
IRIS 2009 
IARC Carcinogenicity classification Group 2Ah IARC 2017 
Occupational 
ACGIH TLV 0.005 ppm ACGIH 2016 
OSHA PEL (8-hour TWA) for general industry, 
shipyards and construction 
50 ppm (300 mg/m3) OSHA 2016a, 2016b, 
2016c 
NIOSH REL (up to 10-hour TWA) 10 ppm (60 mg/m3)i,j NIOSH 2014, 2016 
 IDLH 100 ppmi,k  
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Table 7-1.  Regulations and Guidelines Applicable to 1,2,3-Trichloropropane 
 
Agency Description Information Reference 
Emergency Criteria 
EPA AEGLs-air No data EPA 2016 
AIHA ERPGs No data AIHA 2015 
DOE PACs-air  DOE 2016a 
 PAC-1l 0.015 ppm  
 PAC-2l 170 ppm  
 PAC-3l 1000 ppm  
 
aBased on peribronchial lymphoid hyperplasia in male rats. 
bBased on increased absolute liver weight in male rats. 
cThe EAFUS list of substances contains ingredients added directly to food that FDA has either approved as food 
additives or listed or affirmed as GRAS. 
dA2: suspected human carcinogen. 
eBased on studies in rats and mice that found a wide range of tumors in both sexes following oral exposure, and on 
mechanistic studies that found the mechanism of tumor induction to involve interaction with genetic material. 
fBased on sufficient evidence of carcinogenicity from studies in experimental animals. 
gBased on a statistically significant and dose-related increase in the formation of multiple tumors in both sexes of two 
species in a chronic oral bioassay. 
hGroup 2A: probably carcinogenic to humans. 
iPotential occupational carcinogen. 
jSkin designation indicates the potential for dermal absorption. 
kBased on acute inhalation toxicity data in humans. 
lDefinitions of PAC terminology are available from U.S. DOE (2016b). 
 
ACGIH = American Conference of Governmental Industrial Hygienists; AEGL = acute exposure guideline levels; 
AIHA = American Industrial Hygiene Association; DOE = Department of Energy; EAFUS = Everything Added to Food 
in the United States; EPA = Environmental Protection Agency; ERPG = emergency response planning guidelines; 
FDA = Food and Drug Administration; GRAS = generally recognized as safe; HHS = Department of Health and 
Human Services; IARC = International Agency for Research on Cancer; IDLH = immediately dangerous to life or 
health concentrations; IRIS = Integrated Risk Information System; NIOSH = National Institute for Occupational 
Safety and Health; NTP = National Toxicology Program; OSHA = Occupational Safety and Health Administration; 
PAC = Protective Action Criteria; PEL = permissible exposure limit; REL = recommended exposure limit; 
RfC = inhalation reference concentration; RfD = oral reference dose; TLV = threshold limit values; TWA = time-
weighted average; WHO = World Health Organization 
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APPENDIX A.  ATSDR MINIMAL RISK LEVEL WORKSHEETS 
 
MRLs are derived when reliable and sufficient data exist to identify the target organ(s) of effect or the 
most sensitive health effect(s) for a specific duration for a given route of exposure.  An MRL is an 
estimate of the daily human exposure to a hazardous substance that is likely to be without appreciable risk 
of adverse noncancer health effects over a specified route and duration of exposure.  MRLs are based on 
noncancer health effects only; cancer effects are not considered.  These substance-specific estimates, 
which are intended to serve as screening levels, are used by ATSDR health assessors to identify 
contaminants and potential health effects that may be of concern at hazardous waste sites.  It is important 
to note that MRLs are not intended to define clean-up or action levels. 
 
MRLs are derived for hazardous substances using the NOAEL/uncertainty factor approach.  They are 
below levels that might cause adverse health effects in the people most sensitive to such chemical-
induced effects.  MRLs are derived for acute (1–14 days), intermediate (15–364 days), and chronic 
(≥365 days) durations and for the oral and inhalation routes of exposure.  Currently, MRLs for the dermal 
route of exposure are not derived because ATSDR has not yet identified a method suitable for this route 
of exposure.  MRLs are generally based on the most sensitive substance-induced endpoint considered to 
be of relevance to humans.  Serious health effects (such as irreparable damage to the liver or kidneys, or 
birth defects) are not used as a basis for establishing MRLs.  Exposure to a level above the MRL does not 
mean that adverse health effects will occur. 
 
MRLs are intended only to serve as a screening tool to help public health professionals decide where to 
look more closely.  They may also be viewed as a mechanism to identify those hazardous waste sites that 
are not expected to cause adverse health effects.  Most MRLs contain a degree of uncertainty because of 
the lack of precise toxicological information on the people who might be most sensitive (e.g., infants, 
elderly, nutritionally or immunologically compromised) to the effects of hazardous substances.  ATSDR 
uses a conservative (i.e., protective) approach to address this uncertainty consistent with the public health 
principle of prevention.  Although human data are preferred, MRLs often must be based on animal studies 
because relevant human studies are lacking.  In the absence of evidence to the contrary, ATSDR assumes 
that humans are more sensitive to the effects of hazardous substance than animals and that certain persons 
may be particularly sensitive.  Thus, the resulting MRL may be as much as 100-fold below levels that 
have been shown to be nontoxic in laboratory animals. 
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Proposed MRLs undergo a rigorous review process:  Health Effects/MRL Workgroup reviews within the 
Division of Toxicology and Human Health Sciences, expert panel peer reviews, and agency-wide MRL 
Workgroup reviews, with participation from other federal agencies and comments from the public.  They 
are subject to change as new information becomes available concomitant with updating the toxicological 
profiles.  Thus, MRLs in the most recent toxicological profiles supersede previously published MRLs.  
For additional information regarding MRLs, please contact the Division of Toxicology and Human 
Health Sciences, Agency for Toxic Substances and Disease Registry, 1600 Clifton Road NE, Mailstop 
S102-1, Atlanta, Georgia 30329-4027. 
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APPENDIX A 
MINIMAL RISK LEVEL (MRL) WORKSHEET 
Chemical Name: 
CAS Numbers: 
Date: 
Profile Status: 
Route: 
Duration: 
Provisional MRL: 
Critical Effect: 
Reference: 
Point of Departure: 
Uncertainty Factor: 
LSE Graph Key: 
Species: 
1,2,3-Trichloropropane 
96-18-4
May 2019
Final, Draft for Public Comment
Inhalation
Acute
0.001 ppm
Decreased thickness of nasal olfactory epithelium
Miller et al. 1986b
NOAELHEC of 0.03 ppm
30
5
Rat
MRL Summary:  A provisional acute-duration inhalation MRL of 0.001 ppm was derived for 1,2,3-tri-
chloropropane based on decreased thickness of the nasal olfactory epithelium of rats exposed 6 hours/day 
for 9 days over an 11-day period (Miller et al. 1986b).  The MRL is based on a NOAELHEC of 0.03 ppm 
and a total uncertainty factor of 30 (3 for extrapolation from animals to humans with dosimetric 
adjustment and 10 for human variability). 
Selection of the Critical Effect:  A small number of studies have evaluated the toxicity of 1,2,3-trichloro-
propane following acute-duration inhalation exposure.  In humans, a 15-minute exposure to 100 ppm 
1,2,3-trichloropropane resulted in eye and throat irritation (Silverman et al. 1946).  Acute inhalation 
studies in experimental animals (rats and mice) identify the respiratory tract and liver as the most 
sensitive targets of 1,2,3-trichloropropane toxicity; a summary of relevant NOAEL and LOAEL values 
for respiratory and hepatic effects is presented in Table A-1.  The respiratory effects consisted of 
decreases in the thickness of nasal olfactory epithelium at the lowest adverse effect levels (3 ppm in rats 
and 10 ppm in mice) (Miller et al. 1986b), degeneration and inflammation of olfactory epithelium at 
13 ppm in rats (Miller et al. 1986a), subacute inflammation of olfactory epithelium at 40 ppm in mice 
(Miller et al. 1986b), and multifocal fibrosis of nasal submucosa at 132 ppm in rats (Miller et all. 1986a).  
The Miller et al. (1986a) rat study demonstrated that the severity of the nasal lesions increased with 
concentration; the degeneration of olfactory epithelium was graded as slight at 13 ppm, moderate at 
40 ppm, and severe at 132 ppm.  The liver effects consisted of increases in liver weights in rats exposed 
to ≥40 ppm (Miller et al. 1986a) and mice exposed to 132 ppm (Miller et al. 1986a), very slight 
individual cell hepatocellular necrosis in male rats exposed to 132 ppm (Miller et al. 1986a), and very 
slight hepatocellular vacuolization at 132 ppm in mice (Miller et al. (1986a).  Other acute-duration 
studies have primarily focused on lethality (Gushow and Quast 1984; Johannsen et al. 1988; Smyth et al. 
1965; Union Carbide 1958).  Based on the available data, the nasal olfactory epithelium appears to be the 
most sensitive target of toxicity following acute-duration inhalation exposure.
***DRAFT FOR PUBLIC COMMENT*** 
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Table A-1.  Summary of Relevant LOAEL Values Following Acute Inhalation Exposure to 1,2,3-Trichloropropane 
 
 Species Exposure  NOAEL (ppm) LOAEL (ppm) Effect Reference 
Nasal effects 
 F344 rat 6 hours/day 
5 days/week 
2 weeks 
 13 Degeneration and inflammation of nasal olfactory 
epithelium  
Miller et al. 1986a 
 F344 rat 6 hours/day 
5 days/week 
2 weeks 
1 3 Decreased thickness of olfactory epithelium  Miller et al. 1986b 
 B6C3F1 
mouse 
6 hours/day 
5 days/week 
2 weeks 
 13 Decreased thickness of olfactory epithelium Miller et al. 1986a 
 B6C3F1 
mouse 
6 hours/day 
5 days/week 
2 weeks 
3 10 Nasal olfactory inflammation Miller et al. 1986b 
Hepatic effects 
 F344 rat 6 hours/day 
5 days/week 
2 weeks 
40 132 Very slight hepatocellular necrosis Miller et al. 1986a 
 B6C3F1 
mouse 
6 hours/day 
5 days/week 
2 weeks 
40 132 Hepatocellular vacuolization Miller et al. 1986a 
 
LOAEL = lowest-observed-adverse-effect level; NOAEL = no-observed-adverse-effect level 
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Selection of the Principal Study:  Based on a comparison of NOAEL and LOAEL values and the 
observed effects, rats appear to be more sensitive than mice to 1,2,3-trichloropropane-induced nasal 
toxicity.  The Miller et al. (1986b) rat study, which identified a NOAEL of 1 ppm and LOAEL of 3 ppm, 
was selected as the principal study. 
 
Summary of the Principal Study: 
 
Miller RR, Quast JF, Momany-Pfruender JJ.  1986b.  1,2,3-Trichloropropane: 2-Week vapor inhalation 
study to determine the no-adverse-effect level in rats and mice.  Dow Chemical Company.  Submitted to 
the U.S. Environmental Protection Agency under TSCA Section 8D.  
 
Groups of five male and five female Fischer 344 rats were exposed to 0, 1, 3, or 10 ppm 1,2,3-trichloro-
propane 6 hours/day, 5 days/week for 9 exposures in an 11-day period.  The following parameters were 
used to assess toxicity:  observations after each exposure period, body weight measurements prior to 1st, 
3rd, 5th, and 7th exposure, urinalysis (bilirubin, glucose, ketones, occult blood, pH, protein, urobilinogen, 
and specific gravity), organ weights (brain, heart, liver, kidneys, thymus, and testes), gross necropsy of 
major tissues and organs, and histopathological examination of nasal tissue.   
 
There were no deaths or alterations in body weight gain, or urinalysis, or organ weights.  A very slight 
decrease in olfactory epithelial thickness was observed in 10/10 rats exposed to 3 ppm, but was not 
observed in controls or other groups of exposed rats.  Very slight olfactory epithelial degeneration was 
observed in 10/10 rats at 10 ppm and in 0/10 control rats.  Very slight multifocal, bilateral subacute 
inflammation of olfactory epithelium was observed in 6/10, 4/10, 2/10, and 10/10 rats in the 0, 1, 3, and 
10 ppm groups, respectively.  No alterations were observed during the gross necropsy. 
 
Selection of the Point of Departure for the MRL:  The NOAEL/LOAEL approach was used to select the 
point of departure (POD) for the MRL.  The incidence data for olfactory epithelial alterations were not 
considered suitable for benchmark dose (BMD) modeling due to the lack of concentration-response data, 
0% incidence in controls and 1 ppm groups and 100% in the 3 ppm group.  Thus, the NOAEL of 1 ppm 
was selected as the POD for the MRL. 
 
Intermittent Exposure:  The NOAEL of 1 ppm was adjusted for intermittent exposure as follows:  1 ppm 
x 6 hours/24 hours x 9 exposures/11 days = 0.20 ppm. 
 
Human Equivalent Concentration:  The NOAELADJ of 0.20 ppm was converted to a human equivalent 
concentration (HEC) of 0.03 ppm using the following equation:  NOAELHEC = NOAELADJ x RGDRET, 
where RGDRET is the extrathoracic regional gas dose ratio (animal:human) for the extrathoracic region.  
Extrathoracic regional gas doses were calculated for each species as follows: VE (minute volume) ÷ SAET 
(surface area of the extrathoracic region); where VE = 138 mL/minute (calculated using the average body 
weight for males and females, 0.181 k) and SAET = 15 cm2 in rats and VE = 13,800 mL/minute and SAET 
= 200 cm2 in humans (EPA 1994). 
 
NOAELHEC = NOAELADJ x RGDRET 
 NOAELHEC = 0.20 ppm x (138 mL/minute ÷ 15 cm2)/(13,800 mL/minute ÷ 200 cm2) 
 NOAELHEC = 0.20 ppm x 0.133 
NOAELHEC = 0.03 ppm 
 
Uncertainty Factor:  The NOAELHEC was divided by a total uncertainty factor of 30: 
• 3 for extrapolation from animals to humans with dosimetric adjustments 
• 10 for human variability 
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  MRL = NOAELHEC ÷ UFs 
  0.03 ppm ÷ (3 x 10) = 0.001 ppm  
 
Other Additional Studies or Pertinent Information that Lend Support to this MRL:  Although the 
principal study only included histological examination of the nasal cavity, a companion study (Miller et 
al. 1986a) examined a wide range of endpoints and demonstrated that the olfactory epithelium was the 
most sensitive target of toxicity. 
 
Agency Contact (Chemical Manager):  Malcolm Williams 
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MINIMAL RISK LEVEL (MRL) WORKSHEET 
Chemical Name: 1,2,3-Trichloropropane 
CAS Numbers: 96-18-4 
Date: September 1993 
March 2017—Update literature search 
Profile Status: Final, Draft for Public Comment 
Route: Inhalation 
Duration: Intermediate 
MRL Summary:  The available intermediate inhalation data were not considered adequate for derivation 
of an intermediate-duration inhalation MRL for 1,2,3-trichloropropane. 
Rationale for Not Deriving an MRL:  An intermediate-duration inhalation MRL was not derived for 
1,2,3-trichloropropane because derivation of an MRL based on the available intermediate studies resulted 
in an MRL that was higher than the acute-duration inhalation MRL and the only available study did not 
examine nasal tissue (the most sensitive target following acute exposure). 
Reliable information on the intermediate-duration toxicity of 1,2,3-trichlorochloropropane is limited to a 
series of studies in rats conducted by Johannsen et al. (1988).  These studies identified several sensitive 
targets of toxicity including the respiratory tract, liver, and the hematological system.  In a 4-week 
preliminary study (6 hours/day, 5 days/week), increases in liver weight were observed at ≥95 ppm; the 
study did not include histological examinations.  In a more extensive 13-week study (6 hours/day, 
5 days/week), exposure to 4.5 ppm resulted in peribronchial lymphoid hyperplasia, midzonal 
hepatocellular hypertrophy, and extramedullary hematopoiesis in the spleen.  At 15 ppm, decreases in 
body weight gain and excessive lacrimation were observed.  No adverse effects were observed at the two 
lowest test concentrations (0.05 and 1.54 ppm).  It is noted that the Johannsen et al. (1988) study did not 
include examination of nasal tissue, which was the most sensitive target of toxicity following acute 
inhalation exposure.  In a reproductive/developmental toxicity study, no alterations in mating, fertility, 
histopathology of reproductive tissues, gestation length, number of live births, litter size at birth or 
postnatal days 4–21, birth weight, pup body weight, or pup survival through postnatal day 21 were 
observed in male and female rats exposed to concentrations as high as 15 ppm for a 10-week pre-mating 
period, 30–40-day mating period, and gestation days 0–14. 
Based on the available data, an MRL could be derived based on the lung, liver, and spleen effects 
observed in rats exposed to ≥4.5 ppm; the NOAEL for these effects is 1.54 ppm.  Adjusting the NOAEL 
concentration for intermittent exposure results in a NOAELADJ of 0.275 ppm.  A NOAELHEC of 
0.275 ppm is calculated by multiplying the NOAELADJ by an extra-respiratory regional gas dose ratio 
(RGDR) of 1.  Because blood:gas partition coefficients are not available for rats or humans, the default 
ratio of 1 was used for the RGDRER.  It is noted that the peribronchial lymphoid hyperplasia observed in 
the lungs was not considered a portal-of-entry effect since the effect occurred in lymphoid tissue rather 
than lung tissue.  Dividing the NOAELHEC POD of 0.275 ppm by a total uncertainty factor of 30 (3 for 
extrapolation from animals to humans with dosimetric adjustments and 10 for human variability) results 
in a candidate MRL of 0.009 ppm.  This value is higher than the acute-duration inhalation MRL of 
0.001 ppm based on nasal lesions observed in rats exposed to 1,2,3-trichloropropane for 11 exposures 
(Miller et al. 1986b).  Thus, an intermediate-duration inhalation MRL was not derived for 1,2,3-trichloro-
propane. 
Agency Contact (Chemical Manager):  Malcolm Williams 
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MINIMAL RISK LEVEL (MRL) WORKSHEET 
Chemical Name: 1,2,3-Trichloropropane 
CAS Numbers: 96-18-4 
Date: September 1993 
March 2017—Update literature search 
Profile Status: Final, Draft for Public Comment 
Route: Inhalation 
Duration: Chronic 
MRL Summary:  The available chronic inhalation data were not considered adequate for derivation of 
chronic-duration inhalation MRL for 1,2,3-trichloropropane. 
Rationale for Not Deriving an MRL:  No chronic-duration inhalation studies were identified for 
1,2,3-trichloropropane.   
Agency Contact (Chemical Manager):  Malcolm Williams 
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Chemical Name: 1,2,3-Trichloropropane 
CAS Numbers: 96-18-4 
Date: September 1993 
March 2017—Update literature search 
Profile Status: Final, Draft for Public Comment 
Route: Oral 
Duration: Acute 
MRL Summary:  The available acute oral data were not considered adequate for derivation of an acute-
duration oral MRL for 1,2,3-trichloropropane. 
Rationale for Not Deriving an MRL:  A small number of studies have examined the toxicity of 1,2,3-tri-
chloropropane following acute oral exposure.  Increases in mortality were observed at ≥150 mg/kg 
(Alpert 1983; NTP 1993; Smyth et al. 1962).  The most sensitive effect identified in the available 
database was an increase in relative liver weights observed in rats administered via gavage 
≥29.5 mg/kg/day for 10 days (Merrick et al. 1991).  At 118 mg/kg/day, decreases in body weight gain; 
myocardial inflammation, degeneration, and necrosis; and thymic atrophy were observed in rats 
administered 1,2,3-trichloropropane via gavage for 10 days (Merrick et al. 1991).  Two studies examining 
reproductive effects in male rats did not find increases in the incidence of histological alterations 
60 mg/kg/day for 10 days (Dix 1979) or 80 mg/kg/day for 5 days (Saito-Suzuki et al. 1982) or dominant 
lethality at 80 mg/kg/day (Saito-Suzuki et al. 1982). 
Although the available acute-duration studies identified several effects, the database was not considered 
suitable for MRL derivation.  The increase in liver weight was considered a LOAEL based on 
intermediate and chronic studies that reported histological alterations in the liver.  However, no 
significant increases in liver lesions were observed in the Merrick et al. (1991) study, although 
centrilobular hepatic necrosis was observed in 3/20 animals at 118 mg/kg/day.  Heart lesions were 
observed in acute- and intermediate-duration studies conducted by Merrick et al. (1991), but no 
cardiovascular effects have been observed in other acute, intermediate, or chronic oral studies; this 
endpoint was not considered suitable for MRL derivation due to the lack of corroborative data.  
Interpretation of the thymic atrophy observed at 118 mg/kg/day is difficult given that a 22–25% decrease 
in body weight gain was also observed at this dose level. 
Agency Contact (Chemical Manager):  Malcolm Williams 
***DRAFT FOR PUBLIC COMMENT*** 
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Chemical Name: 
CAS Numbers: 
Date: 
Profile Status: 
Route: 
Duration: 
MRL: 
Critical Effect: 
Reference: 
Point of Departure: 
Uncertainty Factor: 
LSE Graph Key: 
Species: 
1,2,3-Trichloropropane 
96-18-4
May 2019
Final, Draft for Public Comment
Oral
Intermediate
0.06 mg/kg/day
Increased absolute liver weight, decreased hemoglobin, decreased erythrocytes
NTP 1993
NOAEL of 5.7 mg/kg/day
100
9
Rat
MRL Summary:  A provisional intermediate-duration oral MRL of 0.06 mg/kg/day was derived for 
1,2,3-trichloro-propane based on increased absolute liver weight, decreased hemoglobin levels, and 
decreased erythrocyte levels observed in female rats administered via gavage 1,2,3-trichloropropane 
5 days/week for 17 weeks (NTP 1993).  The MRL is based on a duration-adjusted NOAEL of 
5.7 mg/kg/day and a total uncertainty factor of 100 (10 for extrapolation from animals to humans and 
10 for human variability). 
Selection of the Critical Effect:  Four studies have evaluated the intermediate-duration oral toxicity of 
1,2,3-trichloropropane.  These studies have identified a number of targets of toxicity:  body weight, 
respiratory tract, heart, forestomach, hematological system, liver, kidney, and reproductive/
developmental systems.  The NOAEL and LOAEL values for these effects are summarized in Table A-2. 
Based on a comparison of the lowest LOAEL values for each endpoint, the liver appears to be one of the 
most sensitive targets of toxicity.  At gavage doses ≥11 mg/kg/day, >10% increases in absolute liver 
weight were observed in rats (NTP 1993); a similar LOAEL of 14.7 mg/kg/day was identified in another 
rat gavage study (Merrick et al. 1991).  An increase in liver weight was also observed in mice 
administered ≥89 mg/kg/day (NTP 1993).  Serum clinical chemistry alterations have also been observed 
at lower doses; decreases in pseudocholinesterase levels, likely due to decreased synthesis in the liver, 
were observed at ≥5.7 mg/kg/day (NTP 1993) and increases in serum total bilirubin and alanine 
aminotransferase were observed at ≥58.9 mg/kg/day (NTP 1993).  At higher doses, hepatocellular 
necrosis was observed in rats and mice administered 89 and 179 mg/kg/day, respectively (NTP 1993), 
and anisokaryosis and fatty vacuolation was observed in rats at 113 mg/kg/day (Villeneuve et al. 1985).  
Additionally, bile duct hyperplasia was observed in rats at 58.9 mg/kg/day (Merrick et al. 1991), 
89 mg/kg/day (NTP 1993), and 149 mg/kg/day (Villeneuve et al. 1985).   
The lowest LOAEL for hematological effects is also 11 mg/kg/day identified in the NTP (1993) rat study.  
The hematological effects consisted of decreases in hematocrit, hemoglobin, and erythrocyte levels in 
female rats.  NTP noted that the observed anemia was nonregenerative and possibly associated with 
depressed erythropoiesis.  No hematological effects were observed in a 13-week rat drinking water study 
(Villenueve et al. 1985) or in a 17-week gavage mouse study (NTP 1993). 
***DRAFT FOR PUBLIC COMMENT*** 
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Table A-2.  Summary of NOAEL and LOAEL Values Following Intermediate-Duration Oral Exposure to 
1,2,3-Trichloropropane 
 
Species Exposure  
NOAEL 
(mg/kg/day) 
LOAEL 
(mg/kg/day) Effect Reference 
Body weight effects 
 Sprague-
Dawley rat 
30 days 
(GO) 
14.7 58.9 14–20% decrease in body weight gain Merrick et al. 1991 
 F344 rat 17 weeks, 
5 days/week 
(GO) 
23a 45a 11% decreases in body weight gain in males (females at 
89 mg/kg/day)  
NTP 1993 
 Sprague-
Dawley rat 
13 weeks 
(W) 
17 113 Reduced body weight gain Villeneuve et al. 
1985 
 B6C3F1 
mouse 
17 weeks,  
5 days/week 
(GO) 
179a  No effect on body weight gain  NTP 1993 
Respiratory effects 
 F344 rat 17 weeks, 
5 days/week 
(GO) 
45a 89a Necrosis in nasal turbinates NTP 1993 
 B6C3F1 
mouse 
17 weeks,  
5 days/week 
(GO) 
23a 45a Regeneration of bronchiolar epithelium in the lungs in females 
(males at ≥89 mg/kg/day)  
NTP 1993 
Cardiovascular effects 
 Sprague-
Dawley rat 
30 days 
(GO) 
14.7 58.9 Myocardial inflammation, degeneration, and necrosis Merrick et al. 1991 
 F344 rat 17 weeks,  
5 days/week 
(GO) 
89a  No histological alterations NTP 1993 
 Sprague-
Dawley rat 
13 weeks 
(W) 
113  No histological alterations Villeneuve et al. 
1985 
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Table A-2.  Summary of NOAEL and LOAEL Values Following Intermediate-Duration Oral Exposure to 
1,2,3-Trichloropropane 
 
Species Exposure  
NOAEL 
(mg/kg/day) 
LOAEL 
(mg/kg/day) Effect Reference 
 B6C3F1 
mouse 
17 weeks,  
5 days/week 
(GO) 
179a  No histological alterations NTP 1993 
Gastrointestinal effects 
 F344 rat 17 weeks, 
5 days/week 
(GO) 
89a  No histological alterations NTP 1993 
 B6C3F1 
mouse 
17 weeks,  
5 days/week 
(GO) 
23a 45a Hyperkeratosis and acanthosis of forestomach NTP 1993 
Hematological effects 
 F344 rat 17 weeks,  
5 days/week 
(GO) 
5.7a 11a Decreases in hematocrit, hemoglobin, and erythrocyte levels 
after 8 and 17 weeks 
NTP 1993 
 Sprague-
Dawley rat 
13 weeks 
(W) 
113  No hematological alterations Villeneuve et al. 
1985 
 B6C3F1 
mouse 
17 weeks,  
5 days/week 
(GO) 
179a  No hematological alterations NTP 1993 
Hepatic effects 
 Sprague-
Dawley rat 
30 days 
(GO) 
7.4 14.7 Increased relative liver weight Merrick et al. 1991 
 14.7 58.9 Bile duct hyperplasia 
 F344 rat 17 weeks,  
5 days/week 
(GO) 
5.7a 11a Increased absolute liver weight NTP 1993 
  89a Hepatocellular necrosis and hemorrhage, bile duct hyperplasia 
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Table A-2.  Summary of NOAEL and LOAEL Values Following Intermediate-Duration Oral Exposure to 
1,2,3-Trichloropropane 
 
Species Exposure  
NOAEL 
(mg/kg/day) 
LOAEL 
(mg/kg/day) Effect Reference 
 Sprague-
Dawley rat 
13 weeks 
(W) 
17 113 Anisokaryosis, accentuated zonation and fatty vacuolation Villeneuve et al. 
1985  149 Biliary hyperplasia (females only) 
 B6C3F1 
mouse 
17 weeks,  
5 days/week 
(GO) 
45a 89a Increased liver weights  NTP 1993 
 179a Focal hepatocellular necrosis  
Renal effects 
 F344 rat 17 weeks,  
5 days/week 
(GO) 
11a 23a Increased absolute and relative liver weight in males NTP 1993 
 45a Regenerative hyperplasia after 8 weeks of exposure; not 
observed after 17 weeks of exposure 
 Sprague-
Dawley rat 
13 weeks 
(W) 
17 113 Eosinophilic inclusions, pyknosis, nuclear displacement, fine 
glomerular adhesions, interstitial reactions, and histologic 
proteinuria 
Villeneuve et al. 
1985 
 B6C3F1 
mouse 
17 weeks,  
5 days/week 
(GO) 
 179a Multifocal tubular necrosis in animals dying early NTP 1993 
Reproductive/developmental effects 
 Swiss 
mice 
98 days 
(GO) 
30 60 Decreased number of live pups per litter NTP 1990 
120  No alterations in epididymal sperm motility, count, or 
morphology or estrous cycle length 
 120 Ovarian amyloidosis 
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Table A-2.  Summary of NOAEL and LOAEL Values Following Intermediate-Duration Oral Exposure to 
1,2,3-Trichloropropane 
 
Species Exposure  
NOAEL 
(mg/kg/day) 
LOAEL 
(mg/kg/day) Effect Reference 
 Swiss 
mice 
Prenatal 
exposure, 
post 
weaning, 
mating, and 
gestation 
exposure 
60 120 Decreases in mating, fertility, and pregnancy indices NTP 1990 
 
aAdminstered doses of 8, 16, 32, 63, 125, or 250 mg/kg were adjusted for intermittent exposure (5 days/week) resulting in continuous doses of 5.7, 11, 23, 45, 
89, and 179 mg/kg/day. 
 
GO = gavage in oil; LOAEL = lowest-observed-adverse-effect level; NOAEL = no-observed-adverse-effect level; W = drinking water administration 
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At the next highest LOAEL of 23 mg/kg/day, increases in kidney weights were observed in male rats 
(NTP 1992); the adversity of this finding is supported by histological alterations in the kidney observed at 
≥45 mg/kg/day (NTP 1993; Villeneuve et al. 1985).  Other effects that have been observed in rats and 
mice at higher LOAELs included decreases in body weight gain (lowest LOAEL of 45 mg/kg/day) 
(Merrick et al. 1991; NTP 1993; Villeneuve et al. 1985), regeneration of bronchiolar epithelium 
(45 mg/kg/day) (NTP 1993), hyperkeratosis and acanthosis of the forestomach, myocardial inflammation, 
degeneration, and necrosis (58.9 mg/kg/day) (Merrick et al. 1991), decreases in reproductive function 
(60 mg/kg/day) (NTP 1990), and necrosis in nasal turbinates (89 mg/kg/day) (NTP 1993). 
 
Selection of the Principal Study:  NTP (1993) was selected as the principal study because it identified the 
lowest LOAEL (11 mg/kg/day) for liver and hematological effects.  
 
Summary of the Principal Study: 
 
NTP.  1993.  Toxicology and carcinogenesis studies of 1,2,3-trichloropropane (CAS No. 96-18-4) in 
F344/N rats and B6C3F1 mice (gavage studies).  National Toxicology Program Tech Rep Ser 384.   
 
Groups of 20 male and 20 female F344/N rats were administered 8, 16, 32, 63, 125, or 250 mg/kg 
1,2,3-trichloropropane in corn oil 5 days/week for 17 weeks; a vehicle control group consisted of 
30 males and 30 females.  After 8 weeks of exposure, 10 rats/sex/group were sacrificed.  The following 
parameters were used to assess toxicity:  weekly clinical observations, weekly body weights, organ 
weights (brain, epididymis, heart, kidney, liver, lung, testis, thymus), urinalysis, hematology, serum 
clinical chemistry, and histopathology of major tissues and organs (control and 125 mg/kg groups and 
other groups as needed). 
• Death.  Deaths were observed in all male and female rats in the 250 mg/kg group by week 5 and 
2, respectively, and in 1/10 males and 4/10 females at 125 mg/kg.  The cause of death in the 
250 mg/kg group was kidney or hepatic toxicity.  There was no mortality at lower doses.   
• Body weight.  Body weight gain was reduced in males at 63 mg/kg (11% lower than controls) and 
in males (21%) and females (24%) at 125 mg/kg.  Food consumption markedly reduced at 
250 mg/kg prior to death.   
• Respiratory.  There was a significant increase in relative lung after 17 weeks in males at 
125 mg/kg.  Epithelial necrosis and attenuation of epithelial lining of the dorsal portion of nasal 
turbinates was observed at 125 mg/kg; in females, the lesions were observed after 8 and 17 weeks 
of exposure.   
• Hematological.  Significant decreases in hematocrit, hemoglobin, and erythrocyte levels were 
observed at 63 and 125 mg/kg after 17 weeks of exposure; decreases in hemoglobin levels were 
also observed in females at 16 and 32 mg/kg.  After 8 weeks of exposure, decreases in hematocrit, 
hemoglobin, and erythrocyte levels were observed at ≥16 mg/kg and hematocrit and erythrocyte 
levels were decreased in females at 8 mg/kg.   
• Hepatic.  After 8 weeks of exposure, significant increases were observed in total bilirubin at 
≥63 mg/kg, ALT in females at ≥63 mg/kg, aspartate aminotransferase (AST) in females at 
≥125 mg/kg, lactic dehydrogenase (LDH) at ≥63 mg/kg in females and 125 mg/kg in males, and 
sorbitol dehydrogenase (SDH) at 125 mg/kg.  Pseudocholinesterase levels were significantly 
decreased in males 32 and 125 mg/kg after 8 weeks and ≥32 mg/kg in males at 17 weeks, and 
≥8 mg/kg in females at 8 and 17 weeks.  The investigators suggested that the decrease in 
pseudocholinesterase levels suggest a decrease in synthesis due to hepatocellular damage.  
Significant increases in absolute liver weight was observed in males after 17 weeks of exposure at 
≥8 mg/kg and in females at ≥16 mg/kg; the increases in absolute liver weight in the males did not 
appear to be dose-related.  Significantly increased relative liver weights were observed at 
≥32 mg/kg in males and ≥16 mg/kg in females.  In the liver, necrosis, hemorrhage, and bile duct 
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hyperplasia were observed in females at 125 mg/kg after 8 or 17 weeks of exposure; degeneration 
and hemorrhage were observed in males at 250 mg/kg after 8 weeks of exposure.  There were no 
treatment-related effects in lower dose groups after 17 weeks.   
• Renal.  Blood urea nitrogen (BUN) levels were decreased in females at 16, 63, and 125 mg/kg
after 8 weeks of exposure and in males at 125 mg/kg and females at ≥32 mg/kg after 17 weeks.
Absolute and relative kidney weights were increased (p<0.05) after 17 weeks at ≥32 mg/kg in
males and at ≥63 mg/kg in females.  Renal regenerative hyperplasia was observed at ≥63 mg/kg
after 8 weeks of exposure and at 125 mg/kg after 17 weeks of exposure in males; necrosis and
karyomegaly (males only) were also observed at 250 mg/kg after 8 weeks of exposure.
• Other Effects.  The investigators noted that thymic lymphoid depletion, hypocellularity of sternal
bone marrow, splenic atrophy, uterine hypoplasia, adrenal cortical cell vacuolation, and
myocardial chronic inflammation occurred less frequently in animals dying during the study;
however, incidence data were not provided and NOAEL and LOAEL values could not be
identified for these effects.
Selection of the Point of Departure for the MRL:  The lowest LOAEL identified in the NTP (1993) rat 
study was 11 mg/kg/day.  At this dose level, increases in absolute liver weight in females, increases in 
relative liver weight, decreases in hemoglobin levels in females, and decreases in erythrocyte counts in 
females were observed.  BMD modeling was attempted for these endpoints; the results of the modeling 
are presented in the Benchmark Dose Modeling section.  None of the BMD models provided adequate fit 
to the absolute liver weight data; thus, the highest dose associated with a <10% increase in absolute liver 
weight (11 mg/kg/day) was selected as the POD.  The hemoglobin and erythrocyte doses also did not 
provide adequate fit with any of the BMD models and the NOAEL values were used as PODs for these 
effects. 
Four PODs were considered for the MRL: 
• NOAEL of 8 mg/kg (5.7 mg/kg/day) for absolute liver weight increases in female rats
• BMDLRD10 of 15.74 mg/kg (11 mg/kg/day) for relative liver weight increases in female rats
• NOAEL of 8 mg/kg (5.7 mg/kg/day) for decreases in hemoglobin levels in female rats
• NOAEL of 8 mg/kg (5.7 mg/kg/day) for decreases in erythrocyte levels in female rats
The NOAEL value of 5.7 mg/kg/day for increases in absolute liver weight and decreases in hemoglobin 
and erythrocyte levels was selected as the basis of the MRL since this value is lower than the BMDLRD10 
for increases in relative liver weight. 
Intermittent Exposure:  The NOAEL of 8 mg/kg was adjusted for intermittent exposure (5 days/7 days) 
resulting in an adjusted BMDLRD10 of 5.7 mg/kg/day. 
Uncertainty Factor:  The adjusted NOAEL was divided by a total uncertainty factor of 100: 
• 10 for extrapolation from animals to humans
• 10 for human variability
MRL = NOAEL÷ UFs 
5.7 mg/kg/day ÷ (10 x 10) = 0.06 mg/kg/day 
Other Additional Studies or Pertinent Information that Lend Support to this MRL:  Similar liver and 
erythrocyte effects have been observed in rats administered 1,2,3-trichloropropane for 15 months (NTP 
1993). 
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Benchmark Dose Modeling:  The absolute and relative liver weights in females, hemoglobin levels in 
females, and erythrocyte levels in females were fit to all available continuous models in EPA’s 
Benchmark Dose Software (BMDS, version 2.6.0).  The following procedure for fitting continuous data 
was used:  the simplest model (linear) was first applied to the data while assuming constant variance; if 
the data were consistent with the assumption of constant variance (p≥0.1), then the fit of the linear model 
to the means was evaluated and the polynomial, power, and Hill models were fit to the data while 
assuming constant variance.  Adequate model fit was judged by three criteria:  goodness-of-fit p-value 
(p>0.1), visual inspection of the dose-response curve, and scaled residual at the data point (except the 
control) closest to the predefined benchmark dose response (BMR).  Among all of the models providing 
adequate fit to the data, the lowest BMDL (the lower limit of a one-sided 95% CI on the BMD) was 
selected as a reasonably conservative POD when differences between the BMDLs estimated from these 
models are >2–3-fold; otherwise, the BMDL from the model with the lowest Akaike's information 
criterion (AIC) was chosen.  If the test for constant variance was negative, the linear model was run again 
while applying the power model integrated into the BMDS to account for nonhomogenous variance.  If 
the nonhomogenous variance model provided an adequate fit (p≥0.1) to the variance data, then the fit of 
the linear model to the means was evaluated and the polynomial, power, and Hill models were fit to the 
data and evaluated while the variance model was applied.  Model fit and POD selection proceeded as 
described earlier.  A BMR of 10% change from the control was used for liver weights and 1 standard 
deviation change relative to controls was used for hemoglobin and erythrocyte levels.   
 
The model predictions for the relative liver weight in females are presented in Table A-3 and the fit of the 
selected model is presented in Figure A-1.  The available BMD models did not provide adequate fit for 
absolute liver weights in females, hemoglobin levels in females, or erythrocyte levels in females; 
dropping the highest and second highest dose levels did not sufficiently improve the fit of the models. 
 
Table A-3.  Model Predictions for 1,2,3-Trichloropropane, Increased Relative Liver 
Weight in Female Rats for 17 weeks (NTP 1993)  
Model 
Test for 
significant 
difference 
p-valuea 
Variance 
p-valueb 
Mean 
p-valueb 
Scaled residualsc 
AIC 
BMDRD10 
(mg/kg) 
BMDLRD10 
(mg/kg) 
Dose 
below 
BMD 
Dose 
above 
BMD 
Overall 
largest 
All Doses 
Constant variance 
Lineard <0.0001 <0.0001 0.00 1.02 0.78 -2.82 177.25 12.38 11.14 
Nonconstant variance 
Exponential 
(model 2)e 
18.12 0.70 0.16 1.20 -0.92 1.20 141.63 18.12 16.57 
Exponential 
(model 3)e 
20.97 0.70 0.11 1.43 -0.52 1.43 143.12 20.97 16.71 
Exponential 
(model 4)e 
15.44 0.70 0.01 0.75 0.78 2.19 149.56 15.44 13.43 
Exponential 
(model 5)e 
23.54 0.70 0.01 1.66 -0.36 1.66 148.15 23.54 15.85 
Hille 23.57 0.70 0.01 1.66 -0.36 1.66 148.19 23.57 15.81 
Lineard 15.44 0.70 0.01 0.75 0.78 2.19 147.56 15.44 13.43 
Polynomial 
(2-degree)d 
21.83 0.70 0.12 1.46 -0.34 1.46 142.81 21.83 16.75 
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Table A-3.  Model Predictions for 1,2,3-Trichloropropane, Increased Relative Liver 
Weight in Female Rats for 17 weeks (NTP 1993)  
Model Test for 
 
 
 
Variance 
 
Mean 
 
Scaled residualsc AIC BMDRD10 
 
BMDLRD10 
 Polynomial 
(3-degree)d 
20.27 0.70 0.30 1.25 -0.41 1.25 140.66 20.27 16.46 
Polynomial 
(4-degree)d 
19.14 0.70 0.38 1.13 -0.57 1.13 140.05 19.14 16.00 
Polynomial 
(5-degree)d,f 
18.58 0.70 0.41 1.07 -0.69 1.07 139.90 18.58 15.74 
Powerd 23.54 0.70 0.03 1.66 -0.36 1.66 146.15 23.54 15.85 
 
aValues >0.05 fail to meet conventional goodness-of-fit criteria. 
bValues <0.10 fail to meet conventional goodness-of-fit criteria. 
cScaled residuals at doses immediately below and above the benchmark dose; also the largest residual at any dose. 
dCoefficients restricted to be positive.  
ePower restricted to ≥1. 
fSelected model.  Constant variance model did not provide adequate fit to the variance data but nonconstant variance 
did.  With nonconstant variance model applied, the Exponential 2 and 3 and Polynomial models 2–5 provided 
adequate fit to the means.  BMDLs for models providing adequate fit were sufficiently close (differed by <3-fold).  
Therefore, the model with lowest AIC was selected (Polynomial 5-degree). 
 
AIC = Akaike Information Criterion; BMD = maximum likelihood estimate of the exposure concentration associated 
with the selected benchmark response; BMDL = 95% lower confidence limit on the BMD (subscripts denote 
benchmark response: i.e., 10 = exposure concentration associated with 10% extra risk); DF = degrees of freedom; 
NA = not applicable (BMDL computation failed); RD = relative deviation 
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Figure A-1.  Fit of 5th Degree Polynomial Model to Data on Relative Liver Weight in 
Female Rats Administered 1,2,3-Trichloropropane for 17 Weeks (NTP 1993) 
Agency Contact (Chemical Manager):  Malcolm Williams 
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MINIMAL RISK LEVEL (MRL) WORKSHEET 
Chemical Name: 
CAS Numbers: 
Date: 
Profile Status: 
Route: 
Duration: 
Provisional MRL: 
Critical Effect: 
Reference: 
Point of Departure: 
Uncertainty Factor: 
LSE Graph Key: 
Species: 
1,2,3-Trichloropropane 
96-18-4
May 2019
Final, Draft for Public Comment
Oral
Chronic
0.005 mg/kg/day
Bile duct hyperplasia
NTP 1993
BMDL10 of 0.47 mg/kg/day
100
14
Rat
MRL Summary:  A provisional chronic-duration oral MRL of 0.005 mg/kg/day was derived for 1,2,3-tri-
chloropropane based on an increased incidence of bile duct hyperplasia in male rats administered gavage 
doses 5 days/week for 15 months (NTP 1993).  The MRL is based on an adjusted BMDL10 of 
0.47 mg/kg/day and a total uncertainty factor of 100 (10 for extrapolation from animals to humans with 
dosimetric adjustment and 10 for human variability). 
Selection of the Critical Effect:  The oral toxicity of 1,2,3-trichloropropane following chronic-duration 
exposure has been investigated in rats and mice (NTP 1993).  The rats and mice were administered via 
gavage 1,2,3-trichloropropane in corn oil 5 days/week for up to 2 years.  Decreased survival was observed 
in rats administered 10 or 30 mg/kg and a decrease in body weight gain (15%) was observed in females at 
30 mg/kg.  A number of non-neoplastic and neoplastic alterations were observed.  Neoplastic lesions were 
observed at ≥3 mg/kg and included squamous cell papillomas or carcinomas in the forestomach and 
adenomas of the pancreas at ≥3 mg/kg; squamous cell papillomas or carcinomas in oral mucosa, adenoma 
in renal tubules, adenoma or carcinoma of the clitoral gland, and adenocarcinoma of the mammary gland 
(females only) at ≥10 mg/kg; and adenoma or carcinoma in preputial gland and carcinoma in Zymbal’s 
gland (females only) at 30 mg/kg.  Non-neoplastic target tissues included esophagus, tongue, 
hematopoietic tissues, liver and bile duct, kidney, pancreas, and testes; however, some of observed lesions 
were considered precancerous or were secondary to cancerous lesions.  A summary of the effects and 
NOAEL and LOAEL values for the non-neoplastic lesions is presented in Table A-4.  NTP (1993) 
considered the hematological effects to likely be due to depressed hematopoiesis or by blood loss from 
neoplasms in the forestomach or oral mucosa.  NTP (1993) noted that hyperplasia observed in the 
pancreas was part of the morphological continuum to adenoma to adenocarcinoma, and focal hyperplasia 
in the kidney and renal adenomas constituted a morphological continuum.  The bile duct and nephropathy 
effects do not appear to be associated with carcinogenicity and were considered as possible critical effects 
for the MRL. 
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Table A-4.  Summary of the Results of the NTP (1993) Chronic-Duration Rat 
Studya 
 
 
NOAEL 
(mg/kg) 
LOAEL  
(mg/kg) Effect 
Body weight 3 10 15% decrease in body weight gain in females 
Gastrointestinal 3 10 Hyperkeratosis of esophagus  
Acute inflammation of tongue in females (males at 
30 mg/kg) 
Hematological 3 10 Hematopoietic cell proliferation in spleen at ≥10 mg/kg 
Decreased hemoglobin, increased leukocytes, increased 
segmented neutrophils (measured after 15 months) at 
30 mg/kg 
Hepatic 3 10 Increased liver weight at ≥10 mg/kg 
Bile duct hyperplasia in males at 10 mg/kg at 15 months, 
30 mg/kg at 2 years 
Renal 3 10 Renal tubular hyperplasia and increased severity of 
nephropathy (males only)  
Endocrine  3 Focal hyperplasia of pancreatic acini 
Reproductive 10 30 Interstitial cell hyperplasia in testes 
 
aRats were administered 1,2,3-trichloropropane 5 days/week for up to 2 years. 
 
LOAEL = lowest-observed-adverse-effect level; NOAEL = no-observed-adverse-effect level 
 
A summary of the hepatic and renal effects observed in the NTP (1993) study are presented in Table A-5.  
These data clearly demonstrate a LOAEL of 10 mg/kg for increases in the incidences of bile duct 
hyperplasia in male rats and an increased severity of nephropathy in male rats.  The increases in absolute 
liver and kidney weights in male rats administered 3 mg/kg were considered minimally adverse because 
the liver and kidney are target tissues and the increases in organ weight may be representative of early-
stage adverse effects. 
 
Table A-5.  Summary of Hepatic and Renal Effects Observed in Rats 
Administered 1,2,3-Trichloropropane for 2 Years (NTP 1993) 
 
 Dose (mg/kg, 5 days/week) 
0 3 10 30 
Hepatic effects     
 Serum alanine aminotransferase (IU/L) 
  Males 99  91 (-8.1%)a 90 (-9.1%) 68 (-31%)b 
  Females 58 57 (-1.7%) 65 (12%) 66 (14%) 
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Table A-5.  Summary of Hepatic and Renal Effects Observed in Rats 
Administered 1,2,3-Trichloropropane for 2 Years (NTP 1993) 
 
 Dose (mg/kg, 5 days/week) 
0 3 10 30 
 Absolute liver weight at 15 months (g)     
  Males 14.27 15.63b (9.5%) 16.8b (17.7%) 18.23b (27.7%) 
  Females 7.79 8.87b (13.9%) 9.00b (15.5%) 10.4b (33.5%) 
 Relative liver weight at 15 months (mg organ weight/g body weight) 
  Males 31.2 33.1 (6.1%) 36b (15.4%) 39.8b (27.6%) 
  Females 30.8 30.9 (0.32%) 34.6b (12.3%) 43.2b (40.3%) 
 Bile duct hyperplasia at 15 months     
  Males 1/10 2/10 5/10c 8/10c 
  Females 0/10 0/10 1/8 3/8 
 Bile duct hyperplasia at 2 years     
  Males 0/50 0/50 1/49 12/52c 
  Females 0/50 0/49 0/52 2/52 
Renal effects     
 Absolute kidney weight at 15 months (g) 
  Males 1.35 1.46b (8.1%) 1.51b (11.8%) 1.75b (29.6%) 
  Females 0.786 0.839 (6.7%) 0.869b (10.6%) 0.971b (23.5%) 
 Relative kidney weight at 15 months (mg organ weight/g body weight)  
  Males 2.96 3.09 (4.4%) 3.25b (9.8%) 3.82b (29.0%) 
  Females 3.08 2.93 (-4.9%) 3.34b (8.4%) 4.04b (31.2%) 
 Nephropathy at 2 years     
  Males 48/50 (2.0)d 50/50 (2.0) 48/49 (2.6) 52/52 (2.4) 
  Females 18/50 21/47 17/52 5/51 
 
aPercent differences from controls. 
bSignificantly different (p≤0.05) from controls. 
cSignificantly different (p≤0.05) from controls; Fisher Exact Test performed by ATSDR. 
dMean severity score; 1=minimal (<25% renal tubules involved), 2=mild (25–50% involvement), 3=moderate (50–
75% involvement) and 4=marked (>75% involvement). 
 
The toxicity of 1,2,3-trichloropropane appears to differ in mice, as compared to rats.  A decrease in 
survival was observed in mice administered ≥6 mg/kg 5 days/week for 2 years (NTP 1993); a 12–18% 
decrease in body weight gain was observed at 60 mg/kg.  Non-neoplastic effects observed in mice 
included bronchiole hyperplasia at 60 mg/kg and hepatocellular necrosis at 60 mg/kg.  Squamous cell 
hyperplasia was also observed in the forestomach, but this was part of the continuum to forestomach 
adenocarcinomas.  Likewise, the hematopoietic cell proliferation observed in the spleen at ≥6 mg/kg may 
have been due to bleeding from the forestomach tumors.  Increases in the incidence of neoplastic lesions 
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were observed at all dose levels:  squamous cell papilloma or carcinoma in the forestomach and 
hepatocellular adenoma or carcinoma in males at ≥6 mg/kg; harderian gland adenoma in males at 
≥20 mg/kg; squamous cell papilloma or carcinoma in oral mucosa in females, harderian gland adenoma in 
females, and uterine stromal polyps and endometrial adenoma or adenocarcinoma at 60 mg/kg.  The 
lowest LOAEL for an effect unrelated to carcinogenicity is 60 mg/kg for increases in bronchiole 
hyperplasia and hepatocellular necrosis. 
 
Selection of the Principal Study:  The NTP (1993) rat gavage study was selected as the principal study 
because it identified the lowest LOAELs for non-carcinogenic effects. 
 
Summary of the Principal Study: 
 
NTP.  1993.  Toxicology and carcinogenesis studies of 1,2,3-trichloropropane (CAS No. 96-18-4) in 
F344/N rats and B6C3F1 mice (gavage studies).  National Toxicology Program Tech Rep Ser 384.   
 
Groups of 60 male and 60 female F344/N rats were administered 0, 3, 10, or 30 mg/kg 1,2,3-trichloro-
propane in corn oil by gavage 5 days/week for 2 years.  Due to high mortality, rats in the 30 mg/kg groups 
were terminated after 77 (males) or 67 (females) weeks of exposure.  After 15 months of exposure, 
10 animals/sex/group were sacrificed.  Parameters used to assess toxicity included twice daily clinical 
observations, body weights (weekly for 13 weeks and monthly thereafter), organ weights (brain, liver, 
kidney; evaluated at 15 months), hematological and serum clinical chemistry indices (evaluated at 
15 months), and histopathology of major tissues and organs. 
 
Significant decreases in survival were observed in rats at 10 and 30 mg/kg; mean survival days were 
596 and 465 days in the 10 mg/kg males and females, respectively, and 580 and 366 days in the 30 mg/kg 
males and females, respectively, compared to 647 and 649 days in control males and females, 
respectively.  No compound-related clinical signs were observed.  Small decreases in body weight gain 
(<5%) were observed at 30 mg/kg in males; in females, body weight in the last year of the study was 15% 
lower than controls.  In rats dying early, emaciation, lethargy, diarrhea, dyspnea, and tissue masses were 
observed; most of these signs were attributed to neoplasms of the oral mucosa or forestomach.  Increases 
in absolute liver weights were observed at ≥3 mg/kg; relative liver weights were observed at ≥10 mg/kg.  
Increases in absolute kidney weights were observed at ≥3 mg/kg in males and ≥10 mg/kg in females; 
increases in relative kidney weights were observed at ≥10 mg/kg.  Decreased hemoglobin levels were 
observed at 30 mg/kg; increases in leukocytes and segmented neutrophils were also observed at this dose 
level.  Hematopoietic cell proliferation was observed at 10 and 30 mg/kg.  Histological alterations were 
observed in the oral mucosa (pharynx and tongue), forestomach, pancreas, liver, kidney, preputial gland, 
clitoral gland, mammary gland, Zymbal’s gland, and intestines.  Acute inflammation was observed in the 
tongue of male rats treated with 30 mg/kg and female rats at 10 mg/kg.  Oral mucosal lesions consisted of 
squamous cell papillomas or carcinomas at 10 mg/kg (37 and 54% in males and females, respectively) 
and 30 mg/kg (77 and 62% in males and females, respectively); but not at 3 mg/kg (8 and 12% in males 
and females, respectively) or controls (2 and 2% in males and females, respectively).  Hyperkeratosis of 
the esophagus was observed in males at 30 mg/kg and females at ≥10 mg/kg.  Squamous cell papillomas 
or carcinomas were also observed in the forestomach at 3 (20 and 33% in males and females, 
respectively), 10 mg/kg (40 and 63% in males and females, respectively), and 30 mg/kg (83 and 37% in 
males and females, respectively); no tumors were observed in controls.  Increases in the incidence of 
forestomach tumors were also observed in the 10 and 30 mg/kg groups after 15 months of exposure.  In 
the pancreas, focal hyperplasia of pancreatic acini was observed at ≥3 mg/kg/day (56, 92, 94, and 92% in 
males at 0, 3, 10, or 30 mg/kg and 10, 29, 46, and 17% in females) and adenomas were observed in males 
at ≥3 mg/kg (10, 42, 73, 56% in males and 0, 0, 4, 0% in females); the investigators noted that there was a 
morphologic continuum from the acinar hyperplasia to adenomas.  Bile duct hyperplasia was observed in 
males at 10 and 30 mg/kg after 15 months and at 30 mg/kg after 2 years.  Renal tubular hyperplasia in 
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males at ≥10 mg/kg and females at 30 mg/kg; an increase in nephropathy was observed in males at 10 or 
30 mg/kg, although the incidence was similar to controls (98–100% compared to 96% in controls).  The 
mean severity scores were 2.0, 2.0, 2.6, and 2.4 in the 0, 3, 10, and 30 mg/kg groups, respectively.  An 
increase in the incidence of adenomas in the kidneys was observed in males at 10 and 30 mg/kg; an 
increased incidence was also observed in the 30 mg/kg group after 15 months of exposure.  Significant 
increases in the incidence of adenoma or carcinoma were observed in the preputial gland at 30 mg/kg and 
in the clitoral gland at ≥10 mg/kg.  In females, increases in the incidence of adenocarcinomas of the 
mammary gland were observed at 10 and 30 mg/kg.  An increased incidence on Zymbal’s gland 
carcinoma was observed in females at 30 mg/kg.  Adenomatous polyps or adenocarcinomas were 
observed in the 30 mg/kg group; although the incidence was not statistically higher than controls, the 
investigators considered them to be treatment-related given the rarity of the lesion in historical controls 
and the decreased survival in rats in this group.  In the testes, interstitial cell hyperplasia was observed at 
30 mg/kg. 
 
Selection of the Point of Departure for the MRL:  Exposure data for several endpoints were considered 
as the POD for the MRL:  increases in absolute liver weight at 15 months, bile duct hyperplasia at 
15 months, increases in absolute kidney weight at 15 months, and increases in the severity of nephropathy 
in male rats at 2 years.  The 15-month data were used for liver and kidney weights because organ weights 
were not assessed at 2 years; 15-month incidence data for bile duct hyperplasia were used because the 
LOAEL was lower than after 2 years of exposure.  BMD modeling was attempted for the increases in 
absolute liver and kidney weights and for bile duct hyperplasia; the results of the modeling is presented in 
the Benchmark Dose Modeling section.  Because only mean severity scores were reported for 
nephropathy, the data was not suitable for BMD modeling.   
 
Four PODs were considered for the MRL:   
• BMDRD10 of 3.77 mg/kg for absolute liver weight increases in male rats 
• BMDRD10 of 11.22 mg/kg for absolute kidney weight increases in male rats 
• BMD10 of 2.56 mg/kg for increases in incidence of bile duct hyperplasia in male rats at 15 months 
• NOAEL of 3 mg/kg for increases in severity of nephropathy in male rats 
 
The BMDL10 of 0.66 mg/kg, which is associated with the lowest POD of 2.56 mg/kg, was selected as the 
basis of the MRL. 
 
Intermittent Exposure:  The BMDL10 of 0.66 mg/kg was adjusted for intermittent exposure 
(5 days/7 days) resulting in adjusted value of 0.47 mg/kg/day. 
 
Uncertainty Factor:  The adjusted BMDL10 was divided by a total uncertainty factor of 100: 
• 10 for extrapolation from animals to humans  
• 10 for human variability 
 
  MRL = BMDL10÷ UFs 
  0.47 mg/kg/day ÷ (10 x 10) = 0.005 mg/kg/day  
 
Other Additional Studies or Pertinent Information that Lend Support to this MRL:  Identification of the 
liver and kidney as sensitive targets of toxicity is supported by intermediate-duration oral studies, which 
also found increases in liver and kidney weights, bile duct hyperplasia, and regenerative tubular 
hyperplasia in rats exposed for up to 17 weeks (NTP 1993). 
 
Benchmark Dose Modeling:  The absolute liver and kidney weight were fit to all available continuous 
models in EPA’s BMDS (version 2.6.0).  The following procedure for fitting continuous data was used:  
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the simplest model (linear) was first applied to the data while assuming constant variance; if the data were 
consistent with the assumption of constant variance (p≥0.1), then the fit of the linear model to the means 
was evaluated and the polynomial, power, and Hill models were fit to the data while assuming constant 
variance.  Incidence data for bile duct hyperplasia at 15 months were fit to all available dichotomous 
models in EPA’s BMDS (version 2.6.0) using the extra risk option.  For the continuous and dichotomous 
models, adequate model fit was judged by three criteria:  goodness-of-fit p-value (p>0.1), visual 
inspection of the dose-response curve, and scaled residual at the data point (except the control) closest to 
the predefined BMR.  Among all of the models providing adequate fit to the data, the lowest BMDL (the 
lower limit of a one-sided 95% CI on the BMD) was selected as a reasonably conservative POD when 
differences between the BMDLs estimated from these models are >2–3-fold; otherwise, the BMDL from 
the model with the lowest AIC was chosen.  For the continuous models in which the test for constant 
variance was negative, the linear model was run again while applying the power model integrated into the 
BMDS to account for nonhomogenous variance.  If the nonhomogenous variance model provided an 
adequate fit (p≥0.1) to the variance data, then the fit of the linear model to the means was evaluated and 
the polynomial, power, and Hill models were fit to the data and evaluated while the variance model was 
applied.  Model fit and POD selection proceeded as described earlier.  For the liver and kidney datasets, a 
BMR of 10% change from the control was used; a BMR of 10% was used for the bile duct hyperplasia 
incidence data.   
 
The model predictions for the liver weight, kidney weight, and bile duct hyperplasia are presented in 
Tables A-6, A-7, and A-8 and the fit of the selected models are presented in Figures A-2, A-3, and A-4.   
 
Table A-6.  Model Predictions for 1,2,3-Trichloropropane, Increased Absolute 
Liver Weights in Male Rats at 15 Months (NTP 1993)  
Model 
Test for 
significant 
difference 
p-valuea 
Variance 
p-valueb 
Mean 
p-valueb 
Scaled residualsc 
AIC 
BMDRD10 
(mg/kg) 
BMDL RD10 
(mg/kg) 
Dose 
below 
BMD 
Dose 
above 
BMD 
Overall 
largest 
Constant variance 
Exponential 
(model 2)d 
<0.0001 0.78 0.03 1.58 -0.57 -1.73 68.70 NA NA 
Exponential 
(model 3)d 
<0.0001 0.78 0.03 1.58 -0.57 -1.73 68.70 NA NA 
Exponential 
(model 4)d 
<0.0001 0.78 0.51 0.50 -0.34 0.50 64.32 4.33 2.17 
Exponential 
(model 5)d 
<0.0001 0.78 0.51 0.50 -0.34 0.50 64.32 4.33 2.17 
Hilld,e <0.0001 0.78 0.68 0.28 -0.27 0.28 64.06 3.77 1.60 
Linearf <0.0001 0.78 0.05 1.48 -0.63 -1.61 68.03 NA NA 
Polynomial 
(2-degree)f 
<0.0001 0.78 0.05 1.48 -0.63 -1.61 68.03 NA NA 
Polynomial 
(3-degree)f 
<0.0001 0.78 0.05 1.48 -0.63 -1.61 68.03 NA NA 
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Table A-6.  Model Predictions for 1,2,3-Trichloropropane, Increased Absolute 
Liver Weights in Male Rats at 15 Months (NTP 1993)  
Model Test for 
 
 
 
Variance 
 
Mean 
 
Scaled residualsc AIC BMDRD10 
 
BMDL RD10 
 Powerd <0.0001 0.78 0.05 1.48 -0.63 -1.61 68.03 NA NA 
 
aValues >0.05 fail to meet conventional goodness-of-fit criteria. 
bValues <0.10 fail to meet conventional goodness-of-fit criteria. 
cScaled residuals at doses immediately below and above the benchmark dose; also the largest residual at any dose. 
dPower restricted to ≥1. 
eSelected model.  Constant variance model provided adequate fit to variance data.  With constant variance model 
applied, the only models that provided adequate fit to the means were the Exponential 4 and 5 models (the 
Exponential 5 converged on to the Exponential 4) and the Hill model.  BMDLs for models providing adequate fit were 
sufficiently close (differed by <3-fold).  Therefore, the model with lowest AIC was selected (Hill). 
fCoefficients restricted to be positive. 
 
AIC = Akaike Information Criterion; BMD = maximum likelihood estimate of the exposure concentration associated 
with the selected benchmark response; BMDL = 95% lower confidence limit on the BMD (subscripts denote 
benchmark response: i.e., 10 = exposure concentration associated with 10% extra risk); DF = degrees of freedom; 
NA = not applicable; model did not provide adequate fit; RD = relative deviation 
 
Figure A-2.  Fit of Exponential 2 Model to Data on Absolute Liver Weight in Male 
Rats Administered 1,2,3-Trichloropropane for 15 Months (NTP 1993) 
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Table A-7.  Model Predictions for 1,2,3-Trichloropropane, Increased Absolute 
Kidney Weights in Male Rats at 15 Months (NTP 1993)  
Model 
Test for 
significant 
difference 
p-valuea 
Variance 
p-valueb 
Mean 
p-valueb 
Scaled residualsc 
AIC 
BMDRD10 
(mg/kg/day) 
BMDL RD10 
(mg/kg/day) 
Dose 
below 
BMD 
Dose 
above 
BMD 
Overall 
largest 
Constant variance 
Exponential 
(model 2)d 
<0.0001 0.40 0.27 0.21 -0.16 -1.14 -123.27 12.21 10.09 
Exponential 
(model 3)d 
<0.0001 0.40 0.27 0.21 -0.16 -1.14 -123.27 12.21 10.09 
Exponential 
(model 4)d 
<0.0001 0.40 0.17 1.08 -0.49 1.08 -121.98 8.77 4.62 
Exponential 
(model 5)d 
<0.0001 0.40 0.17 1.08 -0.49 1.08 -121.98 8.77 4.62 
Hilld <0.0001 0.40 0.17 1.07 -0.52 1.07 -122.01 8.61 4.12 
Lineare,f <0.0001 0.40 0.32 0.04 -0.14 1.09 -123.57 11.22 9.02 
Polynomial 
(2-degree)e 
<0.0001 0.40 0.32 0.04 -0.14 1.09 -123.57 11.22 9.02 
Polynomial 
(3-degree)e 
<0.0001 0.40 0.32 0.04 -0.14 1.09 -123.57 11.22 9.02 
Powerd <0.0001 0.40 0.32 0.04 -0.14 1.09 -123.57 11.22 9.02 
 
aValues >0.05 fail to meet conventional goodness-of-fit criteria. 
bValues <0.10 fail to meet conventional goodness-of-fit criteria. 
cScaled residuals at doses immediately below and above the benchmark dose; also the largest residual at any dose. 
dPower restricted to ≥1. 
eCoefficients restricted to be positive. 
fSelected model.  Constant variance model provided adequate fit to variance data.  With constant variance model 
applied, all models provided adequate fit to the means.  BMDLs for models providing adequate fit were sufficiently 
close (differed by <3-fold).  Therefore, the model with lowest AIC was selected (Linear; the polynomial and power 
models converged onto the linear model). 
 
AIC = Akaike Information Criterion; BMD = maximum likelihood estimate of the exposure concentration associated 
with the selected benchmark response; BMDL = 95% lower confidence limit on the BMD (subscripts denote 
benchmark response: i.e., 10 = exposure concentration associated with 10% extra risk); DF = degrees of freedom; 
RD = relative deviation 
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Figure A-3.  Fit of Exponential 2 Model to Data on Absolute Kidney Weight in Male 
Rats Administered 1,2,3-Trichloropropane for 15 Months (NTP 1993) 
 
 
 
Table A-8.  Model Predictions for 1,2,3-Trichloropropane, Incidence of Bile Duct 
Hyperplasia in Male Rats at 15 Months (NTP 1993)  
Model DF χ2 
χ2 
Goodness-
of-fit 
p-valuea 
Scaled residualsb 
AIC 
BMD10 
(mg/kg) 
BMDL10 
(mg/kg) 
Dose 
below 
BMD 
Dose 
above 
BMD 
Overall 
largest 
Gammac 1 0.1 0.75 0.05 -0.19 0.24 46.49 2.05 1.21 
Logistic 2 1.15 0.56 -0.14 0.82 0.82 45.54 4.68 3.02 
LogLogisticd,e 1 0.01 0.92 0.02 -0.06 0.07 46.39 2.56 0.66 
LogProbitd 2 0.13 0.94 0.16 0.15 -0.24 44.51 3.50 2.03 
Multistage (1-degree)f 2 0.1 0.95 0.05 -0.20 0.23 44.49 2.01 1.21 
Multistage (2-degree)f 2 0.1 0.95 0.05 -0.20 0.23 44.49 2.01 1.21 
Multistage (3-degree)f 2 0.1 0.95 0.05 -0.20 0.23 44.49 2.01 1.21 
Probit 2 1.11 0.57 -0.12 0.84 0.84 45.50 4.54 3.09 
Weibullc 2 0.1 0.95 0.05 -0.20 0.23 44.49 2.01 1.21 
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aValues <0.1 fail to meet conventional goodness-of-fit criteria. 
bScaled residuals at doses immediately below and above the BMD; also the largest residual at any dose. 
cPower restricted to ≥1. 
dSlope restricted to ≥1. 
eSelected model.  All models provided adequate fit to the data.  BMDLs for models providing adequate fit were not 
sufficiently close (differed by >3-fold).  Therefore, the model with lowest BMDL was selected. 
fBetas restricted to ≥0. 
 
AIC = Akaike Information Criterion; BMD = maximum likelihood estimate of the exposure concentration associated 
with the selected benchmark response; BMDL = 95% lower confidence limit on the BMD (subscripts denote 
benchmark response: i.e., 10 = exposure concentration associated with 10% extra risk); DF = degrees of freedom 
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Figure A-4.  Fit of Gamma Model to Data on Bile Duct Hyperplasia in Male Rats 
Administered 1,2,3-Trichloropropane for 15 Months (NTP 1993) 
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APPENDIX B.  LITERATURE SEARCH FRAMEWORK FOR 
1,2,3-TRICHLOROPROPANE 
 
The objective of the toxicological profile is to evaluate the potential for human exposure and the potential 
health hazards associated with inhalation, oral, or dermal/ocular exposure to 1,2,3-trichloropropane. 
 
B.1  LITERATURE SEARCH AND SCREEN  
 
A literature search and screen was conducted to identify studies examining health effects, toxicokinetics, 
mechanisms of action, susceptible populations, biomarkers, and chemical interactions data for 1,2,3-tri-
chloropropane.  ATSDR primarily focused on peer-reviewed articles without publication date or language 
restrictions.  Non-peer-reviewed studies that were considered relevant to the assessment of the health 
effects of 1,2,3-trichloropropane have undergone peer review by at least three ATSDR-selected experts 
who have been screened for conflict of interest.  The inclusion criteria used to identify relevant studies 
examining the health effects of 1,2,3-trichloropropane are presented in Table B-1. 
 
Table B-1.  Inclusion Criteria for the Literature Search and Screen 
 
Health Effects 
 Species 
  Human 
  Laboratory mammals 
 Route of exposure 
  Inhalation 
  Oral 
  Dermal (or ocular) 
  Parenteral (these studies will be considered supporting data) 
 Health outcome 
  Death 
  Systemic effects 
  Body weight effects  
  Respiratory effects 
  Cardiovascular effects 
  Gastrointestinal effects 
  Hematological effects 
  Musculoskeletal effects 
  Hepatic effects 
  Renal effects 
  Dermal effects 
  Ocular effects 
  Endocrine effects 
  Immunological effects 
  Neurological effects 
  Reproductive effects 
  Developmental effects 
  Other noncancer effects 
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Table B-1.  Inclusion Criteria for the Literature Search and Screen 
Cancer 
Toxicokinetics 
Absorption 
Distribution 
Metabolism 
Excretion 
PBPK models 
Biomarkers 
Biomarkers of exposure 
Biomarkers of effect 
Interactions with other chemicals 
B.1.1  Literature Search
The current literature search was intended to update the health effects sections of the existing 
toxicological profile for 1,2,3-trichloropropane (ATSDR 1992), thus, the literature search was restricted 
to studies published between January 1990 to March 2017.  The following main databases were searched 
in March 2017: 
• PubMed
• National Library of Medicine’s TOXLINE
• Scientific and Technical Information Network’s TOXCENTER
The search strategy used the chemical names, Chemical Abstracts Service (CAS) numbers, 
synonyms, and Medical Subject Headings (MeSH) terms for 1,2,3-trichloropropane.  The query 
strings used for the literature search are presented in Table B-2.  
The search was augmented by searching the Toxic Substances Control Act Test Submissions (TSCATS), 
NTP website, and National Institute of Health Research Portfolio Online Reporting Tools Expenditures 
and Results (NIH RePORTER) databases using the queries presented in Table B-3.  Additional databases 
were searched in the creation of various tables and figures, such as the TRI Explorer, the Substance 
priority list (SPL) resource page, and other items as needed.  Regulations applicable to 1,2,3-trichloro-
propane were identified by searching international and U.S. agency websites and documents. 
Review articles were identified and used for the purpose of providing background information and 
identifying additional references.  ATSDR also identified reports from the grey literature, which included 
unpublished research reports, technical reports from government agencies, conference proceedings and 
abstracts, and theses and dissertations.   
Table B-2.  Database Query Strings 
Database 
search date Query string 
PubMed 
03/2017 (("1,2,3-Trichloropropane"[tw] OR "Allyl trichloride"[tw] OR "Glycerol trichlorohydrin"[tw] OR 
"Glyceryl trichlorohydrin"[tw] OR "Trichlorohydrin"[tw] OR "Trichloropropane"[tw]) AND 
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Table B-2.  Database Query Strings  
 
Database 
search date Query string 
(1990/01/01 : 3000[dp] OR 1990/01/01 : 3000[crdat] OR 1990/01/01 : 3000[edat])) OR 
(("1,2,3-trichloropropane"[supplementary concept] OR 96-18-4[rn] OR 3MJ7QCK0Z0[rn] 
OR "1,2,3-trichloropropane"[nm]) AND (1990/01/01 : 3000[dp] OR 1990/01/01 : 
3000[mhda])) 
Toxline  
03/2017 ( "1 2 3-trichloropropane" OR "allyl trichloride" OR "glycerol trichlorohydrin" OR "glyceryl 
trichlorohydrin" OR "trichlorohydrin" OR "trichloropropane" OR 96-18-4 [rn] ) AND 
1990:2017 [yr] AND ( ANEUPL [org] OR BIOSIS [org] OR CIS [org] OR DART [org] OR 
EMIC [org] OR EPIDEM [org] OR HEEP [org] OR HMTC [org] OR IPA [org] OR RISKLINE 
[org] OR MTGABS [org] OR NIOSH [org] OR NTIS [org] OR PESTAB [org] OR PPBIB [org] 
) AND NOT PubMed [org] AND NOT pubdart [org] 
Toxcenter  
03/2017      FILE 'TOXCENTER' ENTERED AT 14:44:17 ON 21 MAR 2017 
L1          797 SEA 96-18-4  
L2          754 SEA L1 NOT TSCATS/FS  
L3          717 SEA L2 NOT PATENT/DT  
L4          577 SEA L3 AND PY>=1990  
                ACTIVATE TOXQUERY/Q 
               --------- 
L5              QUE (CHRONIC OR IMMUNOTOX? OR NEUROTOX? OR TOXICOKIN? OR  
                BIOMARKER? OR NEUROLOG?)  
L6              QUE (PHARMACOKIN? OR SUBCHRONIC OR PBPK OR  
EPIDEMIOLOGY/ST,CT, 
                IT)  
L7              QUE (ACUTE OR SUBACUTE OR LD50# OR LD(W)50 OR LC50# OR  
                LC(W)50)  
L8              QUE (TOXICITY OR ADVERSE OR POISONING)/ST,CT,IT  
L9              QUE (INHAL? OR PULMON? OR NASAL? OR LUNG?  OR RESPIR?)  
L10             QUE ((OCCUPATION? OR WORKPLACE? OR WORKER?) AND EXPOS?)  
L11             QUE (ORAL OR ORALLY OR INGEST? OR GAVAGE? OR DIET OR DIETS 
OR  
                DIETARY OR DRINKING(W)WATER?)  
L12             QUE (MAXIMUM AND CONCENTRATION? AND (ALLOWABLE OR 
PERMISSIBLE)) 
 
L13             QUE (ABORT? OR ABNORMALIT? OR EMBRYO? OR CLEFT? OR FETUS?)  
L14             QUE (FOETUS? OR FETAL? OR FOETAL? OR FERTIL? OR MALFORM? 
OR  
                OVUM?)  
L15             QUE (OVA OR OVARY OR PLACENTA? OR PREGNAN? OR PRENATAL?)  
L16             QUE (PERINATAL? OR POSTNATAL? OR REPRODUC? OR STERIL? OR  
                TERATOGEN?)  
L17             QUE (SPERM OR SPERMAC? OR SPERMAG? OR SPERMATI? OR 
SPERMAS? OR  
                SPERMATOB? OR SPERMATOC? OR SPERMATOG?)  
L18             QUE (SPERMATOI? OR SPERMATOL? OR SPERMATOR? OR 
SPERMATOX? OR  
                SPERMATOZ? OR SPERMATU? OR SPERMI? OR SPERMO?)  
L19             QUE (NEONAT? OR NEWBORN? OR DEVELOPMENT OR 
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Table B-2.  Database Query Strings  
 
Database 
search date Query string 
DEVELOPMENTAL?)  
L20             QUE (ENDOCRIN? AND DISRUPT?)  
L21             QUE (ZYGOTE? OR CHILD OR CHILDREN OR ADOLESCEN? OR 
INFANT?)  
L22             QUE (WEAN? OR OFFSPRING OR AGE(W)FACTOR?)  
L23             QUE (DERMAL? OR DERMIS OR SKIN OR EPIDERM? OR CUTANEOUS?)  
L24             QUE (CARCINOG? OR COCARCINOG? OR CANCER? OR PRECANCER? 
OR  
                NEOPLAS?)  
L25             QUE (TUMOR? OR TUMOUR? OR ONCOGEN? OR LYMPHOMA? OR 
CARCINOM?)  
L26             QUE (GENETOX? OR GENOTOX? OR MUTAGEN? OR 
GENETIC(W)TOXIC?)  
L27             QUE (NEPHROTOX? OR HEPATOTOX?)  
L28             QUE (ENDOCRIN? OR ESTROGEN? OR ANDROGEN? OR HORMON?)  
L29             QUE (OCCUPATION? OR WORKER? OR WORKPLACE? OR EPIDEM?)  
L30             QUE L5 OR L6 OR L7 OR L8 OR L9 OR L10 OR L11 OR L12 OR L13 OR  
                L14 OR L15 OR L16 OR L17 OR L18 OR L19 OR L20 OR L21 OR L22 OR  
                L23 OR L24 OR L25 OR L26 OR L27 OR L28 OR L29  
L31             QUE (RAT OR RATS OR MOUSE OR MICE OR GUINEA(W)PIG? OR 
MURIDAE  
                OR DOG OR DOGS OR RABBIT? OR HAMSTER? OR PIG OR PIGS OR 
SWINE  
                OR PORCINE OR MONKEY? OR MACAQUE?)  
L32             QUE (MARMOSET? OR FERRET? OR GERBIL? OR RODENT? OR 
LAGOMORPHA  
                OR BABOON? OR CANINE OR CAT OR CATS OR FELINE OR MURINE)  
L33             QUE L30 OR L31 OR L32  
L34             QUE (NONHUMAN MAMMALS)/ORGN  
L35             QUE L33 OR L34  
L36             QUE (HUMAN OR HUMANS OR HOMINIDAE OR MAMMALS OR MAMMAL? 
OR  
                PRIMATES OR PRIMATE?)  
L37             QUE L35 OR L36  
               --------- 
L38         372 SEA L4 AND L37  
L39          34 SEA L38 AND MEDLINE/FS  
L40          18 SEA L38 AND BIOSIS/FS  
L41         293 SEA L38 AND CAPLUS/FS  
L42          27 SEA L38 NOT (MEDLINE/FS OR BIOSIS/FS OR CAPLUS/FS)  
L43         329 DUP REM L39 L40 L42 L41 (43 DUPLICATES REMOVED) 
L*** DEL     34 S L38 AND MEDLINE/FS 
L*** DEL     34 S L38 AND MEDLINE/FS 
L44          34 SEA L43  
L*** DEL     18 S L38 AND BIOSIS/FS 
L*** DEL     18 S L38 AND BIOSIS/FS 
L45          11 SEA L43  
L*** DEL    293 S L38 AND CAPLUS/FS 
L*** DEL    293 S L38 AND CAPLUS/FS 
L46         264 SEA L43  
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Table B-2.  Database Query Strings  
 
Database 
search date Query string 
L*** DEL     27 S L38 NOT (MEDLINE/FS OR BIOSIS/FS OR CAPLUS/FS) 
L*** DEL     27 S L38 NOT (MEDLINE/FS OR BIOSIS/FS OR CAPLUS/FS) 
L47          20 SEA L43  
L48         295 SEA (L44 OR L45 OR L46 OR L47) NOT MEDLINE/FS  
                D SCAN L48 
 
Table B-3.  Strategies to Augment the Literature Search 
 
Source Query and number screened when available 
TSCATSa  
03/2017 Compound searched: 96-18-4 
NTP  
03/2017 96-18-4 
1,2,3-Trichloropropane 
NIH RePORTER 
06/2017 Text Search: "1,2,3-Trichloropropane" OR "Allyl trichloride" OR "Glycerol 
trichlorohydrin" OR "Glyceryl trichlorohydrin" OR "Trichlorohydrin" OR 
"Trichloropropane" (Advanced), Search in: Projects Admin IC: All, Fiscal Year: Active 
Projects 
Other Identified throughout the assessment process 
 
aSeveral versions of the TSCATS database were searched, as needed, by CASRN including TSCATS1 via Toxline 
(no date limit), TSCATS2 via https://yosemite.epa.gov/oppts/epatscat8.nsf/ReportSearch?OpenForm (date restricted 
by EPA receipt date), and TSCATS via CDAT (date restricted by ‘Mail Received Date Range’), as well as google for 
recent TSCA submissions. 
 
The 2017 results were:  
• Number of records identified from PubMed, TOXLINE, and TOXCENTER (after duplicate 
removal):  473 
• Number of records identified from other strategies: 32 
• Total number of records to undergo literature screening: 505 
 
B.1.2  Literature Screening  
 
A two-step process was used to screen the literature search to identify relevant studies on 1,2,3-trichloro-
propane:   
 
• Title and abstract screen 
• Full text screen 
 
Title and Abstract Screen.  Within the reference library, titles and abstracts were screened manually for 
relevance.  Studies that were considered relevant (see Table B-1 for inclusion criteria) were moved to the 
second step of the literature screening process.  Studies were excluded when the title and abstract clearly 
indicated that the study was not relevant to the toxicological profile.   
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• Number of titles and abstracts screened: 505 
• Number of studies considered relevant and moved to the next step: 62 
 
Full Text Screen.  The second step in the literature screening process was a full text review of individual 
studies considered relevant in the title and abstract screen step.  Each study was reviewed to determine 
whether it was relevant for inclusion in the toxicological profile.   
 
• Number of studies undergoing full text review: 62 
• Number of studies cited in the health effects sections of the existing toxicological profile 
(September, 1992):  31 
• Total number of studies cited in the health effects sections of the updated profile: 56 
 
A summary of the results of the literature search and screening is presented in Figure B-1. 
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Figure B-1.  March 2017 Literature Search Results and Screen for 
1,2,3-Trichloropropane 
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APPENDIX C.  USER'S GUIDE 
 
Chapter 1.  Relevance to Public Health 
 
This chapter provides an overview of U.S. exposures, a summary of health effects based on evaluations of 
existing toxicologic, epidemiologic, and toxicokinetic information, and an overview of the minimal risk 
levels.  This is designed to present interpretive, weight-of-evidence discussions for human health 
endpoints by addressing the following questions: 
 
 1. What effects are known to occur in humans? 
 
 2. What effects observed in animals are likely to be of concern to humans? 
 
 3. What exposure conditions are likely to be of concern to humans, especially around hazardous 
waste sites? 
 
Minimal Risk Levels (MRLs) 
 
Where sufficient toxicologic information is available, ATSDR derives MRLs for inhalation and oral 
routes of entry at each duration of exposure (acute, intermediate, and chronic).  These MRLs are not 
meant to support regulatory action, but to acquaint health professionals with exposure levels at which 
adverse health effects are not expected to occur in humans. 
 
MRLs should help physicians and public health officials determine the safety of a community living near 
a hazardous substance emission, given the concentration of a contaminant in air or the estimated daily 
dose in water.  MRLs are based largely on toxicological studies in animals and on reports of human 
occupational exposure. 
 
MRL users should be familiar with the toxicologic information on which the number is based.  
Section 1.2, Summary of Health Effects, contains basic information known about the substance.  Other 
sections, such as Section 3.2 Children and Other Populations that are Unusually Susceptible and 
Section 3.4 Interactions with Other Substances, provide important supplemental information. 
 
MRL users should also understand the MRL derivation methodology.  MRLs are derived using a 
modified version of the risk assessment methodology that the Environmental Protection Agency (EPA) 
provides (Barnes and Dourson 1988) to determine reference doses (RfDs) for lifetime exposure.   
 
To derive an MRL, ATSDR generally selects the most sensitive endpoint which, in its best judgement, 
represents the most sensitive human health effect for a given exposure route and duration.  ATSDR 
cannot make this judgement or derive an MRL unless information (quantitative or qualitative) is available 
for all potential systemic, neurological, and developmental effects.  If this information and reliable 
quantitative data on the chosen endpoint are available, ATSDR derives an MRL using the most sensitive 
species (when information from multiple species is available) with the highest no-observed-adverse-effect 
level (NOAEL) that does not exceed any adverse effect levels.  When a NOAEL is not available, a 
lowest-observed-adverse-effect level (LOAEL) can be used to derive an MRL, and an uncertainty factor 
of 10 must be employed.  Additional uncertainty factors of 10 must be used both for human variability to 
protect sensitive subpopulations (people who are most susceptible to the health effects caused by the 
substance) and for interspecies variability (extrapolation from animals to humans).  In deriving an MRL, 
these individual uncertainty factors are multiplied together.  The product is then divided into the 
inhalation concentration or oral dosage selected from the study.  Uncertainty factors used in developing a 
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substance-specific MRL are provided in the footnotes of the levels of significant exposure (LSE) tables 
that are provided in Chapter 2.  Detailed discussions of the MRLs are presented in Appendix A. 
 
Chapter 2.  Health Effects 
 
Tables and Figures for Levels of Significant Exposure (LSE) 
 
Tables and figures are used to summarize health effects and illustrate graphically levels of exposure 
associated with those effects.  These levels cover health effects observed at increasing dose 
concentrations and durations, differences in response by species and MRLs to humans for noncancer 
endpoints.  The LSE tables and figures can be used for a quick review of the health effects and to locate 
data for a specific exposure scenario.  The LSE tables and figures should always be used in conjunction 
with the text.  All entries in these tables and figures represent studies that provide reliable, quantitative 
estimates of NOAELs, LOAELs, or Cancer Effect Levels (CELs). 
 
The legends presented below demonstrate the application of these tables and figures.  Representative 
examples of LSE tables and figures follow.  The numbers in the left column of the legends correspond to 
the numbers in the example table and figure. 
 
TABLE LEGEND 
See Sample LSE Table (page C-5) 
 
(1) Route of exposure.  One of the first considerations when reviewing the toxicity of a substance 
using these tables and figures should be the relevant and appropriate route of exposure.  
Typically, when sufficient data exist, three LSE tables and two LSE figures are presented in the 
document.  The three LSE tables present data on the three principal routes of exposure 
(i.e., inhalation, oral, and dermal).  LSE figures are limited to the inhalation and oral routes.  Not 
all substances will have data on each route of exposure and will not, therefore, have all five of the 
tables and figures.  Profiles with more than one chemical may have more LSE tables and figures. 
 
(2) Exposure period.  Three exposure periods—acute (<15 days), intermediate (15–364 days), and 
chronic (≥365 days)—are presented within each relevant route of exposure.  In this example, two 
oral studies of chronic-duration exposure are reported.  For quick reference to health effects 
occurring from a known length of exposure, locate the applicable exposure period within the LSE 
table and figure. 
 
(3) Figure key.  Each key number in the LSE table links study information to one or more data points 
using the same key number in the corresponding LSE figure.  In this example, the study 
represented by key number 51 identified NOAELs and less serious LOAELs (also see the three 
"51R" data points in sample LSE Figure 2-X). 
 
(4) Species (strain) No./group.  The test species (and strain), whether animal or human, are identified 
in this column.  The column also contains information on the number of subjects and sex per 
group.  Chapter 1, Relevance to Public Health, covers the relevance of animal data to human 
toxicity and Section 3.1, Toxicokinetics, contains any available information on comparative 
toxicokinetics.  Although NOAELs and LOAELs are species specific, the levels are extrapolated 
to equivalent human doses to derive an MRL. 
 
(5) Exposure parameters/doses.  The duration of the study and exposure regimens are provided in 
these columns.  This permits comparison of NOAELs and LOAELs from different studies.  In 
this case (key number 51), rats were orally exposed to “Chemical X” via feed for 2 years.  For a 
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more complete review of the dosing regimen, refer to the appropriate sections of the text or the 
original reference paper (i.e., Aida et al. 1992). 
 
(6) Parameters monitored.  This column lists the parameters used to assess health effects.  Parameters 
monitored could include serum (blood) chemistry (BC), behavioral (BH), biochemical changes 
(BI), body weight (BW), clinical signs (CS), developmental toxicity (DX), enzyme activity (EA), 
food intake (FI), fetal toxicity (FX), gross necropsy (GN), hematology (HE), histopathology 
(HP), lethality (LE), maternal toxicity (MX), organ function (OF), ophthalmology (OP), organ 
weight (OW), teratogenicity (TG), urinalysis (UR), and water intake (WI). 
 
(7) Endpoint.  This column lists the endpoint examined.  The major categories of health endpoints 
included in LSE tables and figures are death, body weight, respiratory, cardiovascular, 
gastrointestinal, hematological, musculoskeletal, hepatic, renal, dermal, ocular, endocrine, 
immunological, neurological, reproductive, developmental, other noncancer, and cancer.  "Other 
noncancer" refers to any effect (e.g., alterations in blood glucose levels) not covered in these 
systems.  In the example of key number 51, three endpoints (body weight, hematological, and 
hepatic) were investigated. 
 
(8) NOAEL.  A NOAEL is the highest exposure level at which no adverse effects were seen in the 
organ system studied.  The body weight effect reported in key number 51 is a NOAEL at 
25.5 mg/kg/day.  NOAELs are not reported for cancer and death; with the exception of these two 
endpoints, this field is left blank if no NOAEL was identified in the study. 
 
(9) LOAEL.  A LOAEL is the lowest dose used in the study that caused an adverse health effect.  
LOAELs have been classified into "Less Serious" and "Serious" effects.  These distinctions help 
readers identify the levels of exposure at which adverse health effects first appear and the 
gradation of effects with increasing dose.  A brief description of the specific endpoint used to 
quantify the adverse effect accompanies the LOAEL.  Key number 51 reports a less serious 
LOAEL of 6.1 mg/kg/day for the hepatic system, which was used to derive a chronic exposure, 
oral MRL of 0.008 mg/kg/day (see footnote "c").  MRLs are not derived from serious LOAELs.  
A cancer effect level (CEL) is the lowest exposure level associated with the onset of 
carcinogenesis in experimental or epidemiologic studies.  CELs are always considered serious 
effects.  The LSE tables and figures do not contain NOAELs for cancer, but the text may report 
doses not causing measurable cancer increases.  If no LOAEL/CEL values were identified in the 
study, this field is left blank. 
 
(10) Reference.  The complete reference citation is provided in Chapter 8 of the profile.  
 
(11) Footnotes.  Explanations of abbreviations or reference notes for data in the LSE tables are found 
in the footnotes.  For example, footnote "c" indicates that the LOAEL of 6.1 mg/kg/day in key 
number 51 was used to derive an oral MRL of 0.008 mg/kg/day. 
 
FIGURE LEGEND 
See Sample LSE Figure (page C-6) 
 
LSE figures graphically illustrate the data presented in the corresponding LSE tables.  Figures help the 
reader quickly compare health effects according to exposure concentrations for particular exposure 
periods. 
 
(13) Exposure period.  The same exposure periods appear as in the LSE table.  In this example, health 
effects observed within the chronic exposure period are illustrated. 
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(14) Endpoint.  These are the categories of health effects for which reliable quantitative data exist.  
The same health effect endpoints appear in the LSE table. 
 
(15) Levels of exposure.  Concentrations or doses for each health effect in the LSE tables are 
graphically displayed in the LSE figures.  Exposure concentration or dose is measured on the log 
scale "y" axis.  Inhalation exposure is reported in mg/m3 or ppm and oral exposure is reported in 
mg/kg/day. 
 
(16) LOAEL.  In this example, the half-shaded circle that is designated 51R identifies a LOAEL 
critical endpoint in the rat upon which a chronic oral exposure MRL is based.  The key number 
51 corresponds to the entry in the LSE table.  The dashed descending arrow indicates the 
extrapolation from the exposure level of 6.1 mg/kg/day (see entry 51 in the sample LSE table) to 
the MRL of 0.008 mg/kg/day (see footnote "c" in the sample LSE table). 
 
(17) CEL.  Key number 59R is one of studies for which CELs were derived.  The diamond symbol 
refers to a CEL for the test species (rat).  The number 59 corresponds to the entry in the LSE 
table. 
 
(18) Key to LSE figure.  The key provides the abbreviations and symbols used in the figure. 
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APPENDIX D.  QUICK REFERENCE FOR HEALTH CARE PROVIDERS 
 
 
Toxicological Profiles are a unique compilation of toxicological information on a given hazardous 
substance.  Each profile reflects a comprehensive and extensive evaluation, summary, and interpretation 
of available toxicologic and epidemiologic information on a substance.  Health care providers treating 
patients potentially exposed to hazardous substances may find the following information helpful for fast 
answers to often-asked questions. 
 
 
Primary Chapters/Sections of Interest 
 
Chapter 1:  Relevance to Public Health: The Relevance to Public Health Section provides an overview 
of exposure and health effects and evaluates, interprets, and assesses the significance of toxicity 
data to human health.  A table listing minimal risk levels (MRLs) is also included in this chapter. 
 
Chapter 2:  Health Effects: Specific health effects identified in both human and animal studies are 
reported by type of health effect (e.g., death, hepatic, renal, immune, reproductive), route of 
exposure (e.g., inhalation, oral, dermal), and length of exposure (e.g., acute, intermediate, and 
chronic).   
 NOTE: Not all health effects reported in this section are necessarily observed in the clinical 
setting.   
 
Pediatrics:    
 Section 3.2 Children and Other Populations that are Unusually Susceptible 
 Section 3.3  Biomarkers of Exposure and Effect  
 
 
ATSDR Information Center  
 
 Phone:   1-800-CDC-INFO (800-232-4636) or 1-888-232-6348 (TTY)   
 Internet:  http://www.atsdr.cdc.gov 
 
The following additional materials are available online: 
 
Case Studies in Environmental Medicine are self-instructional publications designed to increase primary 
health care providers’ knowledge of a hazardous substance in the environment and to aid in the 
evaluation of potentially exposed patients (see https://www.atsdr.cdc.gov/csem/csem.html).   
 
Managing Hazardous Materials Incidents is a three-volume set of recommendations for on-scene 
(prehospital) and hospital medical management of patients exposed during a hazardous materials 
incident (see https://www.atsdr.cdc.gov/MHMI/index.asp).  Volumes I and II are planning guides 
to assist first responders and hospital emergency department personnel in planning for incidents 
that involve hazardous materials.  Volume III—Medical Management Guidelines for Acute 
Chemical Exposures—is a guide for health care professionals treating patients exposed to 
hazardous materials. 
 
Fact Sheets (ToxFAQs™) provide answers to frequently asked questions about toxic substances (see 
https://www.atsdr.cdc.gov/toxfaqs/Index.asp). 
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Other Agencies and Organizations 
 
The National Center for Environmental Health (NCEH) focuses on preventing or controlling disease, 
injury, and disability related to the interactions between people and their environment outside the 
workplace.  Contact:  NCEH, Mailstop F-29, 4770 Buford Highway, NE, Atlanta, GA 
30341-3724 • Phone:  770-488-7000 • FAX:  770-488-7015 • Web Page:  
https://www.cdc.gov/nceh/. 
 
The National Institute for Occupational Safety and Health (NIOSH) conducts research on occupational 
diseases and injuries, responds to requests for assistance by investigating problems of health and 
safety in the workplace, recommends standards to the Occupational Safety and Health 
Administration (OSHA) and the Mine Safety and Health Administration (MSHA), and trains 
professionals in occupational safety and health.  Contact: NIOSH, 395 E Street, S.W., Suite 9200, 
Patriots Plaza Building, Washington, DC 20201 • Phone:  202-245-0625 or 1-800-CDC-INFO 
(800-232-4636) • Web Page: https://www.cdc.gov/niosh/. 
 
The National Institute of Environmental Health Sciences (NIEHS) is the principal federal agency for 
biomedical research on the effects of chemical, physical, and biologic environmental agents on 
human health and well-being.  Contact:  NIEHS, PO Box 12233, 104 T.W. Alexander Drive, 
Research Triangle Park, NC 27709 • Phone:  919-541-3212 • Web Page: 
https://www.niehs.nih.gov/. 
 
 
Clinical Resources (Publicly Available Information) 
 
The Association of Occupational and Environmental Clinics (AOEC) has developed a network of clinics 
in the United States to provide expertise in occupational and environmental issues.  Contact:  
AOEC, 1010 Vermont Avenue, NW, #513, Washington, DC 20005 • Phone:  202-347-4976 
• FAX:  202-347-4950 • e-mail: AOEC@AOEC.ORG • Web Page:  http://www.aoec.org/. 
 
The American College of Occupational and Environmental Medicine (ACOEM) is an association of 
physicians and other health care providers specializing in the field of occupational and 
environmental medicine.  Contact:  ACOEM, 25 Northwest Point Boulevard, Suite 700, Elk 
Grove Village, IL 60007-1030 • Phone:  847-818-1800 • FAX:  847-818-9266 • Web Page:  
http://www.acoem.org/. 
 
The American College of Medical Toxicology (ACMT) is a nonprofit association of physicians with 
recognized expertise in medical toxicology.  Contact:  ACMT, 10645 North Tatum Boulevard, 
Suite 200-111, Phoenix AZ 85028 • Phone:  844-226-8333 • FAX:  844-226-8333 • Web Page:  
http://www.acmt.net. 
 
The Pediatric Environmental Health Specialty Units (PEHSUs) is an interconnected system of specialists 
who respond to questions from public health professionals, clinicians, policy makers, and the 
public about the impact of environmental factors on the health of children and reproductive-aged 
adults.  Contact information for regional centers can be found at http://pehsu.net/findhelp.html. 
 
The American Association of Poison Control Centers (AAPCC) provide support on the prevention and 
treatment of poison exposures.  Contact:  AAPCC, 515 King Street, Suite 510, Alexandria VA 
22314 • Phone:  701-894-1858 • Poison Help Line: 1-800-222-1222 • Web Page:  
http://www.aapcc.org/. 
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APPENDIX E.  GLOSSARY 
 
 
Absorption—The process by which a substance crosses biological membranes and enters systemic 
circulation.  Absorption can also refer to the taking up of liquids by solids, or of gases by solids or liquids. 
 
Acute Exposure—Exposure to a chemical for a duration of ≤14 days, as specified in the Toxicological 
Profiles. 
 
Adsorption—The adhesion in an extremely thin layer of molecules (as of gases, solutes, or liquids) to the 
surfaces of solid bodies or liquids with which they are in contact. 
 
Adsorption Coefficient (Koc)—The ratio of the amount of a chemical adsorbed per unit weight of 
organic carbon in the soil or sediment to the concentration of the chemical in solution at equilibrium. 
 
Adsorption Ratio (Kd)—The amount of a chemical adsorbed by sediment or soil (i.e., the solid phase) 
divided by the amount of chemical in the solution phase, which is in equilibrium with the solid phase, at a 
fixed solid/solution ratio.  It is generally expressed in micrograms of chemical sorbed per gram of soil or 
sediment. 
 
Benchmark Dose (BMD) or Benchmark Concentration (BMC)—is the dose/concentration 
corresponding to a specific response level estimate using a statistical dose-response model applied to 
either experimental toxicology or epidemiology data.  For example, a BMD10 would be the dose 
corresponding to a 10% benchmark response (BMR).  The BMD is determined by modeling the dose-
response curve in the region of the dose-response relationship where biologically observable data are 
feasible.  The BMDL or BMCL is the 95% lower confidence limit on the BMD or BMC.   
 
Bioconcentration Factor (BCF)—The quotient of the concentration of a chemical in aquatic organisms 
at a specific time or during a discrete time period of exposure divided by the concentration in the 
surrounding water at the same time or during the same period. 
 
Biomarkers—Indicators signaling events in biologic systems or samples, typically classified as markers 
of exposure, effect, and susceptibility. 
 
Cancer Effect Level (CEL)—The lowest dose of a chemical in a study, or group of studies, that 
produces significant increases in the incidence of cancer (or tumors) between the exposed population and 
its appropriate control. 
 
Carcinogen—A chemical capable of inducing cancer. 
 
Case-Control Study—A type of epidemiological study that examines the relationship between a 
particular outcome (disease or condition) and a variety of potential causative agents (such as toxic 
chemicals).  In a case-control study, a group of people with a specified and well-defined outcome is 
identified and compared to a similar group of people without the outcome. 
 
Case Report—A report that describes a single individual with a particular disease or exposure.  These 
reports may suggest some potential topics for scientific research, but are not actual research studies. 
 
Case Series—Reports that describe the experience of a small number of individuals with the same 
disease or exposure.  These reports may suggest potential topics for scientific research, but are not actual 
research studies. 
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Ceiling Value—A concentration that must not be exceeded.  
 
Chronic Exposure—Exposure to a chemical for ≥365 days, as specified in the Toxicological Profiles. 
 
Clastogen—A substance that causes breaks in chromosomes resulting in addition, deletion, or 
rearrangement of parts of the chromosome. 
 
Cohort Study—A type of epidemiological study of a specific group or groups of people who have had a 
common insult (e.g., exposure to an agent suspected of causing disease or a common disease) and are 
followed forward from exposure to outcome, and who are disease-free at start of follow-up.  Often, at 
least one exposed group is compared to one unexposed group, while in other cohorts, exposure is a 
continuous variable and analyses are directed towards analyzing an exposure-response coefficient. 
 
Cross-sectional Study—A type of epidemiological study of a group or groups of people that examines 
the relationship between exposure and outcome to a chemical or to chemicals at a specific point in time. 
 
Data Needs—Substance-specific informational needs that, if met, would reduce the uncertainties of 
human health risk assessment. 
 
Developmental Toxicity—The occurrence of adverse effects on the developing organism that may result 
from exposure to a chemical prior to conception (either parent), during prenatal development, or 
postnatally to the time of sexual maturation.  Adverse developmental effects may be detected at any point 
in the life span of the organism. 
 
Dose-Response Relationship—The quantitative relationship between the amount of exposure to a 
toxicant and the incidence of the response or amount of the response. 
  
Embryotoxicity and Fetotoxicity—Any toxic effect on the conceptus as a result of prenatal exposure to 
a chemical; the distinguishing feature between the two terms is the stage of development during which the 
effect occurs.  Effects include malformations and variations, altered growth, and in utero death. 
 
Epidemiology—The investigation of factors that determine the frequency and distribution of disease or 
other health-related conditions within a defined human population during a specified period.  
 
Excretion—The process by which metabolic waste products are removed from the body.  
  
Genotoxicity—A specific adverse effect on the genome of living cells that, upon the duplication of 
affected cells, can be expressed as a mutagenic, clastogenic, or carcinogenic event because of specific 
alteration of the molecular structure of the genome. 
 
Half-life—A measure of rate for the time required to eliminate one-half of a quantity of a chemical from 
the body or environmental media. 
 
Health Advisory—An estimate of acceptable drinking water levels for a chemical substance derived by 
EPA and based on health effects information.  A health advisory is not a legally enforceable federal 
standard, but serves as technical guidance to assist federal, state, and local officials. 
 
Immediately Dangerous to Life or Health (IDLH)—A condition that poses a threat of life or health, or 
conditions that pose an immediate threat of severe exposure to contaminants that are likely to have 
adverse cumulative or delayed effects on health. 
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Immunotoxicity—Adverse effect on the functioning of the immune system that may result from 
exposure to chemical substances.   
 
Incidence—The ratio of new cases of individuals in a population who develop a specified condition to 
the total number of individuals in that population who could have developed that condition in a specified 
time period.  
 
Intermediate Exposure—Exposure to a chemical for a duration of 15–364 days, as specified in the 
Toxicological Profiles. 
 
In Vitro—Isolated from the living organism and artificially maintained, as in a test tube. 
 
In Vivo—Occurring within the living organism. 
 
Lethal Concentration(LO) (LCLO)—The lowest concentration of a chemical in air that has been reported 
to have caused death in humans or animals. 
 
Lethal Concentration(50) (LC50)—A calculated concentration of a chemical in air to which exposure for 
a specific length of time is expected to cause death in 50% of a defined experimental animal population. 
 
Lethal Dose(LO) (LDLo)—The lowest dose of a chemical introduced by a route other than inhalation that 
has been reported to have caused death in humans or animals. 
 
Lethal Dose(50) (LD50)—The dose of a chemical that has been calculated to cause death in 50% of a 
defined experimental animal population. 
 
Lethal Time(50) (LT50)—A calculated period of time within which a specific concentration of a chemical 
is expected to cause death in 50% of a defined experimental animal population. 
 
Lowest-Observed-Adverse-Effect Level (LOAEL)—The lowest exposure level of chemical in a study, 
or group of studies, that produces statistically or biologically significant increases in frequency or severity 
of adverse effects between the exposed population and its appropriate control. 
 
Lymphoreticular Effects—Represent morphological effects involving lymphatic tissues such as the 
lymph nodes, spleen, and thymus. 
 
Malformations—Permanent structural changes that may adversely affect survival, development, or 
function. 
  
Metabolism—Process in which chemical substances are biotransformed in the body that could result in 
less toxic and/or readily excreted compounds or produce a biologically active intermediate. 
 
Minimal Risk Level (MRL)—An estimate of daily human exposure to a hazardous substance that is 
likely to be without an appreciable risk of adverse noncancer health effects over a specified route and 
duration of exposure. 
 
Modifying Factor (MF)—A value (greater than zero) that is applied to the derivation of a Minimal Risk 
Level (MRL) to reflect additional concerns about the database that are not covered by the uncertainty 
factors.  The default value for a MF is 1. 
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Morbidity—The state of being diseased; the morbidity rate is the incidence or prevalence of a disease in 
a specific population. 
 
Mortality—Death; the mortality rate is a measure of the number of deaths in a population during a 
specified interval of time. 
 
Mutagen—A substance that causes mutations, which are changes in the DNA sequence of a cell’s DNA.  
Mutations can lead to birth defects, miscarriages, or cancer. 
 
Necropsy—The gross examination of the organs and tissues of a dead body to determine the cause of 
death or pathological conditions. 
 
Neurotoxicity—The occurrence of adverse effects on the nervous system following exposure to a 
hazardous substance. 
 
No-Observed-Adverse-Effect Level (NOAEL)—The dose of a chemical at which there were no 
statistically or biologically significant increases in frequency or severity of adverse effects seen between 
the exposed population and its appropriate control.  Although effects may be produced at this dose, they 
are not considered to be adverse. 
 
Octanol-Water Partition Coefficient (Kow)—The equilibrium ratio of the concentrations of a chemical 
in n-octanol and water, in dilute solution. 
 
Odds Ratio (OR)—A means of measuring the association between an exposure (such as toxic substances 
and a disease or condition) that represents the best estimate of relative risk (risk as a ratio of the incidence 
among subjects exposed to a particular risk factor divided by the incidence among subjects who were not 
exposed to the risk factor).  An odds ratio that is greater than 1 is considered to indicate greater risk of 
disease in the exposed group compared to the unexposed group. 
 
Permissible Exposure Limit (PEL)—An Occupational Safety and Health Administration (OSHA) 
regulatory limit on the amount or concentration of a substance not to be exceeded in workplace air 
averaged over any 8-hour work shift of a 40-hour workweek. 
 
Pesticide—General classification of chemicals specifically developed and produced for use in the control 
of agricultural and public health pests (insects or other organisms harmful to cultivated plants or animals). 
 
Pharmacokinetics—The dynamic behavior of a material in the body, used to predict the fate 
(disposition) of an exogenous substance in an organism.  Utilizing computational techniques, it provides 
the means of studying the absorption, distribution, metabolism, and excretion of chemicals by the body. 
 
Pharmacokinetic Model—A set of equations that can be used to describe the time course of a parent 
chemical or metabolite in an animal system.  There are two types of pharmacokinetic models:  data-based 
and physiologically-based.  A data-based model divides the animal system into a series of compartments, 
which, in general, do not represent real, identifiable anatomic regions of the body, whereas the 
physiologically-based model compartments represent real anatomic regions of the body. 
 
Physiologically Based Pharmacodynamic (PBPD) Model—A type of physiologically based dose-
response model that quantitatively describes the relationship between target tissue dose and toxic 
endpoints.  These models advance the importance of physiologically based models in that they clearly 
describe the biological effect (response) produced by the system following exposure to an exogenous 
substance.  
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Physiologically Based Pharmacokinetic (PBPK) Model—A type of physiologically based dose-
response model that is comprised of a series of compartments representing organs or tissue groups with 
realistic weights and blood flows.  These models require a variety of physiological information, including 
tissue volumes, blood flow rates to tissues, cardiac output, alveolar ventilation rates, and possibly 
membrane permeabilities.  The models also utilize biochemical information, such as blood:air partition 
coefficients, and metabolic parameters.  PBPK models are also called biologically based tissue dosimetry 
models. 
 
Prevalence—The number of cases of a disease or condition in a population at one point in time.  
 
Prospective Study—A type of cohort study in which a group is followed over time and the pertinent 
observations are made on events occurring after the start of the study.   
 
Recommended Exposure Limit (REL)—A National Institute for Occupational Safety and Health 
(NIOSH) time-weighted average (TWA) concentration for up to a 10-hour workday during a 40-hour 
workweek. 
 
Reference Concentration (RfC)—An estimate (with uncertainty spanning perhaps an order of 
magnitude) of a continuous inhalation exposure to the human population (including sensitive subgroups) 
that is likely to be without an appreciable risk of deleterious noncancer health effects during a lifetime.  
The inhalation RfC is expressed in units of mg/m3 or ppm. 
 
Reference Dose (RfD)—An estimate (with uncertainty spanning perhaps an order of magnitude) of the 
daily oral exposure of the human population to a potential hazard that is likely to be without risk of 
deleterious noncancer health effects during a lifetime.  The oral RfD is expressed in units of mg/kg/day.   
 
Reportable Quantity (RQ)—The quantity of a hazardous substance that is considered reportable under 
the Comprehensive Environmental Response, Compensation, and Liability Act (CERCLA).  RQs are 
(1) ≥1 pound or (2) for selected substances, an amount established by regulation either under CERCLA or 
under Section 311 of the Clean Water Act.  Quantities are measured over a 24-hour period. 
 
Reproductive Toxicity—The occurrence of adverse effects on the reproductive system that may result 
from exposure to a hazardous substance.  The toxicity may be directed to the reproductive organs and/or 
the related endocrine system.  The manifestation of such toxicity may be noted as alterations in sexual 
behavior, fertility, pregnancy outcomes, or modifications in other functions that are dependent on the 
integrity of this system. 
 
Retrospective Study—A type of cohort study based on a group of persons known to have been exposed 
at some time in the past.  Data are collected from routinely recorded events, up to the time the study is 
undertaken.  Retrospective studies are limited to causal factors that can be ascertained from existing 
records and/or examining survivors of the cohort. 
 
Risk—The possibility or chance that some adverse effect will result from a given exposure to a hazardous 
substance. 
 
Risk Factor—An aspect of personal behavior or lifestyle, an environmental exposure, existing health 
condition, or an inborn or inherited characteristic that is associated with an increased occurrence of 
disease or other health-related event or condition. 
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Risk Ratio/Relative Risk—The ratio of the risk among persons with specific risk factors compared to the 
risk among persons without risk factors.  A risk ratio that is greater than 1 indicates greater risk of disease 
in the exposed group compared to the unexposed group. 
 
Short-Term Exposure Limit (STEL)—A STEL is a 15-minute TWA exposure that should not be 
exceeded at any time during a workday.   
 
Standardized Mortality Ratio (SMR)—A ratio of the observed number of deaths and the expected 
number of deaths in a specific standard population. 
 
Target Organ Toxicity—This term covers a broad range of adverse effects on target organs or 
physiological systems (e.g., renal, cardiovascular) extending from those arising through a single limited 
exposure to those assumed over a lifetime of exposure to a chemical. 
 
Teratogen—A chemical that causes structural defects that affect the development of an organism. 
 
Threshold Limit Value (TLV)—An American Conference of Governmental Industrial Hygienists 
(ACGIH) concentration of a substance to which it is believed that nearly all workers may be repeatedly 
exposed, day after day, for a working lifetime without adverse effect.  The TLV may be expressed as a 
Time-Weighted Average (TLV-TWA), as a Short-Term Exposure Limit (TLV-STEL), or as a ceiling 
limit (TLV-C). 
 
Time-Weighted Average (TWA)—An average exposure within a given time period.   
 
Toxicokinetic—The absorption, distribution, metabolism, and elimination of toxic compounds in the 
living organism. 
 
Toxics Release Inventory (TRI)—The TRI is an EPA program that tracks toxic chemical releases and 
pollution prevention activities reported by industrial and federal facilities.   
 
Uncertainty Factor (UF)—A factor used in operationally deriving the Minimal Risk Level (MRL), 
Reference Dose (RfD), or Reference Concentration (RfC) from experimental data.  UFs are intended to 
account for (1) the variation in sensitivity among the members of the human population, (2) the 
uncertainty in extrapolating animal data to the case of human, (3) the uncertainty in extrapolating from 
data obtained in a study that is of less than lifetime exposure, and (4) the uncertainty in using lowest-
observed-adverse-effect level (LOAEL) data rather than no-observed-adverse-effect level (NOAEL) data.  
A default for each individual UF is 10; if complete certainty in data exists, a value of 1 can be used; 
however, a reduced UF of 3 may be used on a case-by-case basis (3 being the approximate logarithmic 
average of 10 and 1). 
 
Xenobiotic—Any substance that is foreign to the biological system. 
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APPENDIX F.  ACRONYMS, ABBREVIATIONS, AND SYMBOLS 
 
AAPCC American Association of Poison Control Centers 
ACGIH American Conference of Governmental Industrial Hygienists 
ACOEM American College of Occupational and Environmental Medicine 
ACMT American College of Medical Toxicology 
ADI acceptable daily intake 
ADME absorption, distribution, metabolism, and excretion 
AEGL Acute Exposure Guideline Level 
AIC Akaike’s information criterion  
AIHA American Industrial Hygiene Association  
ALT alanine aminotransferase 
AOEC Association of Occupational and Environmental Clinics 
AP alkaline phosphatase 
AST aspartate aminotransferase 
atm atmosphere 
ATSDR Agency for Toxic Substances and Disease Registry 
AWQC Ambient Water Quality Criteria 
BCF bioconcentration factor 
BMD/C benchmark dose or benchmark concentration 
BMDX dose that produces a X% change in response rate of an adverse effect 
BMDLX 95% lower confidence limit on the BMDX 
BMDS Benchmark Dose Software 
BMR benchmark response 
BUN  blood urea nitrogen  
C centigrade 
CAA Clean Air Act 
CAS Chemical Abstract Services 
CDC Centers for Disease Control and Prevention 
CEL cancer effect level 
CERCLA Comprehensive Environmental Response, Compensation, and Liability Act 
CFR Code of Federal Regulations 
Ci curie 
CI confidence interval 
cm centimeter 
CPSC Consumer Products Safety Commission 
CWA Clean Water Act 
DHHS Department of Health and Human Services 
DNA deoxyribonucleic acid 
DOD Department of Defense 
DOE Department of Energy 
DWEL drinking water exposure level 
EAFUS  Everything Added to Food in the United States  
ECG/EKG electrocardiogram 
EEG electroencephalogram 
EPA Environmental Protection Agency 
ERPG  emergency response planning guidelines  
F Fahrenheit 
F1 first-filial generation 
FDA Food and Drug Administration 
FIFRA Federal Insecticide, Fungicide, and Rodenticide Act 
1,2,3-TRICHLOROPROPANE  F-2 
 
APPENDIX F 
 
 
 
 
 
 
***DRAFT FOR PUBLIC COMMENT*** 
FR Federal Register 
FSH follicle stimulating hormone 
g gram 
GC gas chromatography 
gd gestational day 
GGT γ-glutamyl transferase  
GRAS  generally recognized as safe  
HEC  human equivalent concentration  
HED  human equivalent dose  
HHS  Department of Health and Human Services  
HPLC high-performance liquid chromatography 
HSDB Hazardous Substance Data Bank  
IARC International Agency for Research on Cancer 
IDLH immediately dangerous to life and health 
IRIS Integrated Risk Information System 
Kd adsorption ratio 
kg kilogram 
kkg kilokilogram; 1 kilokilogram is equivalent to 1,000 kilograms and 1 metric ton 
Koc organic carbon partition coefficient 
Kow octanol-water partition coefficient 
L liter 
LC liquid chromatography 
LC50 lethal concentration, 50% kill 
LCLo lethal concentration, low 
LD50 lethal dose, 50% kill 
LDLo lethal dose, low 
LDH lactic dehydrogenase 
LH luteinizing hormone 
LOAEL lowest-observed-adverse-effect level 
LSE Level of Significant Exposure 
LT50 lethal time, 50% kill 
m meter 
mCi millicurie 
MCL maximum contaminant level 
MCLG maximum contaminant level goal 
MF modifying factor 
mg milligram 
mL milliliter 
mm millimeter 
mmHg millimeters of mercury 
mmol millimole 
MRL Minimal Risk Level 
MS mass spectrometry 
MSHA Mine Safety and Health Administration 
Mt metric ton 
NAAQS National Ambient Air Quality Standard 
NAS National Academy of Science 
NCEH National Center for Environmental Health 
ND not detected 
ng nanogram 
NHANES National Health and Nutrition Examination Survey 
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NIEHS National Institute of Environmental Health Sciences 
NIOSH National Institute for Occupational Safety and Health 
NLM National Library of Medicine 
nm nanometer 
nmol nanomole 
NOAEL no-observed-adverse-effect level 
NPL National Priorities List 
NR not reported 
NRC National Research Council 
NS not specified 
NTP National Toxicology Program 
OR odds ratio 
OSHA Occupational Safety and Health Administration 
PAC  Protective Action Criteria  
PAH polycyclic aromatic hydrocarbon 
PBPD physiologically based pharmacodynamic  
PBPK physiologically based pharmacokinetic  
PEHSU Pediatric Environmental Health Specialty Unit 
PEL permissible exposure limit 
PEL-C permissible exposure limit-ceiling value 
pg picogram 
PND postnatal day 
POD point of departure 
ppb parts per billion 
ppbv parts per billion by volume 
ppm parts per million 
ppt parts per trillion 
REL recommended exposure level/limit 
REL-C recommended exposure level-ceiling value 
RfC reference concentration 
RfD reference dose 
RNA ribonucleic acid 
SARA Superfund Amendments and Reauthorization Act 
SCE sister chromatid exchange 
SD standard deviation 
SE standard error 
SGOT serum glutamic oxaloacetic transaminase (same as aspartate aminotransferase or AST) 
SGPT serum glutamic pyruvic transaminase (same as alanine aminotransferase or ALT) 
SIC standard industrial classification 
SMR standardized mortality ratio 
sRBC sheep red blood cell 
STEL short term exposure limit 
TLV threshold limit value 
TLV-C threshold limit value-ceiling value 
TRI Toxics Release Inventory 
TSCA Toxic Substances Control Act 
TWA time-weighted average 
UF uncertainty factor 
U.S. United States 
USDA United States Department of Agriculture 
USGS United States Geological Survey 
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USNRC U.S. Nuclear Regulatory Commission 
VOC volatile organic compound 
WBC white blood cell 
WHO World Health Organization 
 
> greater than 
≥ greater than or equal to 
= equal to 
< less than 
≤ less than or equal to 
% percent 
α alpha 
β beta 
γ gamma 
δ delta 
μm micrometer 
μg microgram 
q1* cancer slope factor 
– negative 
+ positive 
(+) weakly positive result 
(–) weakly negative result 
 
